<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2701200004
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Ozempic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SEMAGLUTIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        418.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Novo Nordisk Bagsvaerd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Novo Nordisk Bagsvaerd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BJ06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ozempic<sup>&reg;</sup> contains the active substance semaglutide. It<em> </em>helps your body reduce your blood sugar level only when blood sugar is too high and can help prevent heart disease.</p><p>&nbsp;</p><p>Ozempic<sup>&reg;</sup> is used to treat adults (aged 18 years and older) with type 2 diabetes when diet and exercise is not enough:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; on its own when you cannot use metformin (another diabetes medicine) or</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with other medicines for diabetes &ndash; when they are not enough to control your blood sugar levels. These may be medicines you take by mouth or inject such as insulin.&nbsp;</p><p>&nbsp;</p><p>Ozempic is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.</p><p>&nbsp;</p><p>Ozempic is indicated to reduce the risk of sustained eGFR decline, kidney failure including initiation of chronic renal replacement therapy, or death from kidney failure or cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.</p><p>&nbsp;</p><p>Ozempic is indicated to reduce the risk of sustained eGFR decline, kidney failure including initiation of chronic renal replacement therapy, or death from kidney failure or cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.</p><p>&nbsp;</p><p>It is important that you continue with your diet and exercise plan as told by your doctor, pharmacist or nurse.</p><p><strong><u>WARNING: RISK OF THYROID C-CELL TUMORS</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC&reg; causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OZEMPIC&reg; is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)&nbsp; . Counsel patients regarding the potential risk for MTC with the use of OZEMPIC&reg; and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC&reg;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Ozempic<sup>&reg;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-bidi-font-style:italic'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_a875d7ef-19c0-4e1f-9dcf-2a75302d41e6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-bidi-font-style:italic'><span style='mso-element:field-end'></span></span></sup></b><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to semaglutide or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d5403a17-5dc0-460c-a57c-740ae1a571be \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Talk to your doctor, pharmacist or nurse before using this medicine.</p><p>&nbsp;</p><p>This medicine is not the same as insulin and you should not use it if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have type 1&nbsp;diabetes &ndash; a condition where your body does not produce any insulin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you develop diabetic ketoacidosis &ndash; a complication of diabetes with high blood sugar, breathing difficulty, confusion, excessive thirst, a sweet smell to the breath or a sweet or metallic taste in the mouth.<!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c01b04ec-5f75-446c-9125-7e50e4a43a8e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>Ozempic<sup>&reg;</sup> is not an insulin and should therefore not be used as a substitute for insulin.</p><p>&nbsp;</p><p><strong>Effects on the digestive system</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_bdaad9f3-7698-4113-9dee-b568be14a916 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&nbsp;</p><p>During treatment with this medicine, you may feel sick (nausea) or be sick (vomiting), or have diarrhoea. These side effects can cause dehydration (loss of fluids). It is important that you drink plenty of fluids to prevent dehydration. This is especially important if you have kidney problems. Talk to your doctor if you have any questions or concerns.</p><p>&nbsp;</p><p><strong>Severe and on-going stomach pain which could be due to acute pancreatitis</strong></p><p>&nbsp;</p><p>If you have severe and on-going pain in the stomach area &ndash; see a doctor straight away as this could be a sign of acute pancreatitis (inflamed pancreas). Please see section 4 for the warning signs of inflamed pancreas.</p><p>&nbsp;</p><p><strong>Low blood sugar (hypoglycaemia)</strong></p><p>&nbsp;</p><p>Combining a sulfonylurea or an insulin with this medicine might increase the risk of getting low blood sugar levels (hypoglycaemia). Please see section 4 for the warning signs of low blood sugar levels. Your doctor may ask you to test your blood sugar levels. This will help your doctor decide if the dose of the sulfonylurea or insulin needs to be changed to reduce the risk of low blood sugar.</p><p>&nbsp;</p><p><strong>Diabetic eye disease (retinopathy)</strong></p><p>&nbsp;</p><p>If you have diabetic eye disease and are using insulin, this medicine may lead to a worsening of your vision, and this may require treatment. Tell your doctor if you have diabetic eye disease or if you experience eye problems during treatment with this medicine.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>This medicine is not recommended in children and adolescents aged under 18&nbsp;years as the safety and efficacy in this age group have not yet been established.</p><p>&nbsp;</p><p><strong>Acute Gallbladder Disease</strong></p><p>Gallbladder problems have happened in some people who take OZEMPIC. Tell your healthcare provider right away if you get symptoms of gallbladder problems which may include:</p><p>&middot;&nbsp;&nbsp;&nbsp; pain in your upper stomach (abdomen)</p><p>&middot;&nbsp;&nbsp;&nbsp; yellowing of skin or eyes (jaundice)</p><p>&middot;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp; clay-colored stools</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Kidney problems (kidney failure):</strong></p><p>In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Ozempic<sup>&reg;</sup></strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines, including herbal medicines or other medicines you bought without a prescription.</p><p>&nbsp;</p><p>In particular, tell your doctor, pharmacist or nurse if you are using medicines containing any of the following:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warfarin or other similar medicines taken by mouth to reduce blood clotting (oral anti-coagulants). You may need frequent blood tests to check how quickly your blood clots.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are using insulin, your doctor will tell you how to reduce the dose of insulin and will recommend you to monitor your blood sugar more frequently, in order to avoid hyperglycaemia (high blood sugar) and diabetic ketoacidosis (a complication of diabetes that occurs when the body is unable to break down glucose because there is not enough insulin).</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_6da8e35e-ee91-47cb-a905-0e3a48a1aaf1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you are pregnant or breast-feeding, think you might be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p>This medicine should not be used during pregnancy, as it is not known if it affects an unborn baby. Therefore, use of contraception is recommended while using this medicine. If you wish to become pregnant, discuss how to change your treatment with your doctor as you should stop using this medicine at least 2 months in advance. If you become pregnant while using this medicine, talk to your doctor right away, as your treatment will need to be changed.</p><p>&nbsp;</p><p>Do not use this medicine if you are breast-feeding, as it is unknown if it passes into breast milk.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d2f962b7-5b24-4e1c-b618-72438f5e8236 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Ozempic<sup>&reg;</sup> is unlikely to affect your ability to drive and use machines. If you use this medicine in combination with a sulfonylurea or insulin, low blood sugar (hypoglycaemia) may occur which may reduce your ability to concentrate. Do not drive or use machines if you get any signs of low blood sugar. See section 2, &lsquo;Warnings and precautions&rsquo; for information on increased risk of low blood sugar and section 4 for the warning signs of low blood sugar. Talk to your doctor for further information.</p><p>&nbsp;</p><p><strong>Sodium content</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>&nbsp;</p><p><strong>How much to use</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose is 0.25&nbsp;mg once a week for four weeks.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After four weeks your doctor will increase your dose to 0.5&nbsp;mg once a week.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may increase your dose to 1&nbsp;mg once a week if your blood sugar is not controlled well enough with a dose of 0.5&nbsp;mg once a week.</p><p>&nbsp;</p><p>Do not change your dose unless your doctor has told you to.</p><p>&nbsp;</p><p><strong>How </strong><strong>Ozempic<sup>&reg;</sup></strong><strong><em> </em></strong><strong>is given</strong></p><p>Ozempic<sup>&reg;</sup> is given as an injection under the skin (subcutaneous injection). Do not inject it into a vein or muscle.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The best places to give the injection are the front of your thighs, the front of your waist (abdomen), or your upper arm.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before you use the pen for the first time, your doctor or nurse will show you how to use it.</p><p>Detailed instructions for use are on the other side of this package leaflet.</p><p>&nbsp;</p><p><strong>When to use Ozempic<sup>&reg;</sup></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should use this medicine<em> </em>once a week on the same day each week if possible.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can give yourself the injection at any time of the day &ndash; regardless of meals.</p><p>&nbsp;</p><p>To help you remember to inject this medicine once a week only, it is recommended to note the chosen weekday (e.g. Wednesday) on the carton and to write the date on the carton every time you have injected it.</p><p>&nbsp;</p><p>If necessary you can change the day of your weekly injection of this medicine as long as it has been at least 3&nbsp;days since your last injection of it. After selecting a new dosing day, continue with once a week dosing.</p><p>&nbsp;</p><p><strong>If you use more Ozempic<sup>&reg;</sup> than you should</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span lang=EN-GB style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_9c0007f4-dbea-4d60-8f6f-71feeb8fe79e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you use more Ozempic<sup>&reg;</sup> than you should, talk to your doctor straight away. You may get side effects such as feeling sick (nausea).<!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f3f7394a-93ea-4e76-befd-714a6d06f245 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>If you forget to use Ozempic<sup>&reg;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-bidi-font-style:italic'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_0f5b97b7-85c8-42d1-bfd9-10ab7bf14b60 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-bidi-font-style:italic'><span style='mso-element:field-end'></span></span></sup></b><![endif]--></p><p>If you forgot to inject a dose and:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it is 5&nbsp;days or less since you should have used Ozempic<sup>&reg;</sup>, use it as soon as you remember. Then inject your next dose as usual on your scheduled day.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it is more than 5&nbsp;days since you should have used Ozempic<sup>&reg;</sup>, skip the missed dose. Then inject your next dose as usual on your scheduled day.</p><p>Do not use a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop using Ozempic<sup>&reg;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-bidi-font-style:italic'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_94b6dc8f-dabf-44e0-b80f-09ed24e87f7f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-bidi-font-style:italic'><span style='mso-element:field-end'></span></span></sup></b><![endif]--></p><p>Do not stop using this medicine without talking to your doctor. If you stop using it, your blood sugar levels may increase.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.&nbsp;</p><p>&nbsp;</p><p>Serious side effects<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_278847ac-77de-422c-a278-ca29cbf7683f \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Common</strong> (may affect up to 1 in 10 people)<strong> </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; complications of diabetic eye disease (retinopathy) &ndash; you should tell your doctor if you get eye problems, such as changes in vision, during treatment with this medicine.<strong> </strong></p><p><strong>&nbsp;</strong></p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed pancreas (acute pancreatitis) which could cause severe pain in the stomach and back which does not go away. You should see a doctor immediately if you experience such symptoms.</p><p><strong>&nbsp;</strong></p><p><strong>Rare </strong>(may affect up to 1 in 1 000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reactions (anaphylactic reactions, angioedema). You must get immediate medical help and inform your doctor straight away if you get symptoms such as breathing problems, swelling of face, lips, tongue and/or throat with difficulty swallowing and a fast heartbeat.</p><p>&nbsp;</p><p><strong>Not known</strong> (frequency cannot be estimated from the available data)</p><p>&bull; Bowel obstruction. A severe form of constipation with additional symptoms such as stomach ache, bloating, vomiting etc.</p><p>&bull; Cholecystitis, cholelithiasis requiring cholecystectomy</p><p>&bull; Gastrointestinal Disorders: Ileus</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Other side effects <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_38e09f4d-2844-45e9-8050-e171fde1e418 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Very common</strong> (may affect more than 1 in 10 people)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea) &ndash; this usually goes away over time</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea &ndash; this usually goes away over time</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood sugar (hypoglycaemia) when this medicine is used with medicines that contain a&nbsp;&nbsp; sulfonylurea or insulin.</p><p><strong>&nbsp;</strong></p><p><strong>Common</strong> (may affect up to 1 in 10 people)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (vomiting)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood sugar (hypoglycaemia) when this medicine<em> </em>is used with oral diabetes medicine other than sulfonylurea or insulin.</p><p>&nbsp;</p><p>The warning signs of low blood sugar may come on suddenly. They can include: cold sweat, cool pale skin, headache, fast heartbeat, feeling sick (nausea) or very hungry, changes in vision, feeling sleepy or weak, feeling nervous, anxious or confused, difficulty concentrating or shaking.&nbsp;</p><p>Your doctor will tell you how to treat low blood sugar and what to do if you notice these warning signs.</p><p>Low blood sugar is more likely to happen if you also take a sulfonylurea or insulin. Your doctor may reduce your dose of these medicines before you start using this medicine.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed stomach (&lsquo;gastritis&rsquo;) &ndash; the signs include stomach ache, feeling sick (nausea) or being sick (vomiting)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reflux or heartburn &ndash; also called &lsquo;gastro-esophageal reflux disease&rsquo; (GERD)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bloating of the stomach</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; burping</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gall stones</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; less appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gas (flatulence)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of pancreatic enzymes (such as lipase and amylase).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cholelithiasis</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in the way food or drink tastes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast pulse</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site reactions &ndash; such as bruising, pain, irritation, itching and rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions like rash, itching or hives</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a delay in the emptying of the stomach.</p><p>&nbsp;</p><p>Reporting of side effects <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_8cc190f5-e03d-4337-b51d-b2a417f689d8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>To report any side effect(s):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC states</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>&minus; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Council of Arab Health Ministers</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>This is a Medicament</p><p>&minus; Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</p><p>&minus; Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>&minus; The doctor and the pharmacist are the experts in medicines, their benefits and risks.</p><p>&minus; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>&minus; Do not repeat the same prescription without consulting your doctor.</p><p>&minus; Keep all medicaments out of reach of children.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the pen label and carton after &rsquo;Expiry&rsquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p><strong>Before opening:</strong></p><p>&nbsp;</p><p>Store in a refrigerator (2&nbsp;&deg;C &ndash; 8&nbsp;&deg;C). Do not freeze. Keep away from the cooling element. Keep the pen cap on in order to protect from light.</p><p>&nbsp;</p><p><strong>During use:</strong></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can keep the pen for 6&nbsp;weeks when stored at a temperature below 30&nbsp;&deg;C or in a refrigerator (2&nbsp;&deg;C &ndash; 8&nbsp;&deg;C) away from the cooling element. Do not freeze Ozempic<sup>&reg;</sup> and do not use it if it has been frozen.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When you are not using the pen, keep the pen cap on in order to protect from light.</p><p>&nbsp;</p><p>Do not use this medicine if you notice that the solution is not clear and colourless or almost colourless.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Ozempic<sup>&reg;</sup> contains </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is semaglutide. One ml solution for injection contains 1.34&nbsp;mg semaglutide. One pre-filled pen contains 2&nbsp;mg semaglutide in 1.5&nbsp;ml solution. Each dose contains 0.5 mg of semaglutide in 0.37&nbsp;ml.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: disodium phosphate dihydrate, propylene glycol, phenol, water for injections, sodium hydroxide/hydrochloric acid (for pH adjustment). See also section 2, &lsquo;Sodium content&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                			What Ozempic® looks like and contents of the pack
	Ozempic® is a clear and colourless or almost colourless solution for injection in a pre-filled pen. 
	Each pre-filled pen contains 1.5 ml of solution, delivering doses of 0.5 mg. 
	
	Ozempic® 0.5 mg solution for injection is available in the following pack size:
	1 pen and 4 disposable NovoFine® Plus needles.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novo Nordisk A/S</p><p>Novo All&eacute;</p><p>DK-2880 Bagsv&aelig;rd</p><p>Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August/2024 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي اوزمبِك<sup>&trade;</sup> على المادة الفعالة &quot;سيماجلوتايد&quot;. وهو يساعد جسمك على تقليل مستوى السكر في الدم فقط عند الارتفاع الحاد لمستوى السكر في الدم، وقد يساعد في الوقاية من أمراض القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم اوزمبِك&trade; لعلاج البالغين (الذين تبلغ أعمارهم 18 عامًا فأكثر) المصابين بداء السكري من النوع 2 عندما لا يكفي النظام الغذائي والتمارين الرياضية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; بمفرده &ndash; عندما<s> </s>لا يمكنك استخدام ميتفورمين (دواء آخر لعلاج داء السكري) أو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع أدوية أخرى لعلاج داء السكري &ndash; إذا كانت غير كافية للتحكم في مستويات السكر في الدم. قد &nbsp;تكون هذه أدوية تأخذها عن طريق الفم أو الحقن مثل &nbsp;الإنسولين.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">كما يمكن استخدام اوزمبِك<sup>&trade;</sup>&nbsp; للحد من مخاطر الأحداث القلبية الوعائية الجانبية الرئيسية (الموت القلبي الوعائي ، احتشاء عضلة القلب غير المميت أو السكتة الدماغية غير المميتة) عند البالغين المصابين بداء السكري من النوع الثاني وأمراض القلب والأوعية الدموية الثابتة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُوصف لتقليل احتمالية حدوث انخفاض مستمر في معدل الترشيح الكبيبي المقدر (eGFR)، أو فشل كلوي، وكذلك تقليل الشروع في البدائل العلاجية لمرض الكلى المزمن، أو تقليل احتمالات الوفاة الناجمة عن الفشل الكلوي أو أمراض القلب والأوعية الدموية لدى البالغين المصابين بمرض السكري من النوع الثاني ومرض الكلى المزمن</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;من المهم أن تستمر في نظامك الغذائي وخطة التمارين كما أخبرك &nbsp;طبيبك، أو &nbsp;الصيدلي أو &nbsp;الممرضة.</p><p>&nbsp;</p><p><strong><u>تحذير: خطورة الإصابة بسرطان الغدة الدرقي</u></strong><strong>ة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; يحدث سيماجلوتايد سرطان الغدة الدرقية بالقوارض حسب الجرعة المعطاة ومدة العلاج من خلال الدرسات الإكلينيكية التي أجريت عليهم، ومن غير المعروف أذا كان اوزمبِك&trade; يسبب سرطان الغدة الدرقية، بما في ذلك سرطان الغدة الدرقية النخاعي في البشر، حيث لم يتم تحديد تعريض البشر للسيماجلوتايد بشكل محفز لسرطان الغدة الدرقية كما هو الحال مع القوارض</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp; </strong>يمنع استخدام اوزمبِك&trade; للمرضى الذين يشمل تاريخهم الشخصي أو العائلي للإصابة بسرطان الغدة الدرقية النخاعي أوالمرضى الذين يعانون من متلازمة الغدد الصماء نيوبلسا النوع الثاني، ينصح بتقديم المشورة للمرضى فيما يتعلق بالمخاطر المحتملة للإصابة بسرطان الغدة الدرقية النخاعي عند استخدام اوزمبِك&trade; وإبلاغهم بأعراض أورام الغدة الدرقية (مثل كتلة في الرقبة ، وعسر البلع ، وضيق التنفس ، وبحة مستمرة في الصوت).&nbsp; كما وجد أن الفحص المستمر وقياس مستوى الكالسيتونين في الدم أو استخدام الموجات فوق الصوتية ليس له نتائج مؤكدة للكشف المبكر لسرطان الغدة الدرقية النخاعي للمرضى الذين قاموا باستخدام اوزمبِك&trade;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم اوزمبِك<sup>&trade;</sup></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه سيماجلوتايد أو لأي من المكونات الأخرى لهذا الدواء (الواردة في القسم 6: ).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدث إلى &nbsp;طبيبك، أو &nbsp;الصيدلي أو &nbsp;الممرضة قبل استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذا الدواء ليس مثل الإنسولين ويجب ألّا تستخدمه في الحالات التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من داء السكري من النوع الأول - إحدى الحالات التي لا يفرز فيها الجسم أي إنسولين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أُصبت بالحمض الكيتوني السكري - إحدى مضاعفات الداء السكري المصاحب لارتفاع نسبة السكر في الدم وصعوبة التنفس والارتباك والعطش الشديد وتغير رائحة النفس إلى رائحة حلوى أو طعم حلو أو معدني في الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أوزمبِك<sup>&trade;</sup> ليس إنسولين، وبالتالي لا يجوز استعماله كبديل للإنسولين.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>الآثار على الجهاز الهضمي</strong></p><p dir="RTL">قد تشعر أثناء العلاج بهذا الدواء بال مرض (غثيان) أو تعاني من (ال تقيؤ) أو تعاني من الإسهال. يمكن أن تسبب الآثار الجانبية هذه الجفاف (فقدان السوائل). ومن المهم أن تشرب الكثير من السوائل لمنع الجفاف. ويمثل ذلك على نحو الخصوص أهمية إذا كنت تعاني من مشكلات في الكلى. &nbsp;تحدث إلى طبيبك إذا كان لديك أي أسئلة أو مخاوف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ألم شديد ومستمر في البطن قد يكون بسبب التهاب البنكرياس الحاد</strong></p><p dir="RTL">إذا كنت تعاني من ألم شديد ومستمر في منطقة البطن &ndash; فقم بزيارة الطبيب على الفور لأن ذلك قد يكون علامة على التهاب البنكرياس الحاد (التهاب البنكرياس). يُرجى الرجوع إلى القسم 4 للوقوف على العلامات التحذيرية للالتهاب البنكرياس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نقص سكر الدم (</strong><strong>انخفاض السكر في الدم)</strong></p><p dir="RTL">قد يؤدي الجمع بين أدوية سلفونيل يوريا أو الإنسولين وهذا الدواء إلى زيادة خطر التعرض لانخفاض مستويات السكر في الدم (نقص سكر الدم) يُرجى مراجعة القسم 4 للوقوف على العلامات التحذيرية لانخفاض مستويات السكر في الدم. قد يطلب الطبيب منك اختبار مستويات السكر في الدم. وقد يساعد ذلك طبيبك على اتخاذ قرار بشأن الحاجة إلى تغيير جرعة من أدوية سلفونيل يوريا أو الإنسولين لتقليل خطر انخفاض نسبة السكر في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اضطراب بالعين مرتبط بالداء السكري (اعتلال الشبكية السكري)</strong></p><p dir="RTL">إذا كنت تعاني من &nbsp;مرض بالعين مرتبطًا بداء السكري وتستخدم إنسولينًا، فقد يؤدي هذا الدواء إلى تدهور رؤيتك، مما يتطلب علاجه. أخبِر طبيبك أنك تعاني من &nbsp;مرض بالعين مرتبطًا بالداء السكري أو إذا كنت تعاني من مشكلات بالعين أثناء العلاج بهذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مشاكل المرارة</strong></p><p dir="RTL">قد یسبب اوزمبِك&trade;مشاكل في المرارة بما في ذلك حصوات المرارة . اتصل بطبیبك إذا كان لدیك أي من الأعراض التالیة:</p><p dir="RTL">&bull; ألم في الجزء العلوي من معدتك (البطن)</p><p dir="RTL">&bull; حمى</p><p dir="RTL">&bull; اصفرار بشرتك أو عینیك (الیرقان)</p><p dir="RTL">&bull; براز بلون الطین</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مشاكل الكلى (الفشل الكلوي)</strong></p><p dir="RTL">في الأشخاص الذين يعانون من مشاكل في الكلى، قد يتسبب الإسهال والغثيان والقيء في فقدان السوائل (الجفاف) مما قد يؤدي الى تفاقم مشاكل الكلى. من المهم أن تشرب سوائل للمساعدة في تقليل فرصتك في الإصابة بالجفاف.&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُنصح باستخدام هذا الدواء للأطفال والمراهقين الذين تبلغ أعمارهم تحت سن 18 عاماً؛ لأنه لم يثبت في هذه الفئة العمرية الأمان والفاعلية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى ودواء اوزمبِك<sup>&trade;</sup></strong></p><p dir="RTL">أخبر &nbsp;طبيبك، أو &nbsp;الصيدلي أو &nbsp;الممرضة إذا كنت تتناول أي أدوية أخرى، أو تناولتها مؤخر أو قد تتناولها، بما في ذلك الأدوية العشبية أو الأدوية الأخرى المأخوذة بدون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وينبغي عليك إخبار الطبيب أو الصيدلاني أو اختصاصي التمريض على الأخص إذا كنت تستخدم أدوية تحتوي على أي من العناصر الآتية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين أو أدوية أخرى مشابهة تؤخَذ عن طريق الفم للحد من تجلط الدم (مضادات التجلط عن طريق الفم). قد تحتاج إلى إجراء اختبارات دم متكررة للتحقق من سرعة تجلط دمك .يُطلب الاختبار المستمر للدم لتحديد القدرة على تجلط الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &rlm;‫إذا كنت تستخدم الأنسولين، سيخبرك الطبيب بكيفية تقليل جرعة الأنسولين وسيوصيك بمراقبة مستوى السكر في الدم بمعدل أكثر تكراراً، لتجنب ارتفاع مستوى السكر في الدم والحماض الكيتوني السكري (أحد مضاعفات مرض السكري التي تحدث عندما يكون الجسم غير قادر على تكسير الجلوكوز لعدم وجود كمية كافية من الإنسولين).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعة، أو تعتقدين أنكِ قد تكونين حاملاً أو تخططين للإنجاب مستقبلاً، فاستشيري طبيبكِ واطلبي منه المشورة قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم <s>يُحظر</s> استخدام هذا الدواء أثناء الحمل لأنه غير معروف ما إذا كان يؤثر على الجنين . ولذلك، يُنصح باستخدام وسائل منع الحمل أثناء استخدام هذا الدواء. إذا رغبتِ في أن تصبحي حاملاً، فناقشي كيفية تغيير علاجك مع الطبيب المتابع لكِ، حيث ينبغي لكِ وقف استخدام هذا الدواء قبل ذلك بشهرين على الأقل. وإذا أصبحتِ حاملاً أثناء استخدام هذا الدواء، فاستشيري طبيبكِ فوراً لأن العلاج سيحتاج للتغيير.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدمي هذا الدواء إذا كنتِ تُرضعين رضاعة طبيعية لأنه لا يُعرف ما إذا كان ينتقل للرضيع عبر حليب الأم أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستعمال الآلات</strong></p><p dir="RTL">من غير المحتمل أن يؤثر اوزمبِك&trade; على قدرتك على القيادة واستخدام الآلات. . إذا كنت تستخدِم هذا الدواء في توليفة مع أدوية سلفونيل يوريا أو الإنسولين، فقد يحدث انخفاض في سكر الدم (نقص سكر الدم) والذي قد يحد من قدرتك على التركيز. لا تقُد أو تستخدم الآلات إذا كنت تعاني من علامات على انخفاض السكر في الدم. انظر القسم 2، &quot;<em>تحذيرات واحتياطات&quot;</em>، للتعرف على معلومات عن زيادة خطر التعرض لانخفاض نسبة السكر في الدم، وانظر القسم 4 لمعرفة العلامات التحذيرية لانخفاض مستوى السكر في الدم. &nbsp;تحدث إلى طبيبك للحصول على المزيد من المعلومات</p><p dir="RTL"><strong>محتوى الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مللي مول من الصوديوم (23 ملجم) لكل جرعة، وهذا يعني أن هذا الدواء &quot;خالٍ من الصوديوم&quot; بصورة أساسية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدواء بالضبط كما أخبرك طبيبك . ارجع إلى طبيبك، أو &nbsp;الصيدلي أو &nbsp;الممرضة إذا ساورك شك بشأن استخدام الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مقدار الاستخدام</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ جرعة البدء 0.25 ملجم مرة واحدة في الأسبوع لمدة أربعة أسابيع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد أربعة أسابيع، سيزيد طبيبك جرعتك إلى 0.5 ملجم مرة واحدة في الأسبوع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يزيد الطبيب جرعتك إلى 1 ملجم مرة واحدة في الأسبوع إذا تعذر التحكم في مستوى السكر في الدم بطريقة كافية عند تناول جرعة مقدارها 0.5 ملجم مرة واحدة في الأسبوع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تغيّر جرعتك إلا إذا أخبرك طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة تناول اوزمبِك<sup>&trade;</sup></strong></p><p dir="RTL">يُعطى &nbsp;اوزمبِك<sup>&trade;</sup> كحقنة تحت الجلد. ولا تحقنه في وريد أو إحدى العضلات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتمثل أفضل المناطق لإعطاء الحقنة في الجزء الأمامي من الفخذين، أو مقدمة الخصر (البطن) أو أعلى الذراع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل استخدام القلم للمرة الأولى، سيُوضح لك طبيبك، أو &nbsp;الممرضة كيفية استخدامه.</p><p dir="RTL">توجد تعليمات مفصلة عن الاستخدام على الجانب الآخر من نشرة العبوة هذه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موعد استعمال اوزمبِك<sup>&trade;</sup></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليك استخدام هذا الدواء مرة واحدة في الأسبوع في نفس اليوم من كل أسبوع إن أمكن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك إعطاء نفسك الحُقنة أي وقت في اليوم بغض النظر عن الوجبات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ولمساعدتك على تذكر حقن هذا الدواء مرة واحدة فقط في الأسبوع، يُنصح بتدوين اليوم المختار (الأربعاء على سبيل المثال) على العبوة الكرتونية وكتابة التاريخ على العبوة الكرتونية كل مرة تأخذ فيها الحقنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;إذا لزم الأمر يمكنك تغيير يوم حقن هذا الدواء أسبوعيًا طالما قد مرت ثلاثة أيام على الأقل على آخر حقنة منه. وبعد تحديد &nbsp;يوم جديد لإعطاء الجرعة، استمر في أخذ جرعة مرة واحدة في الأسبوع.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>في حالة تناول جرعة من اوزمبِك<sup>&trade; </sup>أكثر مما ينبغي </strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><sup><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span></span></sup></b><sup><span dir=LTR
style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:bold'>DOCVARIABLE</span></sup><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><sup><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span dir=RTL></span><span
dir=RTL></span> </span></sup></b><sup><span dir=LTR style='mso-bidi-font-size:
11.0pt;mso-bidi-font-weight:bold'>VAULT_ND_6547abb8-6674-4858-b5ff-67ab2323c0dd
\* MERGEFORMAT</span></sup><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><sup><span style='mso-bidi-font-size:11.0pt;
font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman"'><span dir=RTL></span><span dir=RTL></span>
<span lang=AR-SA><span style='mso-element:field-separator'></span></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">في حالة تناول جرعة زائدة من اوزمبِك<sup>&trade;</sup> أكثر مما ينبغي، تحدث إلى طبيبك فور. فقد تعاني من آثار جانبية مثل الشعور بال مرض (غثيان).<!--[if supportFields]><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman";mso-ansi-font-weight:bold'><span
style='mso-element:field-begin'></span> </span><b style='mso-bidi-font-weight:
normal'><span dir=LTR style='mso-bidi-font-size:11.0pt'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><span style='mso-bidi-font-size:11.0pt;
font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman";mso-ansi-font-weight:bold'><span
dir=RTL></span><span dir=RTL></span> </span><b style='mso-bidi-font-weight:
normal'><span dir=LTR style='mso-bidi-font-size:11.0pt'>VAULT_ND_c99fa33c-6028-42a2-b1ca-2dd3bc5929c4
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman";mso-ansi-font-weight:
bold'><span dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
mso-ansi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان تناول اوزمبِك<sup>&trade;</sup></strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><sup><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
</span></sup></b><sup><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-bidi-font-weight:bold'>DOCVARIABLE</span></sup><span dir=RTL></span><span
dir=RTL></span><b style='mso-ansi-font-weight:normal'><sup><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span dir=RTL></span><span
dir=RTL></span> </span></sup></b><sup><span dir=LTR style='mso-bidi-font-size:
11.0pt;mso-bidi-font-weight:bold'>VAULT_ND_d5242c8f-240b-4e12-956b-72e068f2d5ba
\* MERGEFORMAT</span></sup><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><sup><span style='mso-bidi-font-size:11.0pt;
font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman"'><span dir=RTL></span><span dir=RTL></span>
<span lang=AR-SA><span style='mso-element:field-separator'></span></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">في حالة نسيان حقن جرعة:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند مرور خمسة أيام أو أقل على الموعد المقرر لاستخدام اوزمبِك<sup>&trade;</sup>، فتناولها بمجرد تذكرها. ثم احقن الجرعة التالية حسب المعتاد في يومك المقرر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند مرور أكثر من خمسة أيام على الموعد المقرر لاستخدام اوزمبِك<sup>&trade;</sup>، فتخطَّ الجرعة الفائتة ثم احقن الجرعة التالية حسب المعتاد في يومك المقرر.</p><p dir="RTL">لا تستخدم &nbsp;جرعة مضاعفة لتعويض جرعة فائتة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام دواء اوزمبِك<sup>&trade;</sup></strong></p><p dir="RTL">لا تتوقف عن استخدام هذا الدواء دون استشارة طبيبك. إذا توقفت عن استخدامه، قد تزيد مستويات السكر في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، فاطرحها على طبيبك، أو &nbsp;الصيدلي أو &nbsp;الممرضة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">على غرار جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية، على الرغم من عدم إصابة جميع المرضى بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة</strong></p><p dir="RTL"><strong>شائعة:</strong> (قد تصيب حتى شخص واحد من بين كل 10 أشخاص)</p><ul><li dir="RTL">عند حدوث اضطرابات بالعين مرتبطة بداء السكري (اعتلال الشبكية السكري) - يجب أن تخبر الطبيب المتابع لك إذا عانيت من مشاكل بالعين، كالتغيرات في الرؤية أثناء التداوي بهذا الدواء.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة:</strong> (قد تصيب حتى شخص واحد من بين كل 100 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &rlm;‫التهاب البنكرياس (التهاب البنكرياس الحاد) الذي يمكن أن يسبب ألماً شديداً لا يزول في المعدة والظهر. &rlm;‫يجب عليك زيارة الطبيب على الفور إذا ظهرت عليك مثل هذه الأعراض.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة</strong>: (قد تصيب حتى شخص واحد من بين كل 1000 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية الشديدة (التفاعلات التأقية، وذمة وعائية). في هذه الحالة؛ يجب عليك الحصول على مساعدة طبية فورية وإبلاغ الطبيب فوراً إذا ما ظهرت عليك أعراض مثل مشاكل في التنفس وحدوث تورم في الوجه، والشفاه، واللسان، و/أو الحلق مع صعوبة في البلع، وسرعة ضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير معروفة (لا يمكن تقدير معدل التكرار من البيانات المتاحة)<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-ansi-font-weight:bold'><span style='mso-element:
field-begin'></span> </span><b style='mso-bidi-font-weight:normal'><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-ansi-font-weight:
bold'><span dir=RTL></span><span dir=RTL></span> </span><b style='mso-bidi-font-weight:
normal'><span lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;mso-ansi-language:
EN-GB'>VAULT_ND_ab6e822c-d38b-4ff0-a982-1c7c72d67850 \* MERGEFORMAT</span></b><span
dir=RTL></span><span dir=RTL></span><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-ansi-font-weight:
bold'><span dir=RTL></span><span dir=RTL></span> </span><span lang=AR-SA
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-ansi-font-weight:bold'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-ansi-font-weight:bold'><span style='mso-element:
field-end'></span></span><![endif]--></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأمعاء. شكل حاد من الإمساك مصحوب بأعراض إضافية من ألم في المعدة، وانتفاخ، وتقيؤ وما إلى ذلك.<!--[if supportFields]><span lang=AR-SA
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman";mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span> </span><span lang=EN-GB
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman";mso-ansi-language:EN-GB'><span dir=RTL></span><span
dir=RTL></span> </span><span lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ansi-language:EN-GB'>VAULT_ND_85da3b28-e3de-4eb4-bea8-49b2ed032cfc \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman";mso-ansi-language:
EN-GB'><span dir=RTL></span><span dir=RTL></span> </span><span lang=AR-SA
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman";mso-ansi-language:
EN-GB'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المرارة ، تحص صفراوي يتطلب استئصال المرارة.<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> </span><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman";mso-ansi-language:EN-GB'><span dir=RTL></span><span
dir=RTL></span> </span><span lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ansi-language:EN-GB'>VAULT_ND_33773a19-d356-425d-bc29-d22d3263a130 \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman";mso-ansi-language:
EN-GB'><span dir=RTL></span><span dir=RTL></span> </span><span lang=AR-SA
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman";mso-ansi-language:
EN-GB'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>اضطرابات الجهاز الهضمي: الانسداد المعوي<!--[if supportFields]><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman";mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> </span><span lang=EN-GB dir=LTR
style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman";mso-ansi-language:EN-GB'><span dir=RTL></span><span
dir=RTL></span> </span><span lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ansi-language:EN-GB'>VAULT_ND_2fe18aac-a60c-49b8-a05e-dd5237227679 \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman";mso-ansi-language:
EN-GB'><span dir=RTL></span><span dir=RTL></span> </span><span lang=AR-SA
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman";mso-ansi-language:
EN-GB'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية أخرى</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
</span></b><span dir=LTR style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:
bold'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman"'><span dir=RTL></span><span dir=RTL></span>
</span></b><span dir=LTR style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:
bold'>VAULT_ND_0f92b89b-157a-4354-b437-cb81b6695328 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>شائعة جداً</strong>: (قد تصيب أكثر من شخص واحدٍ من بين كل 10 أشخاص)<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span
style='mso-element:field-begin'></span> </span><span dir=LTR style='mso-bidi-font-size:
11.0pt'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt'>VAULT_ND_a95ed624-eed2-4b7c-8868-fc17ba311491
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (غثيان) - عادةً ما يزول هذا بمرور الوقت</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال - عادةً ما يزول هذا بمرور الوقت.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض السكر في الدم (انخفاض السكر في الدم) عندما يُستخدم هذا الدواء مع الأدوية التي تحتوي على السلفونيل يوريا أو الإنسولين.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة:</strong> (قد تصيب حتى شخص واحد من بين كل 10 أشخاص)<!--[if supportFields]><span lang=AR-SA
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span
style='mso-element:field-begin'></span> </span><span dir=LTR style='mso-bidi-font-size:
11.0pt'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt'>VAULT_ND_bb9f0bf2-3c0c-437e-b4b6-9eb353c258c2
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة&nbsp; بال بالمرض ( تقيؤ)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى السكر في الدم (نقص سكر الدم) عند استخدام هذا الدواء مع دواء للسكري يؤخذ عن طريق الفم بخلاف السلفونيل يوريا أو الإنسولين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تظهر العلامات التحذيرية لانخفاض مستوى السكر في الدم فجأة. وقد تتضمن: عرق بارد؛ شحوب البشرة وبرودتها؛ صداع؛ سرعة ضربات القلب؛ شعورٌ بال بالمرض (غثيان) أو بالجوع الشديد؛ تغيرات في الرؤية؛ الشعور بالنعاس؛ أو ال ضعف؛ شعورٌ بالعصبية، أو القلق أو الارتباك الارتباك؛ صعوبة في التركيز؛ أو الارتجاف.</p><p dir="RTL">سيخبرك طبيبك بكيفية تدارك انخفاض مستوى السكر في الدم وما الذي يجب عليك القيام به إذا ما لاحظت ظهور &nbsp;هذه العلامات التحذيرية.</p><p dir="RTL">يحدث انخفاض مستوى السكر في الدم على الأرجح إذا كنت تتناول أيضًا أدوية سلفونيل يوريا أو الإنسولين. قد يقوم طبيبك بخفض جرعتك من هذه الأدوية قبل البدء في تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة - تتضمن العلامات ألم المعدة؛ والشعور بالمرض (غثيان) أو الإصابة بالمرض (التقيؤ)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاع أو حرقة الفؤاد - ويُسمى أيضًا &quot;مرض الارتجاع المعدي المريئي&quot; (GERD)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التجشؤ</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصى المرارة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الشهية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غازات (انتفاخ البطن)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في إنزيمات البنكرياس (مثل الليبيز والأميليز).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحص صفراوي</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية غير شائعة:</strong> قد تصيب حتى شخص واحد من بين كل 100 شخص<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span
style='mso-element:field-begin'></span> </span><span dir=LTR style='mso-bidi-font-size:
11.0pt'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt'>VAULT_ND_8ec74cd4-42c3-4c3e-89b9-1ff1a6993b11
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في طريقة تذوق الطعام أو الشراب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النبض السريع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات في موضع الحقن &ndash; كالكدمات؛ والألم؛ والتهيّج؛ والحكة؛ والطفح الجلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &rlm;‫تفاعلات حساسية، مثل الطفح الجلدي والحكة والشرى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأخير في إفراغ المعدة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong><!--[if supportFields]><b style='mso-ansi-font-weight:
normal'><span lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span
style='mso-element:field-begin'></span> </span></b><span dir=LTR
style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman"'><span dir=RTL></span><span
dir=RTL></span> </span></b><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-bidi-font-weight:bold'>VAULT_ND_beafb372-9f8b-4fd5-ae14-aa4f59b0a2c0 \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman"'><span dir=RTL></span><span dir=RTL></span>
<span lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">إذا أُصبت بأي آثار جانبية، فتحدث إلى طبيبك، أو الصيدلي أو الممرضة. ويشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. وبالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ حول الأعراض الجانبية التي قد تحدث يرجى التواصل عبر العناوين التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; المملكة العربية السعودية:</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">فاكس: 2057662-11-966+</p><p dir="RTL">للاتصال بالمركز الموحد للهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">بريد إلكتروني: &nbsp;npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: &nbsp;https://ade.sfda.gov.sa</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>دول الخليج العربي الأخرى:</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>الرجاء الاتصال بالجهات الوطنية في كل دولة</td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجلس وزراء الصحة العرب:</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p dir="RTL">إن هذا الدواء</p><p dir="RTL">- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر.</p><p dir="RTL">- اتبع بدقة وصفة الطبيب، وطريقة الاستعمال المنصوص عليها، وتعليمات الصيدلي الذي صرفها لك.</p><p dir="RTL">- الطبيب والصيدلي هما الخبيران في الدواء، وفي نفعه وضرره.</p><p dir="RTL">- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">- لا تكرر صرف الدواء بدون استشارة الطبيب المختص.</p><p dir="RTL">- لا تترك الأدوية في متناول الاطفال.</p></td></tr></tbody></table><p dir="RTL"><em>مجلس وزراء الصحة العرب</em></p><p dir="RTL"><em>واتحاد الصيادلة العرب</em></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيداً عن متناول الأطفال ونطاق رؤيتهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد انقضاء تاريخ انتهاء صلاحيته، الموضح على ملصق القلم والعبوة الكرتونية بعد كلمة &quot;Expiry&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>قبل فتح العبوة:</strong></p><p dir="RTL">يُخزن في الثلاجة (في درجة حرارة تتراوح ما بين 2-8 درجات مئوية). يُحظر تجميد هذا الدواء. احتفظ بهذا الدواء بعيدًا عن مصدر التبريد. أبقِ القلم بغطائه لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثناء الاستخدام:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك الاحتفاظ بالقلم لمدة 6 أسابيع عند تخزينه في درجة حرارة أقل من 30 درجة مئوية أو في الثلاجة (في درجة حرارة &nbsp;ما بين 2- 8 درجات مئوية) بعيدًا عن مصدر التبريد. يُحظر تجميد اوزمبِك<sup>&trade;</sup>؛ ويحظر استخدامه إذا كان قد تجمد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;عند عدم استخدام القلم؛ حافظ على وضع الغطاء لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء، إذا لاحظت أن المحلول غير صاف وعديم اللون أو قرب انعدام لونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية بإلقائها عبر مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعُد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>محتويات اوزمبِك<sup>&trade;</sup></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتمثل المادة الفعالة هي مادة سيماجلوتايد. يحتوي كل واحد مل من محلول الحقن على 1.34 ملجم سيماجلوتايد. بينما يحتوي كل قلم معبأ مسبقاً على 2 ملجم سيماجلوتايد في محلول الحقن 1.5 مل. لذلك؛ تحتوي كل جرعة على 0.5 ملجم سيماجلوتايد في 0.37 مل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى: فوسفات ثنائي الصوديوم ثنائي الهيدرات وجليكول البروبلين وفينول وماء للحقن وهيدروكسيد الصوديوم<strong>/</strong>حمض الهيدروكلوريك (لضبط درجة الحموضة). راجع أيضًا القسم&nbsp; 2 &quot;محتوى الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشكل الدوائي لاوزمبِك<sup>&trade;</sup> ومحتويات العبوة</strong></p><p dir="RTL">اوزمبِك<sup>&trade;</sup> عبارة عن &nbsp;محلول صافي عديم اللون أو يقرب من انعدام اللون يستخدم للحقن في قلم معبأ مسبق.</p><p dir="RTL">يحتوي كل قلم معبأ مسبقًا على 1.5 مل محلول، ويوفر جرعات مقدارها 0.5 ملجم.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>يتوفر محلول اوزمبِك<sup>&trade;</sup> 0.5 ملجم للحقن بالعبوة التالية:</strong></p><p dir="RTL">قلم و4 إبر نوفوفاين<sup>&trade;</sup> بلس للاستخدام لمرة واحدة فقط.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Novo All&eacute;</p><p dir="RTL">DK-2880 Bagsv&aelig;rd</p><p dir="RTL">Denmark</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس 2024 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ozempic 0.25 mg solution for injection in pre-filled pen
Ozempic 0.5 mg solution for injection in pre-filled pen
Ozempic 1 mg solution for injection in pre-filled pen


WARNING: RISK OF THYROID C-CELL TUMORS
• 	In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma MTC, in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions 4.4 and Preclinical safety data 5.3]. 
• 	OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 MEN 2 [see 
Contraindications 4.3]. Counsel patients regarding the potential risk for MTC with the use of OZEMPIC and inform them of symptoms of thyroid tumors [e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness]. Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC [see Contraindications 4.3 and Warnings and Precautions 4.4]. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ozempic 0.25 mg solution for injection

One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.25 mg of semaglutide in 0.19 ml solution.

Ozempic 0.5 mg solution for injection

One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution.

Ozempic 1 mg solution for injection

One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.74 ml solution.


*Human glucagon-like peptide-1 (GLP 1) analogue produced in Saccharomyces cerevisiae cells by recombinant DNA technology. 

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).
Clear and colourless or almost colourless, isotonic solution; pH=7.4.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as monotherapy when metformin is considered inappropriate due to intolerance or contraindications</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in addition to other medicinal products for the treatment of diabetes.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal &nbsp;&nbsp;myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and&nbsp; established cardiovascular disease</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to reduce the risk of sustained eGFR decline, kidney failure including initiation of chronic renal replacement therapy, or death from kidney failure or cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.</p><p>&nbsp;</p><p>&nbsp;</p><p>For trial results with respect to combinations, effects on glycaemic control and cardiovascular events, kidney events and the populations studied, see sections 4.4, 4.5 and 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>The starting dose is 0.25&nbsp;mg semaglutide once weekly. After 4&nbsp;weeks the dose should be increased to 0.5&nbsp;mg once weekly. After at least 4&nbsp;weeks with a dose of 0.5&nbsp;mg once weekly, the dose can be increased to 1&nbsp;mg once weekly to further improve glycaemic control<u>. After at least 4&nbsp;weeks with a dose of 1&nbsp;mg once weekly, the dose can be increased to 2&nbsp;mg once weekly to further improve glycaemic control.</u></p><p>&nbsp;</p><p>Semaglutide 0.25&nbsp;mg is not a maintenance dose. Weekly doses higher than 2&nbsp;mg are not recommended.</p><p>&nbsp;</p><p>When Ozempic is added to existing metformin and/or thiazolidinedione therapy or to a sodium-glucose cotransporter 2 (SGLT2) inhibitor, the current dose of metformin and/or thiazolidinedione or SGLT2 inhibitor can be continued unchanged.</p><p><em>&nbsp;</em></p><p>When Ozempic is added to existing therapy of sulfonylurea or insulin, a reduction in the dose of sulfonylurea or insulin should be considered to reduce the risk of hypoglycaemia (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p>Self-monitoring of blood glucose is not needed in order to adjust the dose of Ozempic. Blood glucose self-monitoring is necessary to adjust the dose of sulfonylurea and insulin, particularly when Ozempic is started and insulin is reduced. A stepwise approach to insulin reduction is recommended.</p><p>&nbsp;</p><p><em><u>Missed dose</u></em></p><p>If a dose is missed, it should be administered as soon as possible and within 5&nbsp;days after the missed dose. If more than 5&nbsp;days have passed, the missed dose should be skipped, and the next dose should be administered on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.</p><p>&nbsp;</p><p><em><u>Changing the dosing day</u></em></p><p><u>The day of weekly administration can be changed if necessary, as long as the time between two doses is at least 3&nbsp;days (&gt;72 hours). After selecting a new dosing day, once-weekly dosing should be continued.</u></p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dose adjustment is required based on age. Therapeutic experience in patients &ge;75&nbsp;years of age is limited (see section 5.2).</p><p><em><u>&nbsp;</u></em></p><p><em>Renal impairment</em></p><p>No dose adjustment is required for patients with mild, moderate or severe renal impairment. Experience with the use of semaglutide in patients with severe renal impairment is limited. Semaglutide is not recommended for use in patients with end-stage renal disease (see section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is required for patients with hepatic impairment. Experience with the use of Semaglutide in patients with severe hepatic impairment is limited. Caution should be exercised when treating these patients with semaglutide (see section 5.2).</p><p><em><u>&nbsp;</u></em></p><p><em>Paediatric population</em></p><p>The safety and efficacy of semaglutide in children and adolescents below 18&nbsp;years have not yet been established. No data are available.</p><p><u>&nbsp;</u></p><p><u>Method of administration </u></p><p>&nbsp;</p><p><u>Subcutaneous use.</u></p><p>&nbsp;</p><p>Ozempic is to be injected subcutaneously in the abdomen, in the thigh or in the upper arm. The injection site can be changed without dose adjustment. Ozempic<em> </em>should not be administered intravenously or intramuscularly.</p><p>&nbsp;</p><p><u>Ozempic is to be administered once weekly at any time of the day, with or without meals.</u></p><p>&nbsp;</p><p>For further information on administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u><!--[if supportFields]><u><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-style:
italic'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_4dacb882-2d43-463b-91c1-44dddec65e37 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-style:
italic'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.<!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-style:italic'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_7949878c-d320-4d8d-9b8b-b2f0a9a350d2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-style:
italic'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><u>General</u></p><p>&nbsp;</p><p>Semaglutide should not be used in patients with type 1&nbsp;diabetes mellitus or for the treatment of diabetic ketoacidosis. Semaglutide is not a substitute for insulin. Diabetic ketoacidosis has been reported in insulin-dependent patients whom had rapid discontinuation or dose reduction of insulin when treatment with a GLP-1 receptor agonist is started (see section 4.2).</p><p>&nbsp;</p><p>There is no experience in patients with congestive heart failure NYHA class IV and semaglutide is therefore not recommended in these patients.</p><p>&nbsp;</p><p><u>Gastrointestinal effects </u></p><p>&nbsp;</p><p>Use of GLP‑1 receptor agonists may be associated with gastrointestinal adverse reactions. This should be considered when treating patients, with impaired renal function as nausea, vomiting, and diarrhoea may cause dehydration which could cause a deterioration of renal function (see section 4.8).</p><p>&nbsp;</p><p><u>Acute pancreatitis</u></p><p>&nbsp;</p><p>Acute pancreatitis has been observed with the use of GLP‑1 receptor agonists. Patients should be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, semaglutide should be discontinued; if confirmed, semaglutide should not be restarted. Caution should be exercised in patients with a history of pancreatitis.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-style:
italic'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_236074eb-31a5-4c2a-b646-eb6b5dcaf085 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-style:
italic'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><u>Hypoglycaemia</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-style:
italic'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5e697ef2-b834-4b27-b0cf-c75c2eac3ea6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-style:
italic'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p><u>&nbsp;</u></p><p>Patients treated with semaglutide in combination with a sulfonylurea or insulin may have an increased risk of hypoglycaemia. The risk of hypoglycaemia can be lowered by reducing the dose of sulfonylurea or insulin when initiating treatment with semaglutide (see section 4.8).<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-style:
italic'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_fd0b703c-83d6-43c1-9cdf-d4aed6a71550 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-style:
italic'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><u>Diabetic retinopathy</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-style:
italic'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e617a870-ec58-4f15-8b8e-14d29ce03e26 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-style:
italic'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>&nbsp;</p><p>In patients with diabetic retinopathy treated with insulin and semaglutide, an increased risk of developing diabetic retinopathy complications has been observed (see section 4.8). Caution should be exercised when using semaglutide in patients with diabetic retinopathy treated with insulin. These patients should be monitored closely and treated according to clinical guidelines. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy, but other mechanisms cannot be excluded.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_9d199439-a419-4e42-bb75-d7832c36a667 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><u>There is no experience with semaglutide 2&nbsp;mg in patients with type 2 diabetes with uncontrolled or potentially unstable diabetic retinopathy and semaglutide 2&nbsp;mg is therefore not recommended in these patients.</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:10.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_05bb6068-9075-4220-8da6-8a5fe2969aa8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:10.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span></u><![endif]--></p><p>&nbsp;</p><p><u>Sodium content</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE vault_nd_a2090303-e7e9-4a57-9d4e-50da21cb179e
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span></u><![endif]--></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8681b5ba-cfa4-4df3-a936-2e9c5751f9aa \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><u>&nbsp;</u></p><p><u>Risk of Thyroid C-Cell Tumors</u></p><p>In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure at clinically relevant plasma exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.</p><p>&nbsp;</p><p>Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the post marketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans.</p><p>&nbsp;</p><p>OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk for MTC with the use of OZEMPIC and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness).</p><p>&nbsp;</p><p>Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin value may indicate MTC and patients with MTC usually have calcitonin values &gt;50 ng/L. If serum calcitonin is measured and found</p><p>to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.</p><p>&nbsp;</p><p><strong>Acute Gallbladder Disease</strong></p><p>Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients-treated with OZEMPIC 0.5 mg and 1 mg, respectively. Cholelithiasis was not reported in placebo- treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.</p><p>&nbsp;</p><p><strong><u>Acute Kidney Injury</u></strong></p><p><u>There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of OZEMPIC in patients reporting severe adverse gastrointestinal reactions.</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Semaglutide delays gastric emptying and has the potential to impact the rate of absorption of concomitantly administered oral medicinal products. Semaglutide should be used with caution in patients receiving oral medicinal products that require rapid gastrointestinal absorption.</p><p>&nbsp;</p><p><u>Paracetamol</u></p><p>&nbsp;</p><p>Semaglutide delays the rate of gastric emptying as assessed by paracetamol pharmacokinetics during a standardised meal test. Paracetamol AUC<sub>0-60min </sub>and C<sub>max</sub> were decreased by 27% and 23%, respectively, following concomitant use of semaglutide 1 mg. The total paracetamol exposure (AUC0-5h) was not affected. No clinically relevant effect on the rate of gastric emptying was observed with semaglutide 2.4 mg, following 20 weeks of administration of semaglutide, probably due to a tolerance effect. No dose adjustment of paracetamol is necessary when administered with semaglutide.&nbsp;</p><p>&nbsp;</p><p><u>Oral contraceptives</u></p><p>&nbsp;</p><p>Semaglutide is not anticipated to decrease the effect of oral contraceptives as semaglutide did not change the overall exposure of ethinylestradiol and levonorgestrel to a clinically relevant degree when an oral contraceptive combination medicinal product (0.03 mg ethinylestradiol/0.15 mg levonorgestrel) was co-administered with semaglutide. Exposure of ethinylestradiol was not affected; an increase of 20% was observed for levonorgestrel exposure at steady state. C<sub>max</sub> was not affected for any of the compounds.</p><p>&nbsp;</p><p><u>Atorvastatin</u></p><p>&nbsp;</p><p>Semaglutide did not change the overall exposure of atorvastatin following a single dose administration of atorvastatin (40 mg). Atorvastatin C<sub>max</sub> was decreased by 38%. This was assessed not to be clinically relevant.</p><p>&nbsp;</p><p><u>Digoxin</u></p><p>&nbsp;</p><p>Semaglutide did not change the overall exposure or C<sub>max</sub> of digoxin following a single dose of digoxin (0.5 mg).</p><p>&nbsp;</p><p><u>Metformin</u></p><p>&nbsp;</p><p>Semaglutide did not change the overall exposure or C<sub>max </sub>of metformin following dosing of 500 mg twice daily over 3.5 days.</p><p>&nbsp;</p><p><u>Warfarin and other coumarin derivatives</u></p><p>Semaglutide did not change the overall exposure or C<sub>max</sub> of R- and S-warfarin following a single dose of warfarin (25 mg), and the pharmacodynamic effects of warfarin as measured by the international normalised ratio (INR) were not affected in a clinically relevant manner. However, cases of decreased INR have been reported during concomitant use of acenocoumarol and semaglutide. Upon initiation of semaglutide treatment in patients on warfarin or other coumarin derivatives, frequent monitoring of INR is recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Women of childbearing potential are recommended to use contraception when treated with semaglutide.</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). There are limited data from the use of semaglutide in pregnant women. Therefore, semaglutide should not be used during pregnancy. If a patient wishes to become pregnant, or pregnancy occurs, semaglutide should be discontinued. Semaglutide should be discontinued at least 2&nbsp;months before a planned pregnancy due to the long half‑life (see section 5.2).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>In lactating rats, semaglutide was excreted in milk. As a risk to a breast-fed child cannot be excluded, semaglutide should not be used during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>The effect of semaglutide on fertility in humans is unknown. Semaglutide did not affect male fertility in rats. In female rats, an increase in oestrous length and a small reduction in number of ovulations were observed at doses associated with maternal body weight loss (see section 5.3).</p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong>Semaglutide has no or negligible influence on the ability to drive or use machines. When it is used in combination with a sulfonylurea or insulin, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines (see section 4.4).<!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_adbf1aac-2433-41b7-abdf-93520e15be7d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold'><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>&nbsp;</p><p>In 8 phase 3a trials 4&nbsp;792&nbsp;patients were exposed to semaglutide up to 1&nbsp;mg. The most frequently reported adverse reactions in clinical trials were gastrointestinal disorders, including nausea (very common), diarrhoea (very common) and vomiting (common). In general, these reactions were mild or moderate in severity and of short duration.</p><p>&nbsp;</p><p>Tabulated list of adverse reactions</p><p>&nbsp;</p><p>Table&nbsp;1 lists adverse reactions identified in all phase 3 trials (including the long-term cardiovascular outcomes trial) and post-marketing reports in patients with type 2&nbsp;diabetes mellitus (further described in section 5.1). The frequencies of the adverse reactions (except diabetic retinopathy complications, see footnote in Table&nbsp;1) are based on a pool of the phase 3a trials excluding the cardiovascular outcomes trial (see text below the table for additional details).</p><p>&nbsp;</p><p>The reactions are listed below by system organ class and absolute frequency. Frequencies are defined as: very common: (&ge;1/10); common: (&ge;1/100 to &lt;1/10); uncommon: (&ge;1/1&nbsp;000 to &lt;1/100); rare: (&ge;1/10&nbsp;000 to &lt;1/1&nbsp;000); very rare: (&lt;1/10&nbsp;000) and not known: cannot be estimated from available data. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table </strong><strong>1</strong><u> </u><strong>Frequency of adverse reactions </strong><strong>of semaglutide</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>MedDRA</strong></p><p><strong>system organ</strong></p><p><strong>class</strong></p></td><td style="width:153px"><p><strong>Very common</strong></p></td><td style="width:138px"><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Not known</strong></p></td></tr><tr><td><p><strong>Immune system disorders </strong></p></td><td style="width:153px"><p>&nbsp;</p></td><td style="width:138px"><p>&nbsp;</p></td><td><p>Hypersensitivity<sup>c</sup></p></td><td><p>Anaphy&shy;lactic reaction</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Metabolism and nutrition disorders </strong></p></td><td style="width:153px"><p>Hypoglycaemia<sup>a</sup> when used with insulin or sulfonylurea</p></td><td style="width:138px"><p>Hypoglycaemia<sup>a</sup> when used with other OADs</p><p>&nbsp;</p><p>Decreased appetite</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Nervous system disorders</strong></p></td><td style="width:153px"><p>&nbsp;</p></td><td style="width:138px"><p>Dizziness</p></td><td><p>Dysgeusia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Eye disorders</strong></p></td><td style="width:153px"><p>&nbsp;</p></td><td style="width:138px"><p>Diabetic retinopathy</p><p>complications<sup>b</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Cardiac disorders </strong></p></td><td style="width:153px"><p>&nbsp;</p></td><td style="width:138px"><p>&nbsp;</p></td><td><p>Increased heart rate</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Gastrointesti&shy;nal disorders </strong></p></td><td style="width:153px"><p>Nausea</p><p>Diarrhoea</p></td><td style="width:138px"><p>Vomiting</p><p>Abdominal pain</p><p>Abdominal distension</p><p>Constipation</p><p>Dyspepsia</p><p>Gastritis</p><p>Gastro-oesophageal</p><p>reflux disease</p><p>Eructation</p><p>Flatulence</p></td><td><p>Acute pancreatitis</p><p><u>Delayed gastric emptying</u></p></td><td><p>&nbsp;</p></td><td><p>Intestinal obstruction<sup>d</sup></p></td></tr><tr><td><p><strong>Hepatobiliary disorders </strong></p></td><td style="width:153px"><p>&nbsp;</p></td><td style="width:138px"><p>Cholelithiasis</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="width:153px"><p>&nbsp;</p></td><td style="width:138px"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Angioedema<sup>d</sup></p></td></tr><tr><td><p><strong>General </strong></p><p><strong>disorders and administra&shy;tion site conditions </strong></p></td><td style="width:153px"><p>&nbsp;</p></td><td style="width:138px"><p>Fatigue</p></td><td><p>Injection site reactions</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Investigations</strong></p></td><td style="width:153px"><p>&nbsp;</p></td><td style="width:138px"><p>Increased lipase</p><p>Increased amylase</p><p>Weight decreased</p></td><td>&nbsp;</td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong><u>Hepatobiliary</u></strong></p><p><strong><u>Disorders</u></strong></p></td><td style="width:153px"><p><u>&nbsp;</u></p></td><td style="width:138px"><p><u>Cholelithiasis</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p></td><td><p><u>&nbsp;</u></p></td><td><p><u>&nbsp;</u></p></td><td><p><u>Cholecystitis, cholelithiasis requiring cholecystectomy</u></p></td></tr></tbody></table><p><sup>a) </sup>Hypoglycaemia defined as severe (requiring the assistance of another person) or symptomatic in combination with a blood glucose &lt;3.1&nbsp;mmol/L.</p><p><sup>b) </sup>Diabetic retinopathy complications is a composite of: retinal photocoagulation, treatment with intravitreal agents, vitreous haemorrhage, diabetes-related blindness (uncommon). Frequency based on cardiovascular outcomes trial.</p><p><sup>c) </sup>Grouped term covering also adverse events related to hypersensitivity such as rash and urticaria.</p><p><sup>d)</sup> From post-marketing reports.</p><p>&nbsp;</p><p><em><u>2-year cardiovascular outcomes and safety trial</u></em></p><p>In cardiovascular high risk population the adverse reaction profile was similar to that seen in the other phase&nbsp;3a trials (described in section 5.1).</p><p><em>&nbsp;</em></p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Hypoglycaemia</u></em></p><p>No episodes of severe hypoglycaemia were observed when<em> </em>semaglutide was used as monotherapy. Severe hypoglycaemia was primarily observed when semaglutide was used with a sulfonylurea (1.2% of subjects, 0.03&nbsp;events/patient year) or insulin (1.5% of subjects, 0.02&nbsp;events/patient year). Few episodes (0.1% of subjects, 0.001&nbsp;events/patient year) were observed with semaglutide in combination with oral antidiabetics other than sulfonylureas.</p><p>&nbsp;</p><p>American Diabetes Association (ADA) classified hypoglycaemia occurred in 11.3% (0.3&nbsp;events/patient year) of patients when semaglutide 1&nbsp;mg was added to SGLT2 inhibitor in SUSTAIN 9 compared to 2.0% (0.04 events/patient year) of placebo-treated patients. Severe hypoglycaemia was reported in 0.7% (0.01&nbsp;events/patient year) and 0% of patients, respectively.</p><p>&nbsp;</p><p><u>In a 40-week phase 3b trial in patients receiving semaglutide 1&nbsp;mg and 2&nbsp;mg, the majority of the hypoglycaemic episodes (45 out of 49 episodes) occurred when semaglutide was used in combination with sulfonylurea or insulin. Overall, there was no increased risk of hypoglycaemia with semaglutide 2&nbsp;mg.</u></p><p>&nbsp;</p><p><em><u>Gastrointestinal adverse reactions</u></em></p><p>Nausea occurred in 17.0% and 19.9% of patients when treated with semaglutide 0.5&nbsp;mg and 1&nbsp;mg, respectively, diarrhoea in 12.2% and 13.3% and vomiting in 6.4% and 8.4%. Most events were mild to moderate in severity and of short duration. The events led to treatment discontinuation in 3.9% and 5% of patients. The events were most frequently reported during the first months on treatment.</p><p>Patients with low body weight may experience more gastrointestinal side effects when treated with semaglutide.</p><p>&nbsp;</p><p><u>In a 40-week phase 3b trial in patients receiving semaglutide 1&nbsp;mg and 2&nbsp;mg, nausea occurred in similar proportions of patients when treated with semaglutide 1&nbsp;mg</u> <u>and 2&nbsp;mg, respectively. Diarrhoea and vomiting occurred in higher proportions of patients when treated with semaglutide</u> <u>2&nbsp;mg</u> <u>compared to semaglutide</u> <u>1</u>&nbsp;<u>mg</u>. <u>The gastrointestinal adverse reactions led to treatment discontinuation in similar proportions in the semaglutide 1&nbsp;mg and 2&nbsp;mg treatment groups.</u></p><p>&nbsp;</p><p>In concomitant use with an SGLT2 inhibitor in SUSTAIN 9, constipation and gastro-oesophageal reflux disease occurred in 6.7% and 4% respectively of patients treated with semaglutide 1&nbsp;mg compared to no events for placebo-treated patients. The prevalence of these events did not decrease over time.</p><p>&nbsp;</p><p><em><u>Acute pancreatitis</u></em></p><p>The frequency of adjudication-confirmed acute pancreatitis reported in phase 3a clinical trials was 0.3% for semaglutide and 0.2% for the comparator, respectively. In the 2-year cardiovascular outcomes trial the frequency of acute pancreatitis confirmed by adjudication was 0.5% for semaglutide and 0.6% for placebo (see section 4.4).</p><p><em>&nbsp;</em></p><p><em><u>Diabetic retinopathy complications</u></em></p><p>A 2-year clinical trial investigated 3&nbsp;297&nbsp;patients with type 2 diabetes, with high cardiovascular risk, long duration of diabetes and poorly controlled blood glucose. In this trial, adjudicated events of diabetic retinopathy complications occurred in more patients treated with semaglutide (3.0%) compared to placebo (1.8%). This was observed in insulin-treated patients with known diabetic retinopathy. The treatment difference appeared early and persisted throughout the trial. Systematic evaluation of diabetic retinopathy complication was only performed in the cardiovascular outcomes trial. In clinical trials up to 1&nbsp;year involving 4&nbsp;807&nbsp;patients with type 2 diabetes, adverse events related to diabetic retinopathy were reported in similar proportions of subjects treated with semaglutide (1.7%) and comparators (2.0%).</p><p>&nbsp;</p><p><em><u>Discontinuation due to an adverse event</u></em></p><p>The incidence of discontinuation of treatment due to adverse events was 6.1% and 8.7% for patients treated with semaglutide 0.5&nbsp;mg and 1&nbsp;mg, respectively, versus 1.5% for placebo. The most frequent adverse events leading to discontinuation were gastrointestinal.</p><p>&nbsp;</p><p><em><u>Injection site reactions</u></em></p><p>Injection site reactions (e.g. injection site rash, erythema) have been reported by 0.6% and 0.5% of patients receiving semaglutide 0.5&nbsp;mg and 1&nbsp;mg, respectively. These reactions have usually been mild.</p><p>&nbsp;</p><p><em><u>Immunogenicity</u></em></p><p>Consistent with the potentially immunogenic properties of medicinal products containing proteins or peptides, patients may develop antibodies following treatment with semaglutide. The proportion of patients tested positive for anti-semaglutide antibodies at any time point post-baseline was low (1&minus;<u>3</u>%) and no patients had anti-semaglutide neutralising antibodies or anti-semaglutide antibodies with endogenous GLP‑1 neutralising effect at end-of-trial.</p><p>&nbsp;</p><p><em><u>Heart rate increase</u></em></p><p>Increased heart rate has been observed with GLP-1 receptor agonists. In the phase 3a trials, mean increases of 1 to 6 beats per minute (bpm) from a baseline of 72 to 76 bpm were observed in subjects treated with Ozempic. In a long-term trial in subjects with cardiovascular risk factors, 16% of Ozempic-treated subjects had an increase in heart rate of &gt;10 bpm compared to 11% of subjects on placebo after 2 years of treatment.</p><p>Post marketing Experience:</p><p>The following adverse reactions have been reported during post-approval use of semaglutide, the active ingredient of OZEMPIC. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>Gastrointestinal Disorders: Ileus</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>The National Pharmacovigilance Centre (NPC):<br />Fax: +966-11-205-7662<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdoses of up to 4&nbsp;mg in a single dose, and up to 4&nbsp;mg in a week have been reported in clinical trials. The most commonly reported adverse reaction was nausea. All patients recovered without complications.</p><p>&nbsp;</p><p>There is no specific antidote for overdose with semaglutide. In the event of overdose, appropriate supportive treatment should be initiated according to the patient&rsquo;s clinical signs and symptoms. A prolonged period of observation and treatment for these symptoms may be necessary, taking into account the long half-life of semaglutide of approximately 1&nbsp;week (see section 5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group:<em> </em>Drugs used in diabetes, glucagon-like peptide-1 (GLP‑1) analogues, ATC code: A10BJ06<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c9715cc1-5e1b-4ea1-8262-e69591d65851 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><em>&nbsp;</em></p><p><u>Mechanism of action</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_bd36536f-9a9b-49f7-ac8a-10b054c10de0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span></u><![endif]--></p><p>&nbsp;</p><p>Semaglutide is a GLP‑1 analogue with 94% sequence homology to human GLP‑1. Semaglutide acts as a GLP‑1 receptor agonist that selectively binds to and activates the GLP‑1 receptor, the target for native GLP‑1.<!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:bold;mso-bidi-font-style:
italic'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_2a1b6bef-4070-4bb6-8f86-1797485b8b2a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold;mso-bidi-font-style:italic'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>GLP-1 is a physiological hormone that has multiple actions in glucose and appetite regulation, and in the cardiovascular system. The glucose and appetite effects are specifically mediated via GLP‑1 receptors in the pancreas and the brain.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold;mso-bidi-font-style:italic'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_365f4e9d-27dd-4c43-ad58-bc236cecb87a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold;mso-bidi-font-style:italic'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>Semaglutide reduces blood glucose in a glucose dependent manner by stimulating insulin secretion and lowering glucagon secretion when blood glucose is high. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase. During hypoglycaemia, semaglutide diminishes insulin secretion and does not impair glucagon secretion.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c6935cbe-5b0e-4896-983a-d970038817ee \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>The mechanism of action of semaglutide for chronic kidney disease is likely multifactorial, driven by both direct kidney-specific effects and indirect effects via cardio-kidney risk factors (including improvements in glucose metabolism, anti-inflammatory effects, reductions in systolic blood pressure, improvements in lipid profile and weight loss). The effect on chronic kidney disease was not completely explained by effects on cardio-kidney risk factors and therefore may also be explained by direct effects of semaglutide.</p><p>&nbsp;</p><p>Semaglutide reduces body weight and body fat mass through lowered energy intake, involving an overall reduced appetite. In addition, semaglutide reduces the preference for high fat foods.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c53e6af8-54c0-4dbd-91c2-c41c98e4778d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>GLP‑1 receptors are also expressed in the heart, vasculature, immune system and kidneys.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold;mso-bidi-font-style:italic'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_29c0733a-210d-4454-9104-ae86407cc575 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold;mso-bidi-font-style:italic'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Semaglutide had a beneficial effect on plasma lipids, lowered systolic blood pressure and reduced inflammation in clinical studies. In animal studies, semaglutide attenuates the development of atherosclerosis by preventing aortic plaque progression and reducing inflammation in the plaque.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_723b8346-b982-4689-98ce-a15ed867bb66 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>All pharmacodynamic evaluations were performed after 12&nbsp;weeks of treatment (including dose escalation) at steady state with semaglutide 1&nbsp;mg once weekly.</p><p><u>&nbsp;</u></p><p><em><u>Fasting and postprandial glucose</u></em></p><p>Semaglutide reduces fasting and postprandial glucose concentrations. In patients with type 2 diabetes, treatment with semaglutide 1&nbsp;mg resulted in reductions in glucose in terms of absolute change from baseline (mmol/L) and relative reduction compared to placebo (%) for fasting glucose (1.6&nbsp;mmol/L; 22% reduction), 2&nbsp;hour postprandial glucose (4.1&nbsp;mmol/L; 37% reduction), mean 24&nbsp;hour glucose concentration (1.7&nbsp;mmol/L; 22% reduction) and postprandial glucose excursions over 3 meals (0.6‑1.1&nbsp;mmol/L) compared with placebo. Semaglutide lowered fasting glucose after the first dose.</p><p>&nbsp;</p><p><em><u>Beta-cell function and insulin secretion</u></em></p><p>Semaglutide improves beta-cell function. Compared to placebo, semaglutide improved first- and second-phase insulin response with a 3&ndash; and 2&ndash;fold increase, respectively, and increased maximal beta-cell secretory capacity in patients with type 2 diabetes. In addition, semaglutide treatment increased fasting insulin concentrations compared to placebo.</p><p><em>&nbsp;</em></p><p><em><u>Glucagon secretion</u></em></p><p>Semaglutide lowers the fasting and postprandial glucagon concentrations. In patients with type 2 diabetes, semaglutide resulted in the following relative reductions in glucagon compared to placebo: fasting glucagon (8&ndash;21%), postprandial glucagon response (14&ndash;15%) and mean 24&nbsp;hour glucagon concentration (12%).</p><p>&nbsp;</p><p><em><u>Glucose dependent insulin and glucagon secretion</u></em></p><p>Semaglutide lowered high blood glucose concentrations by stimulating insulin secretion and lowering glucagon secretion in a glucose dependent manner. With semaglutide, the insulin secretion rate in patients with type 2&nbsp;diabetes was comparable to that of healthy subjects.</p><p>&nbsp;</p><p>During induced hypoglycaemia, semaglutide compared to placebo did not alter the counter regulatory responses of increased glucagon and did not impair the decrease of C‑peptide in patients with type 2‑diabetes.</p><p><em>&nbsp;</em></p><p><em><u>Gastric emptying</u></em></p><p>Semaglutide caused a minor delay of early postprandial gastric emptying, thereby reducing the rate at which glucose appears in the circulation postprandially.</p><p>&nbsp;</p><p><em><u>Appetite, energy intake and food choice</u></em></p><p>Semaglutide compared to placebo lowered the energy intake of 3&nbsp;consecutive <em>ad libitum</em> meals by 18‑35%. This was supported by a semaglutide-induced suppression of appetite in the fasting state as well as postprandially, improved control of eating, less food cravings and a relative lower preference for high fat food.</p><p>&nbsp;</p><p><em><u>Fasting and postprandial lipids</u></em></p><p>Semaglutide compared to placebo lowered fasting triglyceride and very low density lipoproteins (VLDL) cholesterol concentrations by 12% and 21%, respectively. The postprandial triglyceride and VLDL cholesterol response to a high fat meal was reduced by &gt;40%.</p><p>&nbsp;</p><p><em><u>Cardiac electrophysiology (QTc)</u></em></p><p>The effect of semaglutide on cardiac repolarization was tested in a thorough QTc trial. Semaglutide did not prolong QTc intervals at dose levels up to 1.5&nbsp;mg at steady state.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p>Both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.</p><p><u>&nbsp;</u></p><p>The efficacy and safety of semaglutide 0.5&nbsp;mg and 1&nbsp;mg once weekly were evaluated in six randomised controlled phase 3a trials that included 7&nbsp;215&nbsp;patients with type 2&nbsp;diabetes mellitus (4&nbsp;107&nbsp;treated with semaglutide). Five trials (SUSTAIN 1&ndash;5) had the glycaemic efficacy assessment as the primary objective, while one trial (SUSTAIN 6) had cardiovascular outcome as the primary objective.</p><p>&nbsp;</p><p><u>The efficacy and safety of</u> <u>semaglutide 2&nbsp;mg once weekly was evaluated in a phase 3b trial (SUSTAIN FORTE) including 961&nbsp;patients. </u></p><p>&nbsp;</p><p>In addition, a phase 3b trial (SUSTAIN 7) including 1&nbsp;201&nbsp;patients was conducted to compare the efficacy and safety of semaglutide 0.5&nbsp;mg and 1&nbsp;mg once weekly to dulaglutide 0.75&nbsp;mg and 1.5&nbsp;mg once weekly, respectively. A phase 3b trial (SUSTAIN 9), was conducted to investigate the efficacy and safety of semaglutide as add-on to SGLT2 inhibitor treatment.</p><p>&nbsp;</p><p>Treatment with semaglutide demonstrated sustained, statistically superior and clinically meaningful reductions in HbA<sub>1c</sub> and body weight for up to 2&nbsp;years compared to placebo and active control treatment (sitagliptin, insulin glargine, exenatide ER and dulaglutide).</p><p><strong>&nbsp;</strong></p><p>The efficacy of semaglutide was not impacted by age, gender, race, ethnicity, BMI at baseline, body weight (kg) at baseline, diabetes duration and level of renal function impairment.</p><p>&nbsp;</p><p><u>Results target the on-treatment period in all randomised subjects (analyses based on mixed models for repeated measurements or multiple imputation).</u></p><p><u>&nbsp;</u></p><p>Detailed information is provided below.</p><p><strong>&nbsp;</strong></p><p><em><u>SUSTAIN 1 &ndash; Monotherapy </u></em></p><p>In a 30-week double-blind placebo-controlled trial, 388&nbsp;patients inadequately controlled with diet and exercise, were randomised to semaglutide 0.5&nbsp;mg or semaglutide 1&nbsp;mg once weekly or placebo.</p><p>&nbsp;</p><p><strong>Table 2 SUSTAIN 1: Results at week 30</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td style="width:102px"><p><strong>Semaglutide</strong></p><p><strong>0.5&nbsp;mg</strong></p></td><td style="width:103px"><p><strong>Semaglutide</strong></p><p><strong>1&nbsp;mg</strong></p></td><td><p><strong>Placebo</strong></p></td></tr><tr><td><p>Intent-to-Treat (ITT) Population (N)</p></td><td style="width:102px"><p>128</p></td><td style="width:103px"><p>130</p></td><td><p>129</p></td></tr><tr><td><p><strong>HbA<sub>1c</sub> (%)</strong></p></td><td style="width:102px"><p>&nbsp;</p></td><td style="width:103px"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td style="width:102px"><p>8.1</p></td><td style="width:103px"><p>8.1</p></td><td><p>8.0</p></td></tr><tr><td><p>Change from baseline at week 30</p></td><td style="width:102px"><p>-1.5</p></td><td style="width:103px"><p>-1.6</p></td><td><p>0</p></td></tr><tr><td><p>Difference from placebo [95% CI]</p></td><td style="width:102px"><p>-1.4 [-1.7, -1.1]<sup>a</sup></p></td><td style="width:103px"><p>-1.5 [-1.8, -1.2]<sup>a</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA<sub>1c</sub> &lt;7%</strong></p></td><td style="width:102px"><p>74</p></td><td style="width:103px"><p>72</p></td><td><p>25</p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p></td><td style="width:102px"><p>&nbsp;</p></td><td style="width:103px"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td style="width:102px"><p>9.7</p></td><td style="width:103px"><p>9.9</p></td><td><p>9.7</p></td></tr><tr><td><p>Change from baseline at week 30</p></td><td style="width:102px"><p>-2.5</p></td><td style="width:103px"><p>-2.3</p></td><td><p>-0.6</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td style="width:102px"><p>&nbsp;</p></td><td style="width:103px"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td style="width:102px"><p>89.8</p></td><td style="width:103px"><p>96.9</p></td><td><p>89.1</p></td></tr><tr><td><p>Change from baseline at week 30</p></td><td style="width:102px"><p>-3.7</p></td><td style="width:103px"><p>-4.5</p></td><td><p>-1.0</p></td></tr><tr><td><p>Difference from placebo<sup> </sup>[95% CI]</p></td><td style="width:102px"><p>-2.7 [-3.9, -1.6]<sup>a</sup></p></td><td style="width:103px"><p>-3.6 [-4.7, -2.4]<sup>a</sup></p></td><td><p>-</p></td></tr></tbody></table><p><sup>a</sup>p &lt;0.0001 (2-sided) for superiority</p><p>&nbsp;</p><p><em><u>SUSTAIN 2 &ndash; </u></em><em><u>Semaglutide</u></em><em> <u>vs. sitagliptin both in combination with 1&ndash;2 oral antidiabetic </u></em><em><u>medicinal products</u></em><em><u> (metformin and/or thiazolidinediones)</u></em></p><p>In a 56-week active-controlled double-blind trial, 1&nbsp;231&nbsp;patients were randomised to <u>semaglutide</u> 0.5&nbsp;mg once weekly, <u>semaglutide</u> 1&nbsp;mg once weekly or sitagliptin 100&nbsp;mg once daily, all in combination with metformin (94%) and/or thiazolidinediones (6%).</p><p>&nbsp;</p><p><strong>Table 3 SUSTAIN 2: Results at week 56 </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Semaglutide</strong></p><p><strong>0.5&nbsp;mg</strong></p></td><td><p><strong>Semaglutide</strong></p><p><strong>1&nbsp;mg</strong></p></td><td><p><strong>Sitagliptin</strong></p><p><strong>100&nbsp;mg</strong></p></td></tr><tr><td><p>Intent-to-Treat (ITT) Population (N)</p></td><td><p>409</p></td><td><p>409</p></td><td><p>407</p></td></tr><tr><td><p><strong>HbA<sub>1c</sub> (%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>8.0</p></td><td><p>8.0</p></td><td><p>8.2</p></td></tr><tr><td><p>Change from baseline at week 56</p></td><td><p>-1.3</p></td><td><p>-1.6</p></td><td><p>-0.5</p></td></tr><tr><td><p>Difference from sitagliptin [95% CI]</p></td><td><p>-0.8 [-0.9, -0.6]<sup>a</sup></p></td><td><p>-1.1 [-1.2, -0.9]<sup>a</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA<sub>1c</sub> &lt;7%</strong></p></td><td><p>69</p></td><td><p>78</p></td><td><p>36</p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>9.3</p></td><td><p>9.3</p></td><td><p>9.6</p></td></tr><tr><td><p>Change from baseline at week 56</p></td><td><p>-2.1</p></td><td><p>-2.6</p></td><td><p>-1.1</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>89.9</p></td><td><p>89.2</p></td><td><p>89.3</p></td></tr><tr><td><p>Change from baseline at week 56</p></td><td><p>-4.3</p></td><td><p>-6.1</p></td><td><p>-1.9</p></td></tr><tr><td><p>Difference from sitagliptin<sup> </sup>[95% CI]</p></td><td><p>-2.3 [-3.1, -1.6]<sup>a</sup></p></td><td><p>-4.2 [-4.9, -3.5]<sup>a</sup></p></td><td><p>-</p></td></tr></tbody></table><p><sup>a</sup>p &lt;0.0001 (2-sided) for superiority</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><img alt="" width="349" height="233" src="data:image/png;base64,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" /><br /><!--[if gte mso 9]><xml>
   <o:OLEObject Type="Embed" ProgID="Word.Document.12" ShapeID="_x0000_i1025"
    DrawAspect="Content" ObjectID="_1669471193">
    <o:WordFieldCodes>\s</o:WordFieldCodes>
   </o:OLEObject>
  </xml><![endif]--></strong></p><p>&nbsp;</p></td><td><p><br /><strong><!--[if gte mso 9]><xml>
   <o:OLEObject Type="Embed" ProgID="Word.Document.12" ShapeID="_x0000_i1026"
    DrawAspect="Content" ObjectID="_1669471194">
    <o:WordFieldCodes>\s</o:WordFieldCodes>
   </o:OLEObject>
  </xml><![endif]--></strong></p><p>&nbsp;</p></td></tr></tbody></table><p><strong>Figure 1 Mean change in HbA<sub>1c</sub> (%) and body weight (kg) from baseline to week 56</strong></p><p><strong>&nbsp;</strong></p><p><em><u>SUSTAIN 7 &ndash; </u></em><em>Semaglutide</em><em><u> vs. dulaglutide both in combination with metformin </u></em></p><p>In a 40-week, open-label trial, 1&nbsp;201&nbsp;patients on metformin were randomised 1:1:1:1 to once weekly <u>semaglutide</u> 0.5&nbsp;mg, dulaglutide 0.75&nbsp;mg, <u>semaglutide</u> 1&nbsp;mg or dulaglutide 1.5&nbsp;mg, respectively .</p><p>The trial compared 0.5&nbsp;mg of <u>semaglutide</u> to 0.75&nbsp;mg of dulaglutide and 1&nbsp;mg of <u>semaglutide</u> to 1.5&nbsp;mg of dulaglutide.</p><p>&nbsp;</p><p>Gastrointestinal disorders were the most frequent adverse events, and occurred in similar proportion of patients receiving <u>semaglutide</u> 0.5&nbsp;mg (129 patients [43%]), <u>semaglutide</u> 1&nbsp;mg (133 [44%]), and dulaglutide 1.5&nbsp;mg (143 [48%]); fewer patients had gastrointestinal disorders with dulaglutide 0.75&nbsp;mg (100 [33%]).</p><p>At week 40, the increase in pulse rate for <u>semaglutide</u> (0.5&nbsp;mg and 1&nbsp;mg) and dulaglutide (0.75&nbsp;mg and 1.5&nbsp;mg) was 2.4, 4.0, and 1.6, 2.1, beats/min, respectively.</p><p>&nbsp;</p><p><strong>Table 4 SUSTAIN 7: Results at week 40</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Semaglutide</strong></p><p><strong>0.5&nbsp;mg</strong></p></td><td><p><strong>Semaglutide</strong></p><p><strong>1&nbsp;mg</strong></p></td><td><p><strong>Dulaglutide</strong></p><p><strong>0.75&nbsp;mg</strong></p></td><td><p><strong>Dulaglutide</strong></p><p><strong>1.5&nbsp;mg</strong></p></td></tr><tr><td><p>Intent-to-Treat (ITT)</p><p>Population(N)</p></td><td><p>301</p></td><td><p>300</p></td><td><p>299</p></td><td><p>299</p></td></tr><tr><td><p><strong>HbA<sub>1c</sub> (%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>8.3</p></td><td><p>8.2</p></td><td><p>8.2</p></td><td><p>8.2</p></td></tr><tr><td><p>Change from baseline at week 40</p></td><td><p>-1.5</p></td><td><p>-1.8</p></td><td><p>-1.1</p></td><td><p>-1.4</p></td></tr><tr><td><p>Difference from dulaglutide</p><p>[95% CI]</p></td><td><p>-0.4<sup>b</sup></p><p>[-0.6, -0.2]<sup>a</sup></p></td><td><p>-0.4<sup>c</sup></p><p>[-0.6, -0.3]<sup>a</sup></p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA<sub>1c</sub> &lt;7%</strong></p></td><td><p>68</p></td><td><p>79</p></td><td><p>52</p></td><td><p>67</p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>9.8</p></td><td><p>9.8</p></td><td><p>9.7</p></td><td><p>9.6</p></td></tr><tr><td><p>Change from baseline at week 40</p></td><td><p>-2.2</p></td><td><p>-2.8</p></td><td><p>-1.9</p></td><td><p>-2.2</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>96.4</p></td><td><p>95.5</p></td><td><p>95.6</p></td><td><p>93.4</p></td></tr><tr><td><p>Change from baseline at week 40</p></td><td><p>-4.6</p></td><td><p>-6.5</p></td><td><p>-2.3</p></td><td><p>-3.0</p></td></tr><tr><td><p>Difference from dulaglutide</p><p>[95% CI]</p></td><td><p>-2.3<sup>b</sup></p><p>&nbsp;[-3.0, -1.5]<sup>a</sup></p></td><td><p>-3.6<sup>c</sup></p><p>&nbsp;[-4.3, -2.8]<sup>a</sup></p></td><td><p>-</p></td><td><p>-</p></td></tr></tbody></table><p><sup>a</sup>p &lt;0.0001 (2-sided) for superiority</p><p><sup>b </sup><u>semaglutide</u> 0.5&nbsp;mg vs dulaglutide 0.75&nbsp;mg</p><p><sup>c</sup> <u>semaglutide</u> 1&nbsp;mg vs dulaglutide 1.5&nbsp;mg</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p><p><br /><strong><!--[if gte mso 9]><xml>
   <o:OLEObject Type="Embed" ProgID="Word.Document.12" ShapeID="_x0000_i1027"
    DrawAspect="Content" ObjectID="_1669471195">
    <o:WordFieldCodes>\s</o:WordFieldCodes>
   </o:OLEObject>
  </xml><![endif]--></strong></p></td><td><p><strong>&nbsp;</strong></p><p><br /><strong><!--[if gte mso 9]><xml>
   <o:OLEObject Type="Embed" ProgID="Word.Document.12" ShapeID="_x0000_i1028"
    DrawAspect="Content" ObjectID="_1669471196">
    <o:WordFieldCodes>\s</o:WordFieldCodes>
   </o:OLEObject>
  </xml><![endif]--></strong></p></td></tr></tbody></table><p><img alt="" width="624" height="243" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAnAAAADzCAYAAAAGqCv8AAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAFiUAABYlAUlSJPAAAHjjSURBVHhe7d159HRVded/slyxO52kV6+e0v/ZodMdk07/VhuHpU8wthMGFJWAgTAICj4OERUHcEIxKqCgfjXaEIFWEEVB4oA+ikOrUaM4hWjU6ONsa+I8xBiHxPur16k6Vafu91Z9ax73m3V5vjXcW3fc53P23mefQ6oOR93nvp2/quprX/96deoDT6s+/OGPpNeXXnpp+jcIgiAIgiBYPocQboMWIg4h4IIgCIIgCFaH8MAFQRAEQRCsGY0CDkRcJgRcEARBEATB6pAE3Kc+/ekk4ErRVhICLgiCIAiCYHU4hHgTLs05b00iLgRcEARBEATB6pA8cHLdypy3OiHggiAIgiAIVoduDtwwQsAFQRAEQRCsDocQZ6MsQRAEQRAEwWowkgfuT/7kT9JS/h2v43W8jtfxOl7H63gdr+fzei9GFnBBEATrRNitIAg2mZEEXBAEwboRAi4IgnUkPHBBEGw1YbeCIFhHQsAFQRAEQRCsGSHggiDYasJuBUGwyUQOXBAEG0kIuCAI1pHwwAVBsNWE3QqCYB0JARcEQRAEQbBmhIALgmCrCbsVBMEmEzlwQRBsJCHggiBYR8IDFwTBVhN2KwiCdSQEXBAEQRAEwZoRAi4Igq0m7FYQBJtM5MAFQbCRhIALgmAdCQ9cEARbTditIAjWkRBwQRAEQRAEa0YIuCAItpqwW0EQbDKRAxcEwUYSAi4IgnUkPHBBEGw1YbeCIFhHQsC1+NnPftb5KwiCRRPPXxAEwfiEgAuCYKksW8CF3QqCYJOJHLggCDaSTRBwP/7xj6uvfOUr1Ze//OVYYollAcuXvvSl6gc/+EHnCVwOW++Bu+SSS6onPelJ1R//8R9XT3va02KJJZYFLp67s846q3rb297WeSIXz7Ls1g9/+MPqPe95T/W1r32t805V/cM//EN679Of/nTnnR4f/OAHq8985jOdV/1cc8011YMf/ODqmc98ZvX0pz89llhimePyjGc8o3rMYx6T/l0mWy/gHvvYx1bve9/7qs9//vPV5z73uVhiiWWBi+fuqquuqv73//7fnSdyO/jHf/zHJFyf8IQnVI9//OOT9+w73/lO9chHPjI1EARZyZ/+6Z9WD3/4w6v9+/dXN954Y+fdHi94wQuqt771rSkcHUssscx/+epXv5qe32Wy9QKOsfzmN7/ZeRUEwaL5i7/4i+r//J//03m1eJZht3jTeMzw+te/vnrZy15WveIVr6he9KIXVX//93+f3s98+9vfrk4//fQUJn3nO9+ZhF+dF7/4xdX//b//t/MqCIJ5w3P+lKc8pfNqtdnIHDgqWgjnb//2bzvvBEGwKDx/+PM///OtE3A8bieccEJ13XXXJa/bs571rNQYnHzyySk0c+mll3a+WVUf+9jHqkc84hHp709+8pPVH/3RH6W/2a3nPve51UUXXVQdc8wxKfQaBMFi+Lu/+7ulC7it98DJwwkBFwTL413veld1+eWXd14tnmXZrb/5m7+prrzyypSDy/v26Ec/unrpS19a/dM//VN10kknVV/4whfS94Sas2izzqMe9aj0t3y5v/zLv6xuuumm6olPfGI6j0EQLIYQcAsg9/IHER64IFguy/bALYN//ud/TiGYz372s9XDHvawNGjhVa96VUrpEF499dRTqxufcdtq/4EqCbozzjijestb3lLt7OykMGsdHru3v/3tnVdBEMybEHBTkpMJpyEEXBAsl20MoRJwvI5PfvKTuyNwDWy4+OKLUwi1Hg4l8DQWQqb1HDkYBBI5cEGwOFZBwI3KyubAZQEnlPC6170uJfzW8Z2//uu/TsP264SAC4Llso0CbtaEgAuCxRIeuBnxpje9KeWIGGr/0Ic+dFcP9c/+7M+q//yf/3P10Y9+tPNOjxBwQbBcQsBNTwi4IFgsIeBmxNVXX12dd955aWSX0VqlgFMi5CEPeUj1oAc9qPrIRz7SebeHQnwh4IJgeWxjDtysCQEXBIslBNyM+O53v1vd5z73qX7nd36nevazn915tw1hJ7nXv9kDp+6U3JOnPvWp1Yknnlh94xvfSO8HQbB4wgM3PSHggmCxRA7cjHj+85+fCmGqjHzve9+7uuGJt0qjtwy5/93f/d1U5PKoo46qnvOc51Q/+clPkuAz+svwfFXQXYggCJZDCLjpCQEXBIslPHAzgjAz/P6v/uqvqiOPPLI6ePBget+Ahne/+93JA3f00UenRuKnP/1p+iwTIdQgWC4h4KYnBFwQLJYQcDPiBz/4QXXZZZclETeoFpL5Ts01WCcGMQTBcokcuOkJARcEiyUE3AKIQr5BsNqEB256RhFw09bMDIKgxyABV3/OPvOZz6SBlk259opz33DDDZ1X83tGVzoHbhpCwAXBcgkBNz0E3ChTaWkg1MM0DZdiwkEQTIaZVAyEHMbnP//5VAHDXMdKnYkWZkyjZ/o8hbtNoTcJG++B24sQcEGwXELATQ8B9/rXvz5Nu5Uxs8P3v//9vl79m9/85pRqcv7556dcYZ8Z1GVwV4bAq6/nte1l5BJbr8wp9rkSTuV63/ve9/oKqOdBZOV6Pi9LP1nfeuXv/fjHP07rlcc36XrEa9mQ5nPwox/9qPNOez3bKkVufT2fWc93M7ZRX8861s00rWefm9Yrz51jsF55rfxe/Vo5J+V+Wk/60CjrlfvpGlmvfo3L9fzrdbmfg9arX6v6evbPeqNc4/p69Wvs8/q1GnRvlOfc8Ze/l9cr7w2/Z98NmnzCE56QtmEpv5Mx24pnE4973OO6nSzbUN7s61//eip1dvrpp/fdD6OyUQKuvBlHZRIBN8nvBEHQTOTATY+R9sccc0yacSZD0BFqZaPMG3D44Yen8knKKQkDnX322dUnPvGJzjeq6tWvfnUqx1Q2SF6/8Y1v7Lyqqk996lNpPVN8ZRRUzyP9ofEjFm0vY/+spwJAxgw6KgnkhtT6PBv2P6OGp8byy1/+cued9n6aFzbbY43zk570pCRSMzfeeGOa6L+08a94xStS0feMhl41gjIEbSozpabKsBePSXmfarQ1yuW0Z+94xztSWK3Mt9aIq5KQ0WDzunzgAx/ovFOlMNrTnva0JAwyl1xySZofN+NanXnmmdVNN93UeadKg/SUyCqv8Qtf+MK+/XTOHvWoR1Uf//jHO+9U6Vh5hfI1du7Ns1vup2tkvfIaO7cXXXRR9xoTaV6X++n71uN9yriWtp+vsd+94IILUpH9jP2z3v/7f/+v805VXXfddX1z/zpOAw+vv/76zjvtWZicF+cn88pXvrLvGjuvzm8ZrnRvuA6uR+blL3952s8sBg2EdD1d14zBknSDe/m+971vunfcB+9973s73+hx4YUXpvAp3OPZ02a7D37wg5PQdC78Xe7HqGykB24cgbWXgLOtEGxBMD9GEXB6p294wxuS8azzpS99qXrNa15Tfetb3+q8M54NWJbdOnDgQAqhEAYaNg0m0fDMZz6zr0GEkkgaCUKqbKwzevkap9xAQiOUG9oM0aYhIexyY6YRblqvPIdelx4O369/x+el1wW+U75XrpfXzevN4vfcJ4PWy+taZ5Lfy+tlfFb/PX/v9Xt5Pb+RKdfLWKfcdrle/l7eT+T3Bu1n0++VDFsvb7tcL7/ndbmfvm+9/Dl8Xm4bg9ar/15eb5rf89mw9fK6TefAer6b8bf3eOA8r/4uv1Puh+cyizadmdwJ0tnggePtI+IIuKbnelasZA5ceaJQnuSSJtdmJkKoQbBcRhFwRI1nlaF7//vf33m3SrOvnHbaackL8PCHP7wv/DEqyxBwvBOnnnpqEqS8VoTVO9/5zhRKkfRcepo0OvJnsveDh6UOb82wQQx1W8l7xDvgNzO+U//eLNlr27P+7W3/vWB0JjmXPH6DcuDy9niOTe/JY8hOCZke3NmX6tR6lp/3vOelDhVv6CRshAeOEece5Q695ppr+lT2tddem3qu1G/p1s54XzLiXggPXHrppcltP0wQBkEwHkIPvFCD8HwK/YHgOOecc9Lf8LwzgHjsYx/bJ+5GZRl2S9iHgMMVV1yRwjZEnELkwlhlKE3RceIUQp1nnHFG+pudI8R8lwgswzyjwKsnnFmGAFeFRYuT+L3Zsum/h0GjUDN5n972trelcHEZ+obOpjCvzlf5vI/DRgg4bkohAQLt2GOPTfHljJ4uI0fhljHxjLlTDeXNMKJ6+6XYkzNxj3vcI8Xnxbvlf9ie2nIZhlWuRRmHF/Ih+rJnkKv0uc99bgqdZL74xS8m8Vl6AblZGfQyUVOv235k8nqf/OQnO++0G0L5EOW+awzK9cTZnaty3+Ue1I/5qquuSvuexbB90UgQshm/LeekPOamfZfDUB7zF77whbTvGpCMRqS+nvup3Hf5KPV9b7peed/zeW9aL65Xm1W4XnqiCm37DV6h8jPoxeqcwXXzzGb0YHM+zMUXX5wE3Tog5CIcSnSecsop6Vox4pKc3XNsje9Ark0+ZtcwCzi5QhoQYZwjjjiiMQdnL9wfPAOTrBsE28xeAm4RbISAI6j0ZvUmGb8mNa5x0EDDnKiMPUF38skn9yVbEntel3FwF8qx8dblxkeD7LsZibBCH6V3TgPGO5j3hzCwnkY5vycWLvfFevk9n8vrKUPCQir2o75eGTfP+54NP8TpywbbZ1nUZux7/ZitV+47YZD3PZOPWR5BZtC+l+vlfS9HCdmfQcecse/ERLnv+Zjzvttf4qrcd/tXXy+uV5tlXy94LnWIvG+fy/MB72fRIuSoE5WRX0K8gljMhbzzeRiFZdktuB/YFTl8GULOIAOj34RbTr3mO8kD6boJN0vmh2N0Hp0vxzBJIV/Xj2jm+ZPUHQTBaLB1yxZwo7KSOXCZD3/4w9UjH/nI6qyzzqoe9rCH7erBv/a1r009+NwwaFTkk/C8aRg03HvB0Ilf807UQxX1xsLrcRqQYazadjDLbTWx6O17PavfXLXtYJbbamLS7ef1ePOEEevkz4lRIUQj2RjMP3nAr6ccEvBOETdCqzpxpYAclWUIOMdEeBJvBGkW5byRvG9GLpZ4zYbJhWsKE+uQDpqFZi9ELHgB73rXuyZbGgTB3qyCgBvVdq20B04YwlB0CHUKuUADIAdOEiEvQhM8auMMYhC+8nu8Hdir8Zq0cStp2sag7c7i9/Zimt+w7ijrL+I4mpjF7zZtY9B2F3Gc0/yGdUdZf5rfKAcxlNsp/yZueIrkytU9dDpjnuNJPUjLsFuO7WMf+1gKL2dvJBEnhCpM3IS8OflwTUgjmcQDl7Evd7/73aujjjoqRTSCIBjO0gTcgf3VIYfsq3YOHlhvAZcNvB680WnCpDxxf3nB7VIPXZKgye0JOCPYyly3zLijUHniHKf1SqZpwIJgm4k6cNMzrYCDfDi5dKISQu1BEAxmOQLuQLWfuDmw0xJwG+KBg/Amz1uZW0NsCQ/I1VF1vMzryUxSRkQy9wMe8IC+IoQh4IJgMpYt4JZpt2bFLAScKIWcQgPBNExsZhAEzSxHwB2sdnZ6Am5UVjYHrkk4jSOmJhFwhKERf/e5z31SaCcIgskJATc9sxBwMBBFWYN73eteKZ84PHFB0MxyQ6iHpGVjPHBZtI0j3nx3EgEHXrj9+/en0G0QBJMTAm56ZiXg8MEPfjCJuN/93d9NJUrK8jFBELRZloA7sL8t3jZGwE0i3jKTCjijyIQb7na3u+0qQjrJfgTBtjKJgBv0jG3rszdLAadciXxhUQb2zbUxyCEIgh5LzYHrsDEeuL0YZNjHFXDldowWU5PJQIlydJjvbGtDEgTjMkjA5eeo6Vmqv69DNSnhgduNxsnoXgWpFX9W2Nko2CAI2izLA3dwZ6cl48ZjZXPgmmgy+IOYxAOXt6+cgfpMJqQ2+jUIgvEZxQNnBoczzzyzesYzntE336kBSmqp+SxPzj4uIeCaIdhcGzNGOEdvfetbUyHlIAjGE3BsVlMnUw69Iumjc6Da3wmfbkwI1aAC841x+avkXmJklel91InzvTqThlAzjJwphR74wAemaZCCIBgPIuHlL39559VuhPRM90Q8mGnFc57JM0Iwgscff/yuIt6jEAKuGR1VoVQz16h9aU5pXrkYnRoEows4tWjVWFQpo4RmechDHpIWnaNRObB/f9cDtxECzglSvZxIU1HcFDQZvUfT9Kh2nqfcKdGjn0bAaVxsV+2kW97ylmkUVxAEo6OOo+fHPKamlCqn7MKnP/3p9HyDmODxRulp15M1oGhQwe5NZx4CDjwH7KqOsRpxam2a8SEGNgTbDt3A+z8MTiMOpHve856po5nJs8tIw1I4m4ibJA1kIwScKXbOPffc7jyJ2Yj71zQ7Qp0MfJ5P8Vvf+laagseiZ0lJT8NNN91UvfjFL65ue9vbVve73/067wZBMAoEHGN29dVXp9qKWcAJib7qVa9KBWZ5f8DgCZeWmFCfeHv3u9/deWc8VsUDN07qR515CTjI7+V5M3n+He5whzQ1oanLQsQF24y6suyOZ8NSRv/qzzLtUebJixyYYMBcyHSKihZq1jYjbJq9bv0h1FFZ6Rw4J/Loo4+u7njHOyaPWg6Vmu7K3IGULdHmhBFzH/rQh9L3TH59//vff6S5UIdhYvNXv/rV1XnnnVfd+ta3HhoOCoKgHyFU4q3OJz/5yTQ3p7mL82Tub3zjG6sLLrig8432JP6MYzkZ/LisioAbxCjCbp4CDq6RjqrFnLPsKSE3aNqvINh0pGuceOKJaaAPG5LzQ3VsTO0nogDPL+1R5rrxbPO6EW/smr/LyOEwNi6E6mQRUMSZApR5yLueOcNPwOk9MvR1NyUX6DQh1IxcOI2Q0Vq8CZEnEgSjMcogBp/zlnu23vqkW3Unsxee2LdvX+qMmSt1nXLgiB85fXXPodwYQqnEcb3oRS+qrrvuusZc3nkLOHaTdzQLt7POOit5D3gehLU1TvUcnyDYZOgGOfR1PJ+cOnnOZq91enJR7IM7+6r9b/xZqmCh4ylFQeRwEg/8Rgi4P/3TP63OPvvsZEzufe97V+96ym93DTzD/rznPa8655xzqiuuuKL9ZsG0gxgyLhjjev3116f9cEHKab2mCY8EwSYzioCDXLj6dHhEhBQI4QlpEtlorjr22cAn+buK5X7gAx9I7/M6/vf//t9TSkgJY6+nTzgJK9dReFdu2jxx7vNvs7kGllx22WVp3x7zmMd0jyEItoFRBzFo+9m3r33ta5132ogseHZoheEzOvWHTctlIwRc7h0+//nP31WrSD6NQrs8dHXvG2Yh4LI4MxfrG97whpS7c+c73zkZuSAIhrOXgGvq/AzrEI3bWZqZ3SqmuMlLUXOzD2Inz+Iih5f3EMScgQIGXmWkggjBQJgmD+jQQeQR452z/jve8Y70/jwR3dBBhZkaHKO0Eb8vvP3xj398bUR0EEzDqAKuZFzblDmws1NNE9NbyRy4SU9GyTQCLv9+/lfIljEm4EwIfYtb3CLmEgyCPRjVAzcOw2yDEEYWV6almV7AdXrIDWqtPe1NL2clo2OpdqQUjpNPPjmVIhJOsS9q3pWj24i2PACLh05eL6SFaEBEFxQTf+9735venzdKixgAxnbe/OY3r375l385daCFUIV/HceNN964azRxEGwSkwi4WbP2HrhpRdysQqgZxldOi3y4//k//2cK6TZ5/oIgaDMPATeYAy2x1OrLHtjf8Y4dnNJuHax29u0WaP20BN6+nc7fPeTGyIPjbTPwiTAz2pa3zRRW7zn31mkfNRSSnEHMCVdmbMMivDrvEGpGuohcX+ki/+E//IckhsvafLyCbCBR9653vWtX2DsINoGlCbjk6d9X7Rw8sP4CblpmLeD0OiUlCpFolOSsRCg1CAYzTMAN6qDVvd8le3XqsgcuL7OkHupo/xZj23mjg/CnUhyEm1Aqb5ocGXl+xNjpp5+ePPoZHjlCTwkVXv46F1988VwHMdRhM80FTaARc0Tn+973vs6nbeQnGkXMI8dr11Qjc9oOeBAsi+UIuFZnMIUOdpJNCQE3YwEHXjghBNWVv//976fwh5BDSRiuIGgziYDDJOKtiVnarXbINIdNeeeIt9a/+/s9cLxmhM9LXvKSlONWokZUPalZx/CVr3xlClE2Me9RqE188IMf7A5c4EkUxm0q5yICoVgpj508OSP0w/4F685yBFzLluz0BNyorGQO3CyYh4DLXjilAPRKDbN/2MMeluq9BEHQzyghVDWSiJ1BYUK5YQTFKPREVnuZnYDr9I5xcKfa3zK0ObyqdtM8WYaAI8KUFHHuYYDD7/3e7+3yxJUodipHmNATDt7WmTOC9We5IdTxbNdKe+D0WIUgFPXk8ar37hgNJ7uJeQg4SCgm4HjhGKvDDjussYxJEGw7BNywZ8PzbKi90KI6cNkLlZ9zz7+cMWU59qYQWR3mJeB2DuT8uPa/82QZAg6EtVp88t7A5t33vvfdc5YG9lgIWZ6ciIVrGATrxNIEXMFGCDjD2p1Ii9pEZUVjU1w96UlPSkPv5WHUmZeA44XTO1XrRe0kU2WY0DYqlwdBPwScWo1CiZ7F+qAfHbNcRuP9739/9cQnPjH9nVEMV/kNIi8zLER38ABJNSdy73hfS8Dx9O3bV+3zuiYaZ82yBByEe9WDy3M9yos7/vjjk+3bC7ZaugkhZ//dAzrcRu/X62YFwSqxHAHX6iR27In82rUXcAx1HollTkWjtXIdIp8xJAyMfBP1lepMO5l9Sb3R4IVTFymPSj3ppJNSPpxRXEEQtPHcHnfccakzVc6moBEXliMIzMIAz9MjHvGI9DfUffSZ5H/FvPemYwCLZVkdz1myTAHH7hlgoRRKjnSweUbVjjoCVXqJay31RBFj19h1L/E7dRsbBMtiOQLuYEvL6H6yY6N79dciB87weiHLEl6we97zntVRRx3VHUigF6920lOf+tQ0l9m0c6EOwnxnCvsKLwij6lEabm/EWBAEbXjgeHB43nTEMhLer7rqqhRiy3XQFMtWvTzD68a77Xm+613vumsKqh4tg7fPCNEDfeJttgKuU6Kk4GBL1MzX99ZmmQKOx0x4m4B72ctelkLcRqAaLXu/+91v7PCoa2xeaTbTta8P8giCVWBZAm5nX9tu7WvZmrX3wGW46/Xiy6H3enVEmhCmYfiMvAaCQdG7t+i1517jPFAd3e8IE/Ae6EE++tGP7k58GwTbDk+LAQrDUI6HyFNG4/IH/2Z3hgPiwbOkHMfv//7vjzQfZ73UxywF3P5uyZDs6durRtxsWKaAI7zZWv+KfrBzOs5GqIqIsMvjzM5gOzmfmSAn5HWEbW9ene0gGJflCLh+NkbACb8wYkiTxbasplDMfe5zn9SDE87UGyznJ8UsQ6hN2AfGzGgr03npmaqfZKYG9eEYuyDYZkYZharhvvzyy1MqRBOeL6O9l0/uIbeF2zZ44Jog2FwPXrTf+Z3fSTmMZed6XEQvCDgh1je96U0p3ErgBcGyGEXA0Rvy3gdFBjh3lNUZh3IU/UYIOMbCpPVNQowbn8fLtDUaijrzGsRQkr1wRmYZeeU3/82/+TfVz//8z0c4Ndh6RhFwwyjzogbnSO3OfRvXCDYzeLvtZfM9cMNgmzVe7O9znvOcXQNUJkHFAfcM207MqTE3SBxGzlwwKjoE5cAb0Toe/kEpAHTDXgKOOJMfSoO4/0sHkkGVPNQWpXVGo2VvUvhhd7rGMFY6B26vh9RJK3NrShYh4HjhjLKynwyOsO6//tf/uvqFX/iFroALQxNsK+MKuEmflUETQk/b8Rw20fS2euDqEG5s34te9KLUmZ0F7PrnPve5dNw8ff41YG0WIjHYPjhYDDZ0L0G0jMNFGy2kX4duaBoYWZJ1hw6GAZXf/va302v3qEE+Oh9EntlY6tHBZnrCTW3JtffANRnzvQx8+fkiBBwYFyPlhIIMnPgX/+JfVL/2a7+Wyp64UYJgWxlFwM2zgzOd3TqYZlkY3hduf2eerLqAy9z//vdPg02IuVkJOWggFRRWUopnzihYdp1XhcjzW1FrLmhC+kVZx1CqRsbARw6Xpjx5jhmijGftoosuSoNvwFYRaKXTyCwqyh/lzoV7MacV+H0CLou7vUjT83UGZK29gJuWRQm47IUDA/PsZz87xcaNsrvgggvS+5l5NlZBsGqM44HzbOSlzqD36+S5UEUi5JNMzcGdal/DfKeJYZ+1qHfeGPRBZYaGzVqwLgKOcPvlX/7lVCbECFODE+rThk2LxlH+nbDUlVdemcrMWOTNzZJR77dgtXH/uVfko6spmQdCEWBqGwqBNt2jnDG8aPLrlULKXjqevGc+85nVtddem14Tdg960IO6IhEqVBBtnncDgPxd1q8dlRBwCxJwkAvHC+filUWFKXOfBcE2speAGyTWyn8zezeonRDEgf2dkayjD8UfTm94f9+SesrNKCmkF673Tsjp/Ss6Ttw4JyVey5UxGrfJXq2LgIPi6v/+3//7NKpYI2hgipGm87DDvBoaUmVONNI8dGyt+oEaZZ8PSq8Jtgsj4ZWvIf518u7/ym+kgYfu0yZx5X6lH+qwQcKhvG3utdvc5jZp8I18Ou/lQZae9WuuuSY5dpRG2tt2dSim0hqVGXRTV5NFCjjGwoUEFz/FT7XzxlHgpUIPgm1hmIBj1LJh41kZ1NgysKOGyLIHLi/L6Hjyvpv6S4jPsRMZeVSluURPPvnk9Df00PXg9eyNYDdgq45GZtA8savIhz/84TQ7DuEJeUByj4isHEqalbByb9im+0hh4c9+9rPJK6Jx9Xu8gGrX8aTISdIe8IwEQQ55NuE+2WsQw/XXX5/mQRdmtZihKcO7ZwYZQo64Gw2DpnoDo8IDt0ABBwZDz0+YRNHLD33oQ8mQq1FHyKFstIJg0xklhMpDYx5UHqh6PgpRI0T2/Oc/f6J80mXYLflacmEZcYY99+SVHFKYWF27DFGRCxkTfsI20BioL6kwufNSn7lg1WEDXTdeCLB5wpwaPfOrOq5FICJiZKsOtY41G+1+869zqs6gBpYQ1Mnm6ST4osO9eQifypeUN7nXoIImAVe22/Nqw8tBU6sl4FK+SK9n3F4G549k5FJccsklqReqJ1vmilDQ3jPXYlOdKKNIFing3CCMNPQ4hU/tHwOsgRpU5yoINhWNpM7MIAiVBzzgAamRJfRe8IIXdD5pT6VlBpb8zO9tNNtlP4QwsiduWThmM0nwvrNPIGYlTZeJ1ERbFnC8cPlvQpbNdT7+4A/+IImPdYM4Ovzww1NecIZQ0jDyTLCV7HZTCGueKH8ivKsx/+AHP5i8m9Je7A+vCeHpNSEuLUb5CfVGrWNfF+HBi07+bGA7eL95Z7XF0hrUaN1LwC2ukO/0JZDmLOA6+SON+SLDPmvjIZIcK2HVlFl6VBn5FjxbXOZNbkozNCxSwEHPzgPvhpHsaKQLrxzX/umnn77w/QmCZSIB2OhECcSG7Ncba8+3OkrgoTEbQ4ag88x4jnWI9g679c8lqLs0dcezy3i1mWB/deJMAShUCqKGIAOR+cA/+0EKoSpmS+g05d3Ip1unEGqGQDKDxp3udKeuiCPYhTXlH4lQ8MTxyrHxxOwyR+3bNyLbvhJuigsLvXrP+bfYz7wQed5TjsJ3fFdb5DgcuzaJENAWEBH5HghGh5AlmLX7BLTzybPNi8Z2sBk81fk6CZ27JtphOZH5WnmPZ1Wb7PrsxeIEXL/XbRIW3E0tEoLbmcYjYaiuMEpGL4rh8/DLK8lkl7mF8XQhFgkvXM6Fsw96dW44uLl444JgW+A54gnn6dC45VGYBBmvusacxwPCXKWA87yfeuqp6f0TTjgheaiG07Mt5hKUEDwLAVdWR+9fmgv56t3rXDoWgxjYKmE7ycwGKxAvJQQDD72CuEKqddRX0wCtI0Sa6bZOOeWUdK01uHURL5Kik0sIsZ2Ekby5QSN25wnBsJd3xufEntw7wpudJyjcnwaraI90XAgKIVkCPosJURivvc877fnwfd5m69uO9sJ2bV97ttf+rAPEq2MRmnZsX/7yl9M1d8xZhOVzVoqwLMAszpv3fSefN/dX9pQSzDyl2mCVIVyj+rlzbkcR0osUcINYGQ9c32wSB3eqnY7VG7UQphPOCLjgGWr8sMMOSx64xz3ucd2whIu6iMnsh+HG8yBC74H4tO8eSEY8C7wg2HQGhVAZWp5qxpaXjWH3nORwIzT42YgKRTalSezFPD1ww+yXAUy54wY2jCgZlFulUSujCyUGA6yrgEMOVf7qr/5q9Uu/9EvJozgIos33Ha/OL6HjPtkEEePYcjjP9SY4RGaIGJ0bbRdh4plx3E0Cxvu+w+NE9IjwWF/7QkjargE/PJl7eazdk55D9+ooIdsmEeba6HToZNkfKU/5GFxDYrw8Bq+zeCXEfJ+nk1fMdmzPcQwTYYsgBFyXTq+4620b3wPnwht+XyK2bc5RN6mblzcObkQ9Osuic+AyZS4cPFBe8yjYJ4nKWeAFwSbDSO81iIE3zvMtlPrec2/dKQHS9qbriPlMCYC9e86Fbekss2S3J267p9IaB97WX/zFX6x+7ud+LnknR0HjnVNodHp5aDTu25YflvO4OCOILcJPZ4DoIYyJoOztEyYsQ4f+JqR4tYgmws86zqv35SIKK+b3iKlRRJj3c+g4izAiri7CiD3Xce9nd7VYloBb3blQU32T8Q0eIUacuVEgbyQb+J1WD/jcc89NIRg5cnWWkQOX8eCUIs3NrLCvUamKB5599tmdT4JgcxlFwEFve1BPm5cgM7zx7njJCi//LD1w7XkKF88mCDgDVTRKN7vZzaq73OUuA72Ng9AJlj8oFC1thmAo02O2TdTtBccGL5zzpu3JHm8Ci9eOt4zHz/NxxRVXpNd1EcbDxtNGhLle6ybCpmE5Am4yG7PAHLj2iIuUnzIijLr8AEIukx9WnwmzEEv5vfJBXnQZEeTf99DoNZY3Pdc5UWm/iE8lEoJgkxlVwI3CKI20Hiz7knuysxNwLV144EDVnw0Sc6GOijwnnVY2z2A0HdlJBQE7ymPE9vMEsbM8RnINg/HQPuo8zYpBz+goz+48ybUIhawzPIg6BE33zbI8cKWNWRkPXNct2Bltyos2bOTprFiGgEO+WeX0uEFKuL8lMevVqAnlxgqCTWUcAbeXkR+pESgqmfP4TyfgBg/xby8RQp0EHe/ckR3GKNebp0gYUG4xuyq8R8wRjDxIuYBysN3k6S6VJINwMbukJmGO7pUsR8D1p4CsiIArkn8P7PTqvqW6cPM1gMsScOByVsRTXaF64rKk0xwGMPIs9wCW3UsJglkzTMDNRLD10RJcfR3D6a3LsCH+4YGbDiPyr7766pTcP+lgMwPDeOCuu+665F3hnTMIQnkS50wHOueBGbHoM/Z4GYnxweIh4gl63l4FtDlVIL/PIpyc5zEvWYUQ6sp64BbFMgUcxa/xYjzcIHU3rR4iw3PhhRemBN8g2EQmCaESbsPE27DP6sWyp/PArQabKuB4xwzokoOl6DExV6bKzAK5YGyxgW5ScYTNjO4UfpXwb2CEnC+DA3LBaOkvs96PYDnIASTalRnhoTUCWgTwpJd9JRX09WzJ+6uzCiHUUVlgDtxiWaaAK5GvYfROHSOCjE41b6AEXYzvdQiC1WUvATeb+31wqHOWAq7ujUupICPMJjMtmyrgwGtmgINohJHG6uYtQjxJ8JfYL5RGxBF1xL8QrMnx/StSIkRL3PH0LaMuXTAbDCh0nct8P8KOI6WJUQQcp4z1zf3bhPvH/TU6/XZsZTxwy2JVBBy48Am2OrxvhnEr8BkGItg0RvHAaSDN1GDezFLQCXMJgUlFUKpgGINCnTMVcN0h/lI/5KsQb61/9+90vjEfNk3A1UW7UJZJwQk3Ia+96pfNCw2y86xsjfI19kuj7z2RFALPwpYry+EzjbdGOgs9AiHs+PozioDj1VO30oQBKkuUYXn3izbd1F31qMAwDuzvpZWtiIDLhq7zso6k44bQqofc4kRycVKzHpCm3pn384im0jiskoBjlOS91YuRctdrpJRKKeeBDIJNQCMoRDYIz4U8UPkpcqKkFWQULvVcyGdS87EsjLt4ivyUgzvV/p0DLbvWNraMbhN1oZJt2rhssgcuowxUvbQSe+keWCTql4mYsNN1IUngCfuy2YSmAWgiJ7luGmFXFt/1WsiW0FOot/TohdBbHq7tXmVs6Ab6YRj5/nAtTRqQZxihUaQGEHg8zIqQT5JzuUIeuN0FNrvLHnVPPMDPeMYz0sk0h6CYdome0K1udavu/GarKuAgx4KXoakhotiPPPLIVI8nCDYFHjglczRaOmP1DpiGkLGDJPOyEZezJL1AQ6iXW3/2R2F2Hrh+AbdzgE3LnrhmAbcXo4q5bRBwEEItZ+KQYE7cs+OE1bqgsc6Fd93fQnVEQ55pwbXMIdss9LRjnhXPgLZMzp4QrwEXOTdv28kdILMbOb/ODZvCtjhfwqS8ofUCxxbn13nXKZBv2RQNKxEyJ8pMYyeknh0vRBtnURZk8uruda979eWxs1M8b8L0rh0BZ3uj0Qujjspa5MDpyavUXvaKVHh2okyzpYdTR2hylQQc3HRGwuSRqdmIu9BuFKGESRqqIFhFeB88nxphA3ZyDoo5I32m8TIVHhhegi2jRys/St2w008/PRnucZmdgGuRS5Tsawk44dR9+6p9I3RCp2VbBBwPlzlh1esqeclLXpLuk1VhVOG9F0SAezx79Ai97NEjOhyzjr0ITc7Pcx8QgYQesUK0EDAEwioLPefM/hFebECT8BJpc1zZo+kc8GAabMKRkz2beSGCCbMczrZOLkhM/BucwgPm3GYx7Dwq/s/jWx9YWGI0szJffsc6yn+BF5WuuPbaa9Nrx0KbsGHZq+df4VPHS+z523HvTX+0coU8cONTf0gIGxeo5OKLL04jPM8///xuMqKcBA2FvBkTYXs4VoV8TDxwPHHlA+eGIUbtdxT4DTYFxk3vlOet9L5pjHRkGOzsgRMqVXYnY5SY6edw//vfPxnTcZmn3RpWRkTP/IwzzkjTRmkoNE6OTSeUZ7HEa3lXptlr6rxti4ADe+1aN3XI4Vyukk1fBNmj1xS69Xzl6bMIPc+IZyuLmiz0CKVBQs97vEVNaLOEekvhxSkiFGybBI17O8/lyrNlnwgvAjSL0Cy6/E14uZ99RqTZT88+4aUdJ7yIWcfK88qTqX0kjOxnUxrVqGTvneesHiIvGRZCdU4szoW2nOY45phj0jYPdmaKMh87+6adV6ewrmea6Z9vea0FXImb5KSTTupTzC7w7W9/+5Q7Iz+GmHOjO/FuBkqcsTQVyCriRn3961/fd2Hzxdbj9NAFwbrDQLufh6FHrNNFyL3yEb/VnSpPw3TaaaelDs3xxx8/cMRYj92pGtMhnJGTivtHiLWXXsJxiQZW55Fngd3UsOr9M/Z687yJGTZNiEXDJ1xThhAzROAqeaDmDXFCxBEcdTTg7heC9+ijj073VxOjNZibhXupFHo5dKs9dJ6Iuiym/JvLqOgoaXuyIKwLL/dsKbyyF9C6RJu2lked8HLv+22L/SC+eBldt7L9XnWIs70GMQjTKiBtKk/nrYTHz0AYQs65GI2W/drfGw+wYgKu3z2YRnSNWBfOScpeqaRw39hWv4o3vupVr6qOOOKINACgPjXLKoZQSxjtumGm+t0YjLZjDIJ1RsOxVyFfqRAGL2ho6ujdqpYuJIK9GmaNTcksO57lCDEM8sBlAcLToe4UQ57RIBqskdHg8dRBCFkIEdb1WkdOI8CjsU04T6IuOdHfdc/Xnk3/lV/5lSSiTckVjEeZo0eEnXnmmck77BnTyeD08BmPEuG1jYMtRhFws6e/kzgq03ZTR6RIAk60k3+bDGAJ1W76i5w7g7oRZ7TrbnXfWbVBDE3o1RBsJfaduBsUUgmCdWEUATc7dnvgZho5SDlwOqFtQztoTmchHr8rL4YnjncRwkEnn3xyn3dd+Ik3CSIN+W9269nPfnYqT8DTpKHdNngk2cAmDIwRgeHdhM67e23V7f2qwTOskySMH6NieyxHwLVMTFEOacU8cC365ik8pBsqaSIb92mM/DoIOL0heXyGHNdRG4sBmyR5OwhWgUECrnyuZynkeLRKZifgOh3Q7nSARNzwDqgGUbhPTpJkaqPacqgl58oILymVwiMipFXmAGaEuLYphFrifIwyU42OvjQaApjdF74O5tFJ2g5WwQO3egJuwayygPNg5YdLcqZQcLmv8grkHcj9MTo1ekfBOjLMAzd7+g2gZXYcrHZ2CgE3ZC5nHjh5f/JZdcB00pRCuvvd7548anlQR0Yer3IZwqf1AQ7YpkEMdYTX5QzK3xoF3xeRySF3iM4MS1gPgjqLFHDSybI3fwUL+Q5m3pNBr4MHLos4RsaolVwMUA9Sb9KcfXrujJIQi0TREHPBurBYAUdf9efVztRu9UUQhhQnbyGBvBx0IQVECDUnedc9Izzwg2zVNgs4KOFgEJucwMw4niVimjh+2cteNkZCebDNLE7AdTz7UzDnHLjdeSm9Ze8cuGlYBwFXwrirgZRH65gn9YILLki989/7vd9LxUwZ83GMVxAsk0ULuLZnLNuXfWsZOaiz7QIOIhIGLOT6mRjHDso7VJLGwLcg2IvFCbiD1YEDuSe4omVEBnnawgO3G3V7ypF0BjPIA/lX/+pfpTpxRuQZ5TZNLZwgWBTjCLj6KHK4z+t5bYNp9Wb7RrYfDAG3QUgzUeh5Vh1YpTC0EQaRCV0bGKG+WRAsMoQqH3a3c2sNcuDqw/JnzToKOMj3yEWL5ccdfvjh1S/90i9Vhx12WArDKCnAU6eQYp3wzgWLYpR7TdL+IAGX13dPq3p+9dVXp9cZ+UxKCD3mMY9JuWN7d1rq4YhRhd8oTB/qmJQQcD3cBxdddFHn1XQIa+ssK/Pyq7/6q6nRNKAkbGiwrEEMa1LINycb7y3giBkPrN6RUUaMesYQcjWSGLicF1Y+fOsq4ByD3Dduf0LuZje7WfULv/ALaUqOXJJAoUDfMcJNleogWBS8FaWgENYykjpPJVNCwMk9GgYPiPBYnnUhoxYYI+p5UOy2TEwfSC1PbXZ2y+T19Z7yfDugmRBwPYh4dcvyVEaTUhdphJsoh0LKavAZfKIKgCmcjBAOtovlCLjJmHMOXEnOhxvN8HnIJLAq8Cl3QT2kcsoPVaYZdSf6iiuu6LzbY9UL+Q6DEXHMKlwLoZrInydC1eeysr3EXt44daLKcxME84JYK70gEvbVPGP06rgvFbXVMOqADapryBOik4bcuKoDJg8UCnXnv+uNb4/dXrJZCrhyhOsinXEh4Pox9ZMZOur1M6eB7dRhzl5e9zQHARFn8FiGvVU3LQaSbTarIOBWygPXjvO2R25NkvumFpLZCZowf6gRnDD9irwx04Loqa3qVFrDyA0UF7+eZvY6ajh54Yg5uUUZuUOSfH0uPy6GzAezxj2oTpnR0hrQem0uHShe4To8yGqhmeewbPiUziAC1UeDezcLuAzBl5POeedMPbcXZf4oZuqB64Q3Du7sHzoCddaEgNsNsXW7292u2rdvX8oLXhTq8Z199tmpbXHPD+5MBOtMCLgu7Z5rWbU8C7hRhZze0f3ud7/GufH08ImaXOxWIyHMqHE45ZRTds3QsG6Y2oSIyxMQ88jpeXL513PgCD4u/0H5cUEwKWqZyVVzHzJuzzzu0D4vlDy3pudTR6MphCrcyhtnuzAXo5kHcoFbEH8aSl50HhdekeH0e8ks82G8SMK0hIDbjTbh3/7bf5uu8Xnnndd5d3FoV9yPWcCZekqDb9YgaQNN6QTB+sDmjCrgRAHpjhJ27dWvfnVqu7ONG4litpcV9MC1jeq+lnDbKweu7Nk4CXo9dTwokp9zDli9N7TOIdTyWEy3I3xUviesrLZRFnYlah1df/31KT+uHHYfBLOAx7fubSPemsJKo45C5TE3H2qJcjpCp8roXHXVVem9+jPehqBqe/fnVwdutzg8ZEFx1BBwu+ERZvuPOuqoVOy8yfu7SNyroh/aKoKyHDktBFtOnxasPqN64LSvvMA6mCUihsp+SX/y/I5GJwWkO9vLaCwwB2585CSY1Fh5DRx83h1SD90DfLe73S09xIx8nqKmZF0HMTTxvve9L3nXymm1nJdHP/rRnVe7IfyEpjSOMR1XMC1N4qlZUPUYtw5c0/bq5UV2fyeHN/tHcWGWAq6+7UURAm44Zqw54YQTUrRiFdGZPuuss1IJlJzqE6wm2bYQcEYn74X0LXnpT3/60zvvtO2VQVdSTUQZzCQyWs5k/2wvK+WBmxTux1ybJ59c/3pf9XIhRd4ogx3qbIKAKxsrAk4eYE60NVvDPe5xj6Gj/Nw4xJ9cIoM+djd+QTA68it5fd1XFvfTsHtqXAE3KdPWUlplQsDtjQ68kcwjjVReEtJaSk+clARTrLHf0mJGa+SDRUB4HXvssSl/l5CTY57f52nl8dWuKnNkxhXT5mUIN44lYX7XlJgbuVJEMYp+9QRc3xD/+eePbJIHDoyUcJJwag6d6ikIIbiZhuGmIgCFqaJY5eYyrkCf5PuSxvU8DRbai0UJuDbL85I1IXRWb5T1zpsGGWncB6U7hIAbDR15udIa2HWADRdZUlXAjDulXSb0YkL+5SHHUdUHg6zkOubR866R6yX33udCp8Tbne985+Qg0ZE87XU/Snn5psUUKSTgmlKdmihTQFZMwB2oVUmvv549myTgGH0CjgDjTbPkEXxuKqUaRpnnj6eSS9+IPqEHeXJ6giXjNurBajDtdSM2GB3Gyz3BcKn5pvdJrKnJqBNAUMgPGeXZWqyA283sPHCj2ysijWfFAAznKQsz3nPPad2YG8DByEuJkPZQJwTc6PBkCVkZ9bzOmHVCZ115HvU+g8XCtvG+DUN7S7QZjSyEbyBL5oUvfGGyAfLw6/Uth2Fi++zgGpWF5cDVh/jHTAyjU2+clUfJ9d/g3z/6oz8a2bvG7WukrkaGsQv3/WZCTBgRR0QYaKBX79pr6Igys3ooD0LMK5x7ww03pFIJBIN7yugqokJngagTCrDkkMJeonFzBFyLYp7VclR9HaJXCAVGojHwktyNslUCKPfm4droxfOQqzvWlDjt/LkmwWDK+/BTn/pUikrocKwy9WfH6/I9f0sTKuvQeX4JA/eV9KGxRjhuKfmcElvZboGXkwOjacTwOGVEeNnqHS/tqZllRCtG9b6lTmIeGNWyNSvigWvtVDdsWlvmPIpr00KodeTCKbVAyLmJ9NoOPfTQgfXy6gaDcdD759nTeGi0GYuygQlWD0bb9dboMzS8qrnAqDAS0cRTRozpNPnXaw2aay1sQ8S5/tbVGVBtnsiYdQ3BRQu4nAuXBnO1erMzFXAder1ky+5OqHCoHrnBQ0ai5YaAIX/EIx7RFypl+M8444z0t2uoEwYlgXjbc+1H5zFopm7XwI6dfPLJqYOy6jTt/yA89zpWypVInC9H33qe17Hu6SKQj8ZZobYk6AJFmtlCdq/OOAJudqyogNvXMnJN/dVpJrMf5abfdAGX0WAw9BJ4jYj59V//9RSn38ur5hzmBtsoVSEzgjBP0fWRj3wkhdPGMTAY9/uzoPzN/Pcy9mNSXAfXgHh2zrnnlSJwDXhIGW0CjKeMKOMtI8p4zzRSepZyfzRcvLC8bUQAD1we9LJI8rknPC6//PL09yAIUvdvPacuG1k5JgxtZvB17eTAHdjfqSU3ywSNXke0v9/ZDq3Wca143OTJCKeA4Fb6x78Z3iLvwbUj8MDLKbld+RT1LD2XwXh4BgxscG9tAzy9RroKu7ILQfsekB+uE6k+rHMEtub8889PnsymEi/LEXAt8jiBlk1ZfQ/cHgMZGGrixMnmWWDs6i5jhtJnTWyygKs3YnoYPGgGOAjTqD8zuuu2H2JCz06jSShYCAjemlFE4aLJv9n02/PeH2KJAajnEWacL94tosw5FQLhyi9DmISYc8wLSjgLl7mvfS4clxOa/YY8C9fVc7CMcz0uBFyu4TYI4uSwww5ria9+IUTEELDOA2/KKJ7h7IHLy+w8cEXvuA/2rT9fxfNDNBPQBBlPHBzPAx7wgPSv/bQ5vX8eNvfES1/60u5cxyUEcIRQJ4P9d+/kGT02HfZGaFVbmfG3QUc6frx07Ab7o5M/bhuxDjanhN11PuR9m5pPu+jZO+GlX0zhTc9ck9hdmoCbgDnnwJUjwzp1TjqM4oHTkMnV4i4+8sgjU5J15tJLL60e//jHpxBEU6KndTbZA9f0MPHaOF+nnnrqyO70vR5KDRHvnhvdec6hVu9vChrSciGI3WsWAix7xpzTvBBUXPK8LP4lNvT2CBKiLHvLhDAJM+fNZ0KdziePJ0+bbcnDmIcoW7bBdbwMIREzqFQCz6NQfl3AZXiseFKEj/ZifoV86/TbshLX0f0gCd2UYRn3kdBXfXJ094zvalzcY3UMYggBNzkEM8+UxnobYafZbvMR6yBoI25729umDo52QsfR/cWmZ9g/zhO19XQ8646TdYSdKXPEpSx49kQp6ixLwJXpGSvigSsZbPT2QuNXnlCNLKPuRuOh0NPVWLnRXCiL+i3bJuDg2IVfNBZ6WDwgk3rj6th2DrXmkayEiwfDNfJaL28YPBSlWNKoZ7GUBZM8oVIs5Vwvv5MXPUseKj2svAg3CifmhXCQ98UTlBfGjKCy5Fyx7GksF5/lxXesp0PhOC3+ZvgYRl5gXhT7ZD/tL9Hn+HKYehYsW5CNC8+tkZfEGVHj+oJXTcPh2oLneJCAk7sy6ki8bADzIIPp7Naw6IFlcATBdZ9VoxejUKdHO/HQhz402cRtR2dR/dCb3/zmKeWGJ86zV95j7BcHiE6FWZDKqaLYPe8/7WlPS04U5zYjD1vb49+ynIvOl9fsNaFYduR4qz0vq8RyBFy/l39FBNx0HrgMsVbeRGLbckc0jhp7Q/DdBBpsVa955v7wD/+wb2jvtkF4uG5ycORF5N79rERAGWrVwBoyzRvF60DgEUse9lIIWfKIx/yvJYupcslCyUI8CTdmEUaUudYMQrlICieiLAxFTtTXk8wLUa9X7t6w8PAwKHpiedH4Or5yGcSg8Ok2Ur+3XKumECrB6/rne1IuijBPCbGnE7ZXDl2PngGse+Impbed3Z3P+qj6eRECbjbofGobQsS1qxiwl6NSCiwePd45Hiz2tuyo6EATcJdddllfKRc2kvfvWc96VnqmcwksaDvMKEQUmoIqizvbJRB1kHMnOaPNz20DB4Jrm2Hb2ZXcifJa+yfnrSkC0MSyPHClJloZATdNDhzcaHJHymRsvQi1kzSsTrYwalby1L7P3Sg+21acG+eAmPVwnHPOObsa2Fl6dLjmTRVD1GWxlPO2PERZNLk+pVhyzUqhZAlWF89jXVDwxjLoKO8pAm6UUajWJ1Rybhh0BG51q1ulOkoa3ey9G0zuLLbE1v628JrcbtXpbbNNO/dtERIuBNzs0Eawh/UJ8GdpB4PxEB3SidbR1nZk++9acdrovOvQl5EdbYucNraBMCwdNQat8Cxa5LmxP1lzSOMYhaV54Ap9NCoLzIHrZxQPnAeLOJMjg9LAG53GyFPneaRXyabnwI2CRk8IS2kRPSMiapbUDd+sQrXzYpaGeluNPgMpzzLD6PKAN+VpjSLgnEf3af3e1IvONev0snPvedh5Zx8OOWRftXOgXbNtdgKuRVEHzlJEO+ZKCLjZQhhoO4wSLu+lbX2eNxFOAZ5CNkNqy759+6r73Oc+jTmmTSzLA1fWxl0RD9x0cIEKrzQlMHMDKzOgd87j5gHMD6F/xei3XcBBjiBvpRwxeUfXXntt9fu///vJzT0poxi7pu+Mst68WOZvrzuePz1hBlBvOd87nk/PmfCEvJc6wwTcPK5Hf422+dSBWzQh4OYDz438rjIEuA147tbNFk67v0KsZRh4L5Yn4Ma3XSst4KZhW+rAjQLhZuJdN7J8gP/xP/5HCk9pjINgLzRywuE8rIzbM487NHmghMAJOx7wpg7BqCHU2dCfBDx7yhDHYsKnCAE3P8xBKqQ6TuMebD5LC6Em+9WOWoaACwHXh1CzJFGNqorvBhyYliVEXDAORJuwaYlQRb08BhYr4Krq4IEDRZ7ajHPg9u2retkgLWM757mcMyHgZk/p0dHxYAub7t9gO1mWgMvpZkKpozLnHLjlEQKuH14U9aZ4TGAkj1wQI30kpscUWsEwBoUx6u+Xrxfuget6yMYLQ+zN7lzeaWaSGYcQcPNHKY173vOeqQi6Ee7BdjOKgNNeGiFv9LyR9qUXV04v22OQxTjtasrhTR3DA+GBCwG3G6N1HvSgB6UyG3LiJPJKSFfSwYAQobAs5qbNOwi2k+UJuJbMqpUPmakHrhyFakBDeOA2Bo3vLW5xiyT6Tz/99F0e5mC7GCbgsn1TPuukk05Kg6y0mWWVDO2q/Hz19eojnkdlrQXcLMRDCLhmFKWVA3eb29wmDc/OhRglqMsJOeKII1JSOlGnATZkW9hsGyjvu3HvwVncs+sAQyXcxGjthftnlDpuGlADkZowgKIsE7A0+kahRg7cJpFrxPHAKRwtL+7cc8/ts4/B5pNtON2wlwdOiZPjjz8+1TAt20d5wqbHY7fcOzoEZZ26YWzUIIZpGkTrhoBrxvQhP//zP59uEvW36pjBgDeOF04ZB42wQRBCC2q9NY0IzjjvixAys/yNWWxrnseca+VZ/E3oEFB5kcNoRDYBnheiW12lvCicaTi9auh50XN0rRXctCiUmQswW/xNOOTCynnRAZA35PnaS1i5Z4SnhqG+0zHHHNP4PTWhTPejlNDeyFPrGcBxjOAqEwJu8cjp9Ay4x6WdyB/mcQm2A23fsccem+qoEnLsJNhZNlD0Stkjc+wahS+nPJfQYo/379+fxJv3VIAYrXzXZIOwVj4H7uqrr069Iz35ssgro/bEJz4x5XGV87hlQsA1Y2J055NhUiB5r+KGzqEb2rydZkMwMbA8OlW4N2k+VMgTJJT8a9Fzks+QxZK/iRYPssXfapSpJm6UZhZM5jotxZLvZLGU/zXNVBZM/nVuc9HKvJSzVVhU/8/TgJVTgXkW8qIemxkwiKe82L4eo/3IC3HuuVFmxr8WU5SV4k8oyTGWCwFJbJl5wzEMw2/n6uqMWVORZvuhEvsLXvCC9LoUw0reqGOoKGdmsFju5Kkd3KnypAlTC7jC68a29nrI5YCG3ejoEF5l9XjXxXRizmGJe4ptGzRdWAi45SKc5j7klTPY4YorruibSSDYPHSC2Zw8bSPbD/aQaDMLUMkJJ5yQZqeQw3b663+SPHCec+0jATdqBKschLX2HjiYM9GJlHDvZGTj7V8KmYhQ/d8sA3U0MCHghqPx1lsgkgehmrW5ZvU64GZ0s2q8iTkCgiBww2qoxykWnD1LeeHdy2LJ4prXvUulULIwpqVYshCl2bOUvUvZs5QXjWIplgiiUizlpfyOY9UQZ7HktYLRDPtrXvOatF2ixW+WYsm5K4WSxX6XYsnfjs95zP9q3J1vi3NrEcIkhPIyT+/fIFwnC4Fryb3POp5f3jWdLM9jHvHs+3qoOW+EMK3Pheq6u+8ITx21zLDjJbDMg5qF1nR2i0cvh0o7AyS6PeTBo1Bdt9NOOy019PbbDBXuB0adgBOic69n2C75MkSsIsl1QsCtDp5bRdE9764t+7dpndigLdqF0IfBRqt9Kd2IuC9toEENnmf3yZVXXtl5t4ndA6/yshECTk6WBlLvnFgrEcZh4C3CgiDYqGOvGUqNQDAcjSpjpKQIgZApG0oCiJu4Xm2fgCCoNFAaYTeuRiqH4/JC1NS9S8RPXSzxOJXfsVgvC6a8ZM+SZZh3KS8GbRCdde8SsanBzYuHMAsmi4a2FEuWEgJLePl1r3td2vam47qawibjOfMcEs2oiyuC1v3Aa0fw5fNnZhXPtGsCwqUu4NQtJISsf+9733skr0eZQ2KZjv6Rpwd39vd53QaNQtV50OuGBp4AMwdkfnZMqs5DC/Yqf9d9+6hHPSr9DefS4nzXn7tgubiPXWfJ6iIZEtV1aMtE9mB9GWUUqo6rFCSe86YcNxEVkZC9GDRv80YIOArWpPUa8pNPPrnr3fEAKX8hFOj9PNJNnoKHSpXtU045JankYDTMaCHXiMs4UzbIBA2RMwjGS2OrULCbuhRLlhxydE0swrIEYymYSu+Sv+uCIFguOlHm1c3wOhIo5XNWXjMCrim3zbUuQ6oEHZEjBJGdXAyg9/Vw73a3uyURPvx+2J1DMp3dqgu4fsE2SMARqzo7UjjYIPZIY5BTFVT/z6FnwlcHFDoa1oPOBY+lThXxypMZrCY8cDqfrjExx0OX5wUO1pO9BNwqtUsrnQOnl24OT8jXyr1wD425zaA3y8jVez8RQh0f3q0HPvCB6d9haHyFfcocHxB/8n/WoTjwvB7CTRSdvKV51CmhleGBlNOnFI2cwToE3ChlRGx7kJeJ0G8abNPEbAv5Dg5vtJfBI1GdC+KM+ORd1KHMzxTBpoEnVk96+d8mjxwMMtFhBYGrAyTvlB0jZoPVh0dZyCxPpm4ayGiD1o9BAm72tr1nY6R+9NiQmRh4bkyUzdPGkH3iOXdIPXQ9dz1bYRYGsalUQQximAyDHHg99SQH4UYWqtbjdKNLNOcRnYR5Cx7bn8dv1Lc57+NYJvLVct5WnkYLPG9CyPJQPZP1czCqgCsZ/zxOn0fSTL8Hrs4gD5yOpI4N4Sa/lNfZs5KfKQ17KXaNdFPwk+dagnQd6+zVoQqWx6D7lSA3elVY3EhFHZSmUFuweowSQq0zqf0vow4lGyHgwNsmNNp0gnjfhFaaCAE3OQyN3EO5cXkETqa8Dhoi3k+N5a/92q+lwSZKkKhOzXjlhsc6RIAwknw1Cf1l3S/bKRO7hzHpg1JnnO2U3x11vWHf81n+vGnbTevWv9f0nXkjhaHMk3Sf8BIN2pdJBNwkDMojWQaErJxIo2/LvEj5MPIF62kIni8DHgjhpvMYgxjWG8+Iay8pnpgj1uU7BqvLJAJuMgZ3EtdawM2igQoBNz3C12ZuILgy9euikT7ssMPS+SbChId4IITdSkMlB85MD8JKvKnqf2XkBPGy8kZosMqeKk8GUWjEj15thiDkoXWNhWxzPtW0903JKNua5e81sdf2Z/H7QuJ5O/51Pr/61a+mXCyDVEB8/OZv/mYaWJTP9V4sRsBlD1x/SNOAhmV2PGdFCLjNga1ix3JJEoO+8kCeOvO2K8FgFingJqn9VrKyOXDlDdz0t3+H3eQh4CanPK9GGhJxTXWqhp3/UcjXkPDjvSPq5NGV+YxEgFImckvyPK7g3XCNhSeE0kuRadCLvCxeQHko2Wtku0p6yNuSkF+OUiZKyqHge8GDOKrXsGTYOfOZfTVi073r3/w+Tw1xLNldzlj+DJLchTE1Dnr7WWDJUXPenAde0XL2BOdLCQuDEiTLl3mLtsWA+Uwjg+OOOy55Wm9729uOHApamAfuQLMRDAEXrCqeYwPHVEtQZocHVr5nsHwWJ+DaIdT+/Lc2a+2BmwUh4GYHbwz3v/ugPlhkEMOEyjSU2/W38CvhVeYVEXeEJzGj1IikcBBHBEUuT1MmzusJEyxCHUShhzhjWy996UuTQCL+CCFeR1PvSDDncfQ7pYfQ9oTR5GfyXhGoGYLD/cnjKHyWBRevIuGph25f/FaGwbfP2YNZjvz027ylFuI1nyPb0/gTePaxPCYC1DZd21ziI6/nGjuf5Tl1zGobDRJLTSzMA9dYk230ROBVJgTcZuMZ85yzSfK5/StnclQvdzB7FingQMSVubuWjRRww0RB/bMQcLNFo54Ljg4rJ7KuOD4eK4M45FWWuV48X7xSvFlq1ek5e8hudrObJe+fGmYG1ZSjcoUejZ5UYoDo4UHL9yhxxxPI41jmkPmX6CKoePfW3YiPK+CGPd9D6ZunNC/7Oh+uNyHgtgedPJ44nTcdZh0/naxgsSxawDWx0QJuFEMfAm4+vPa1r00T9Creu614wIUfNa5NTCxENowmAVc/N8KxitWaCaMO4atuGvtD2I7LqtitaQgBt53oSKqhaNSyEcpqLpYe9GB+rIKAG5WVzYHLyIkSZpL/VDf+qvC7ycuE+EwIuNlRP+9G/6ogL6S4aSxCfOXfWMRvLZMc2h2G79z1rndN3t0SngclhIR4eUZ5JJ2vcc5ZCLhgE1BTUA6rsk3SKNwPZYQgmC3hgZsRRhkSCnofco3KkFKeYFgvvanytRs9BNz8UN6Fd0RO1iTekXWgSSzU3xtHUIzz3U3A6GK10HjhDIYoS8dkhK6V3ahPpUX4SfDmnStD0+MQAi5YRwbZCakVHBlyZ4VYjerPc1QHsyME3IxQxJIBq9d6k/hpcmgNhFIHcNN7X0jG4iYPATd/FPA1K8ZRRx21y4sSbDeeT+EfeYAanjx61UALOYX52dVBqws49bKOPfbYJF7+8A//cGC5hU0nBFzQBM+0Z0gnOpck4fAIpoduaBJwdWFtkJxaqaaQzAPlYH36wzayjRuXjRBwjP+JJ56YToRk8ew2VlD0zne+c0r2NBWNWmHI9cR8l9HfxGT7VeS3fuu3UuL4LW95y3SvSL7lVVG49zOf+Uy6XuMm5G+bt2oTER5Vw68Oj7kcSl5cKPVi9G1Zldx7vLswR6gC0OOyLLs1S0LABXuhJJD7hMdam2igVb0AezA6PHCqEQxDGSp2SfumIkBZnUF+tAiC8lcE3jxZ6Rw45RxyA2C6JvNsQsjuvve9byofwTsnzAoqWJjGQvSFB25+lAKL580QePXGlKwgqHlPzzvvvHQN1TmyqDdmflslOYy20iib39boqxg2vznke4OAa5rmrg4PHdFfoi6dEc8MoE5ZDtOPI+xDwAXbhDxRJY/YXfY4j4yPzvBo5PNEkPFqapssTfX52DVhbDn4xFyGnaJHRBvoEzVUm1JH9mIjPHBGsZlDULK8XJq/PP923R46YcC4qYnVtH+RA7cYRjEOPKeK5qqTJpdRyIzAU/OIq1kuo4aa4ZHXkct1qD0mdJY9NcF6QcCVo1AH3SvujxxeLb/jPV7cSRO2Q8AF24qohzJGOs5ZaDQN9gt2Q7Adc8wxyZvp/OUcXPVFOZS8pjvuda97pQL3ooQGW0JbJb2L7WK3/F3WAB2VjRBwUF6Ah6eeB8dFrNfuxmxKoo9RqOuDnoqcDoJNYyV8Jq9ACM119BBxSxN42YNH4BmdJe9jkgrmWSiMIkCDHpKm5X5kssdV2YM6i5qJYdXQgzfIijck45xdf/31fbky8FqHxnlsohRwca8GkyDMx2PEq6TDrI7lSSedlHJMeZimZdPuS7qhKYTqufYsCllzQEj7ACeT4stSQE6//qdp9DzHA8EnxWuSGXs2RsBNSgi4zYBxKAWeBPhrrrkmeepyiJb3TsicR0+DJ/9A0vw0Ai9o5rrrrqsuvPDC9LdrQ1hrEIiQ/F5m2QJuGXZLyRNG2+AeUQNeSCFi70kx0AEpcc/q6cunaaqFpyNTzhgSBNMgCiK8mgteu+90NthLc1ezl+ztpokyKRllJIeHUrH1MnctM8ooVIMTeDbV6SOMy6kNVcYg4pxbXtB5stI5cNMQAm47YGi4q/V2GKC6wCMwjNTSSD7rWc9KDSI3OI8IY2YmhElyFLYJxomI0ANlCHO+mnNPlDBUTfXetlHAGTglB0YdO5EDPXZG3r0J50oDAWkFRB6EiuX81TEdW4RQg0lpEmK85UcccUQKAepoXH311anjm1NaRDx0jIUJ3cM+v+GGG9I9al0Rr3XKWdaRF7VRvxSEnOPj9W5Kzxi1jAhbyPNWireM57+cn3tcwgMXAi5owdAQeHIUGCCGyPB7ZSoYKK5yHjyGi8BjyAzJl6snOVVPqylEz5D5fJL8hnVDCEBvVc+ccXvGcYemXFTnljdODz575Uq2UcBB52Hfvn3V3e9+93S+5PASdcTY4Ycf3i2Jkr0hYOyJO7Bbzqck9KOPPnpgeDUI5gEvMk+cdAmdBx1eXnb2kbBhL3WMtbEKDPucl9mcrsK1OsRNnq1Fo6wY261EkckA8rRkBBy7L8WhntKAvQRckyietcdy7QVc/YSMe4JCwAWjQIR4yAk8pS0YIgZJz5PAI+wYLA+8RlXug3wSJVN+8Rd/MTW6Gl+ePPdbXnhXCEeix+LvTUHPMyMUIUzYVLZgFAE3znM9ayM5D+Tq5pFn7KbwCtxbEp4JOQ0kco4MdAaUgYB7xWuLhkRnIghWBfc2e/exj30szYakQ0zgsY/spIiHUl6qDhB4vPOqDkj+93wQUMTVvCEmpXzYBx13//7lBe2BkDqkcth06uuM6oGbJ2sv4JoYx4CHgAtmgZ4kg8UY6GHmkhe/8iu/knJI7njHOyZPCcPFLW9x7zEAQhFCt3k0k/eMjrb4jn8JRT1Ei3Ak7w2BmBe/xUDyclmEhwkBxrBcGNPstrcYcSZvsBSVcgGzoLSMO7qTUBNyyR6hvZ7HUT1wDHpTzUbnXA4JgzoJy7BbPLPHHXdcOvZ8Lwg9f+hDH0oNnOuc6905fxo73gEdBaOv6zjfEUIN1gkdYgJJB0SIkd3S8SWgssBjDwk8tlN40wAfdsU6OoWTJP4Pgj0UVSEiCUeddvmmOuplZzSzCgJuVNYiB45R5NEoyY2H+HOTuzYEXDAO7qdxOghGwcoNEQaDe5DRYSAsXPPuTeIvLzwuhJVFTUOGhSgkwPxr0VgTiRa/ISGWgGNsFIa0aNQZQ+IvL0bsWuSxWHJ4OItKC6OZRWX+2/tZUFpsQ3i5FJV+z2jvW9/61km03u9+90vHjHzOms7fKALO+bvLXe6SpsxC3gbBc/rppycB+4AHPCCJoHFZVsdT6En+pUbLfUCICj+5X+oNE7tmYIMGpskrEWVEgk1D51HbrMMpjGkUOxvDjuWIRynw2BCF4XUgdVTZgqbQ5zgMi4iEB25GuEgaF/F2F7GeOKkQ7N3udreYzD4IGiAISlHJaJWCkudLGYFSVBrpWwpKBlb4gaA8/vjjq0MPPbSbbF8XbE0CrmlwQ4mQime8PjqTaBF+5DU0TJ83cVxWJXIwDQRcjEINtgm2ikhjk9gg4k1HjsAj6nLnk93QMdJREiqVamDAAgFWRhfYDnmottOUz1wnBNyMED6hwJs8bC6yBOAjjzyyO8KrhAciBFwQzA7Gj2EddZoeIRHhRJ0p+SYEI2wjD4qA0AZPXwkDfPLJJ1f/63/9ryTk6uJwWwgPXBD0w5EjzKrDKYdN+JXAo1O0+8SdHDwCj11hg0QO/uW//JfdAUTD7EkIuBnBnaqeipg5hV2edCElYR2hihzG4l6lxrljhV8mCbsEQbA3owgqHjg9ZCFEnr4cPlQzzojMPPm2EIpwbYlizjpvOmHmNTbP8bgsy27NkhBwQTA+ctukXonSCcn+3M/9XMpbzjZnGJEDNyPUT5LPk424HCL4V+hUaOG0005L7lEeOepab17ekNGB9by5IAgmg2BrEm3DhBwBJ0G/iXJ7nl9Cr5zMXq7fIx/5yJQno2J8CLggCEqG2Z4SkQOhVTnHowyOCA/cjJDYK/RCTQunvOfcWycDT8BJtLZfd7rTnZKrtJ7UGCHUIJg9oxjN/J1yEMOw9eTB1YfzC6/KnzPIgjduVGNdEgIuCIJxCQE3JdlYS2BmwIVRjcRrgpHPnrmSGMQQBMtllFGowXBCwAXBYgkBNwPKHnc5omTUnngIuCBYLssWcOGBC4JgXCIHbkqItCahNqp4Qwi4IFguIeCmJwRcECyW8MAtiGGCLgRcECyXEHDTEwIuCBZLCLgZMY7HrU4IuCBYLsME3CTPtnWmsQnrSAi4IFgsIeBmQJOhHsd4h4ALguUyigfOM900D2qmaa7CUQkPXBAE4xI5cDNg2p52CLggWC6DBFz5bBMoj3vc41LR7u9973udd6tUr0kNSLXgFOeexB4sS8CZiszoecWKlUMxbdkll1yS5qbN5VLy8RhB77s+zzNTlISAC4LFEh64GWJuRvMkmsesNOIaBzXizNAQk9kHwerhGTVjyiA8z2ZLIdbOOuus6g1veEPnkyrNa2gKLdNvmcy+ab7jvViG3WJzTPavcKhjMssEcWbGmA984APVCSecUP3gBz9I3zUl0KMe9ajq2muvTbUsL7/88vR+ycUXXxwCLggWSAi4GcFoP/ShD63e/e53p/lOy8nsvcewMfIKfdYx6W0IuCBYHmZP4EHTyTKvcRYuTXjOTYWXIVysB5NYm+9wHVD13dQ9vG/mZGTD2Cqzypiv8cILL+zaMdP6mDEGf/3Xf53mdobPee3MOWsuxxBwQbA4QsDNiBe+8IXJ+/aud72rrxZcid5tDtPIlzFdhkVYxoUIgmA5EHCKcCu2zctElOC1r31tmq/4y1/+cnpNpHjOSzz7vgf2x/yp47IMu0V8EZy8cEcccUT18Y9/PAm1k046qTrqqKOSqMuzxpjD+eEPf3j625RhWcyZ6F9IWSNy5JFHVu9973vT+0EQzJ/IgZsRj370o9MUWgz8GWec0W0AMp/4xCdSeCUnOgtRCEWYRst6w5KjgyCYL0KoV199dedVDwLFBPfCo0KLnvMf/vCHfakQb33rW6tzzjknhVd55zzr47IMAXfTTTelMCmETwlYoVTHg3vc4x7Vax7z/6UpAb/1rW9V+/fvT++zXb4HIlCH1bETtu94xzvS+0EQzB9zqIcHbgYQYia6ximnnNKXB6PHyrAfPHiw804/Qqjf/OY3O6+CIFg0f/EXfzF0FCoPHEHDW/7kJz+5uuaRv9WdzF4okhdKjhiP1k9/+tP2B2OwDLul08guPec5z6ke/OAHp/QO+buEnJzdBz7wgSnvL2NO5yc84Qnpc3l/dQxiCA9cECwOqQsh4GbAhz70odRD1Qvlgfvos2+fDLxcmrvc5S7JGArP3HjjjZ01ejz+8Y9PicTUNJfosIUnYJTvjbow4nrXTZ9Nusx6H2e9PWLZ0vTZpi7zuM6rvox6nd1bctjkgg3DQAZijdHkcarz1a9+tfPX+mA0rfBvaZfk8AoD18ui8LYRbsKpTTh/D3rQg5LQIwqHLYSupemzSZZZbi9va9b7V/477TLr/Vv1ZVuONV/XfLzDjlu0Tw7rmWee2XkCl8NaC7hytKlh91dddVVqFDJySCQGv/3tb08j15rCK7lnazSqYfrDlvvf//7poo3y3b0W2+A1IDxnsT2L8gNyaHgkZrHNWW/PNuTv8CLM6phXfXGcs77Oq75ITxj1OvvcAKM3velNnSdy8Syr4zlLvvvd76bwqtIkBOGwxfXxTDd9NsnCK3r++ec3fjbOYv/f9773pXQXg1mavjPJogNPFDd9NsnykIc8pHrJS17S+NkmLtq9AwcONH62aQsNwVY3fVZf3KvSPNaBlc6Ba6IUd02Un+vRj7IQb+oxNX02ySLfxSi6ps8mWeQH6RHo2Td9Pu4y6+1ZhLpf8YpXNH62qYvrLMTV9NmmLuNcZ96ladnreR/GsgTcNPs8DTyer3zlKzuvpkcJmFmO/iXsZ5nWopNQduynxQjhQZ7QTUSYUAdhG5Bypa7kurDWHjgwgosyhHqaszQEQiKKj84KDSFvRlOhz0mY9fag8bjmmms6r7aDWV/ndUBO16Ku87TP/yZ44MbhLW95S/KozAribdoSJvkasjnCwdnOzsK2295XvvKVzqvpeelLX5pGDW8LOp+zFNSrzKc+9anGOourytoLuEXBkOhpymWaFepZ3XDDDZ1X02N0Htf+oFIqo+A4s9Gsb6/8bFzyehLWlY3YJmZ9ndcBCfXbdp3XBc91U1HzSTFwZNbbm9TOZMr1pdJMu72SWXmN1wXHO8vzt8q4ro53XQgBNwGreDOv8gO2LQ9/ZtuOd93ZNg/cLIl7fXvZpmu/7se6djlws2IdLtys9nHYdibtYQ/b5ro/FHsxSUmLYPFsk4ATSjSIwQi7afOa8vNrtP/Ozk71uc99Lr2eBqFYdf2UlZGDOylqgQp15ll2pDFIgVH4edhMH4MwAlqCez5GaSVCbQouq4KwSQhfP/vZz07XIc96wqNu4IuC+EaCZzbFhvO8vehFL+rmNhr8ePbZZ3eLhGMVjzU8cCMib0RCP0M1q3ABI6M4qXlcp0WYQJ6VIp+uwzRhVGVVJHLmgsgMlRpcjj1Xhx8HD/yznvWsVCIBzp999YDMMpl6lZDr55wZnef4LYaeO2YNy6aKOwbfdFByZhyjY3aPr/I0T9sk4JRNkgqSyyHMAs/yoYceOnWawBe+8IXq2GOPTXU8Ta2Wa3uOi4ZW3tYtb3nL6sMf/nB6z32peLKKAz4bF2WobC8XWla9gD387Gc/m0rhbBKOx4jgN7/5zak0jWP8gz/4gzSNm/aF/do0jFL+L//lvySRnudVVhjb8atwsaqEgBsBjZECwRIcNcBvfOMbO59Mh97gbW5zm4mm/wFDlXsFhjQb7q2neOKJJ04sCq2vV3mnO92pW0jUcatlpsaeh3pciJnb3/72qeI8/MsLYHRrvd7VOpOvhX8VjnbOzCBw5ZVXpg6A6ZD0/k2fNAtvxapBmJun8w53uEMqvqs0iJHbRna5NzfpWq8jGibFg2E0ved52s5ono5QQfRpB0bo5Bg0ZdABoVkWZB8Hzx+bbRv14sZs7iQCzr1rNCb7x1tz+umnp87nJPZwXfAMK6nhXPJe8lARwJs2AlcpEPcKr6Op/HhrTQ6AK664Ion1VSUE3AhIxs4Vl3kSDEufFjXpGD7GZBZD8BkYBtkQfEaQEJsExomXTa2j+ohb9cz0zMaFJ8ZxZqHquIVwGFPzP24yGjY1CIlhRt/1EZqYxJO5amTBmjHqVDFtoo3x95yoSwZeuVl4mufBtnjgPGs6Ea6b+5G9mCZM6R4mCE2FppHTMavfE+PATujY8faYD5Y4nAYd0VLA8cDpSJQzXIyDfeNldNyHHXZY8sDp0Nfn590EtAPqOJodBLy1rot5e7NXc11xj+b71HHyKmqDeaZ54NQgzN5po+lFj9adrcyByxeZK9XDC2JOLsA0MACKS/JQCDFR+W6kaeDtEarSkzjuuOMm6r2WxpfruBRw3OYK+5Y3/zgQa1nAHX/88WlbDL4e3qRicxUpzw3hJuzuevO4aTCJV41Izs3ZFAi2o48+ujt1nTC83noWbUTdqoYitkXASavwvPEC60C6Nyd5ljNCnp5l3orDDz88NfjTlBzi+TjttNPS366JDuM0EFd5JLT7kM39/Oc/n15PArvPy8hWs7H+JYp1zDYJkREOi1xOg8fNdQYPFfu1KfBKK1avfWe/HJt2WScb7sNVDhmParu22gNnQm3GCZJrp60To/G2Pd6Ze97znsmweGjGpTS+xBDPG7i7p+kVMkynnnpqEnB6xY6ZB6VkXMNPqOrNgIjJPWPh3lmWZlkFnBtilZDJDZrroceOk08+eaaFT1cBlck1vkLGt7vd7ZJglxslfAzzfWrwV5FtEXBQFoidMFPGtKkgwq/yZHUeebsUbp5GEJoOjRhiK6SslAnkk6DT4L7E3e9+99RAewalM0wC73l+bi+77LJkE9nxSXP1VhUh7P/6X/9rmpP30ksv7YbbFTDWsZcPuClo63RohIkdr/tDR8e15WQQiVrlafpCwI2I+DiD4EaelfeEOGIIeGqmMXzwkLnZNKAE4TSFJt3URJawrJv3jne8YzL6BGc2iONCBOYcGd4Z4obHcJJ8lFVHo2bydcfIO/G2t70teTx4P7zWSM2ysOgqoYaSDgSPow6AkJ3nRsjcfRUsH7UYZx3O5smYJhyb7Z/tCGHNIs+KsMwdKPejgQxC+pN2JDTyeWAXdEKdy03DedN+GF0r7Awih3jdtBG3JXmwWf7bgJVVj5SEgBsDBiAPvZ9WcGUYmFnlQwlFMlDTerQcG4+gBleDLGeEARQeI+omOXbGvRwZ68FY1ZyoaeGZYATzOcs5N84dAVw2ApuI48vJ8RrkXIpgVdkmD1zQY1Y2PAhWna3MgQump24kN91oRqPQY13ORQi45XBwZ191yCGHNC77dnaq/Yfsq3YOdr48Uw50t70q9+iB/YdU+6caxNs7pvGYdL0GDuxvXbeZbKjav2+nqm/J/TLdOdo8wgMXBEtgE4XesGNa5eMNu7UcDuzvCQeNc7fxP9gSbzMRAmtCS/gQrYsUJwdbAnmmP+cYZnIAB6udfS0R3yDgML3Q3SxCwAVBEARLpU/AbSGL9S4RSftnKOB48Wa8vQECbvb7vt6EgAuCYKsJu7V8dgu4QhQc3Kn2tRr0A63vpBBrS+n4fvq709DzzJSv+7B+Wq+1vbTB3dveyet3VFR3e4UwGfwbbcGRtuGzjketu/6A32iLkfy9nmep99ud745w/LuOKX2vc7z1/em+5gEt1ktfzd9rLXmHBu5/h673zbZanxf76pqmfe3uZ/EbA99rn0+fNX13sWJ3M4gcuBWn78GzdO/w/gd0ema9vfEpQy+jM8l+T3OsPSM0MS3D2R9Kit7nPAgBt3zqAq5tz9zrPZHT/twzmf/2WcsW7OzvNuj17aDb4LeEhn+btt1ev/287xTb8N30d2dd9P9GfRslvc/qv+FP28l22u+kP7tiCP3rt3+z4fjT7vlOb7t5W91NJdrf399SddmOlOs1/fb+A719aH/U2/9M3/lobSP/fYCA9EfLju3kFZrO4673WnYvC7jW350td+n7vS0nPHAbQesh2+9Gbz1c6cZvve4+MRtG6l1OIuDGoXUe+y3fmDB6/UZufNqGc5eh6vSGw3zNjrBby2d3o1w+Q9muoXzf3y1B0urQZZGTll3PbvtZanuc8uvB296fxVSB/Rv8G+U2OiQ7lX+zef+7os27re37uysYO9QFTbl++++mY/J3ebzeKven/t3e/uz+ba8Hnf82/dcuf976z3633j/YEoy93dh9Hne/17oGnb/r1wH9v7fdhIDbKBoMSfGeG18tsvRg5H+7D0jre+mhKR76TH74k0u++I3W+/s9pGm99kObH7zeAzZgu3pqre3ta62nx5se3PydXdtFNkrltor3WvvEbT/0+Ir9LkMMPQPS2a6eaOv1bsPZ+62DjfvYodsL7Rx7Z9/a2+yEFPrOVz6e2uv0G60/8v529iVdx74fDIL1ZnejXAqF4tnte9/fbQE37HnoJux7rtMXh2872aPaBoc/c+U22t/Nz2o7WtC8/+l7nY2mvz33O2xP3jfrs2HDj7992srt9h/v7v2pb6Pzd7J79d9Ofw34/Q7d89rG76WQb/rublFYP4+738u/1/q3axt7NG1jWwkBt1GUD1qb3sPrYWiJAHd+fuCyQEjfaxkuf7Y+6zek5WcH2sYtba/9cOYHnmFoMqTN2+2sW9tX3+m57HvbtVoyCp31y/fy76XjHHp8PSNWHk/f7qbfb31uX1t/9K/T8Fu1fcx0t4/iuLshhdb/28Kx/9zsOlddAdf6fnsTbYrjCqYn7NYyyc97Zymet/w8ExL+bj8jtee89p38vZL0PHc+s9re297p26e8vUG/0X3fxlv07EP/smv/W3ag3WHrfY767zTvY//xl+8PPN7uQmC1/+16L9P+NB/jwN/v4jhKUaedaK/bNNp12G+US9/vddsK90v5W8EoRA7cWrBbwKUbPoVXW7Qe7PTcecA9OIUQ6HuA+h5OlKKq2F5NAO5reLAGbjfvQ/tF15Clr9S2689SJDW9Zx1Ga9DxtV709rvveLD79wm4cp1dv6Xn33mjK7w69As6v+V3Wv/x2LU+yEatfm52navOMe0Sut39C2ZBCLggmJKWzd1lp+YAGxmmr0d44DaKyQXcsLpA3c+ScDAaqbO9vvVb224Jl/rDNXC7hYDreqby/tW2297Vngcu9cpax5nCkvkHbY+o8rLh+FovuvvdfzyE0+7frwu49Jvlb7XWqe9jZvfr5pBC/dzsOled/S+PPdF3XMG0hN0KghmQ7e6cYAezCQ7ahIDbILIHp+8haj1U3uuGJltCojscPC27vVB9nrIWKd+r81mZW9b+vbZ3KX1O1HS+19tG83Z767YfzPS5pbt/5XZ9q9hOa2lvqnNMab3Wbw87vu55qB2P17Xfz+FmgjB/p/+3Bu1jh12GbFBIoX5u+l/vOr9p39r7W/5cEARBsH2EgAuCmUPs9efFzY6WmOsIuWA2hN0KgmCTiRy4IBiLeQgtwrDjUQxmRgi4IAjWkfDABUGw1YTdCoJgHQkBFwRBEARBsGaEgAuCYKsJuxUEwSYTOXBBEGwkIeCCIFhHwgMXBMFWE3YrCIJ1JARcEARBEATBmhECbo04aO7OAwerg7OsTWGezb6JNpvwnc6f2GOdg2nuzqbP7ftsC2usKutyrdrXpPPnlhJ2a970ClEfqM1SMjtGLdtjX3aX4qnPZ9xELvjdONtAp1B4t3D4WrMJ1ysXXo+yS4gcuGXTMhDtG7Z1Y+7M8JYcOC1TTQiUDJvK6cBOlXYv/9vlYGt7tmlCqQ1nXa5VizQF2gx3cR0JATdfujOHtO7FfYfMp8B1ElcDBUFLBAy7yUfZL9/pbKNJPLBrm8JGXK/E5tfNDA/cAvne975X/dM//VPn1ZiYnql1U/ffs21RRCQcSILJ361e00H/tkREvnOTFyZP55SFVOt7PDOth2F/64umePLxQdtJb7fn30xrpG0X63rAi235fa/QM261h9BDV0wAn2lve8B+1/d1wXzrW9+qvvrVr6brNhZrcq0SrX2t28pVvibzIOzWnGndY7sba54VHpK2vUiiIU/TV0zXh9TYF99tk9fvLN05mtvvJy+Z37VO6/71nbbnrPV5d1+ylyZvu3+fStL+5WfA8933hc56DYJk2HHtPobag7gsNuB6tWkWcGt5TQYQAm4K/vmf/7n65je/Wf3d3/1d9bWvfa36h3/4h84nVfWjH/2o+/7Xv/716h3veEf127/929Wpp55afelLX0rv+fzb3/529bOf/SytM2h7PrdoWNsTtrfvVu7t3EjvtG7EdK+lRr5z43duPuE8zbubOTXG6ePa9/Pr+r/ofIe3Jr3Ved33+53vdieGL36/pM8Qor4f5X7X93UG/OQnP0nnNp/jYcu9733v6ha3uEX1kIc8JF2vpu+Ui2267liHa5VoOrf135vzNQm2gNb9okHMwqe8j/a1Ogqp0XRD+Z5/u/deQXnPpfXan7c7ja1nJgmC3Z/tb/1W9p4lcdERBP7u+17rueztU/v9THd/2y/696312+mVfe8TPq3nZthx7TqG9OfUaEfYuYmdBbC/a3y92jQJuOVck3kRAm4KfvjDH1bPf/7zq6c85Slpef/739/5pKo+8YlPVE9+8pOrpz3tadUzn/nM6swzz0wPxL/7d/+uuuCCC6o//uM/rs4555zqJS95SXrgUN/ejTfemN5HL3esd1P2xFKL1o2X7vnuzVg2um1PTfp+8qhoyHfa6+bv5/Xr/6Lzne7v1V8XdB/08qEoab3fKCC63+/td0vN9O/rDPjiF79YPf3pT6/OPffcdG0GLa7Pf/pP/ylds9/4jd+onvGMZzR+r1ye+tSnVn/zN3+zNtcqUa6bGbJ/87gmy2YbPXA6GjqIltzpgI7iP/7jP6b32aNvfOMb1SmnnFLd+c53TjYtr+OzbLcwbHsluQN3YH+rEdWQFo1pusVa/6YGtHvvodPotpZ8G6K7jdTADxYEOzpT3RV73ysbaHZrX9e701rKH2qR9ztRbL9On9DD0OPydnkMg3EenfN87gctPn/sYx9bHXroodWJJ57YvSZN382Lzwm++rXCul6vNj3728eMrsk6ETlwA3Dj//jHP05L2eNh3PL7vkM4PO5xj6suv/zyZCDzZz/96U/7Hpxye6WBdMPy5hggoAFNuAFbN+j+1g3OW5NuyoZG140v9LbfBOtu/FZjbp3kHHIz+75ttb7PQ5Nu6nRzH2gnuOdtpu+01kvbaH1W/H73IUn7xwOUt98WbMmwJQ9QfwivfVzpj1373f69Yl9ngHOdz+9eyxVXXFGdd9551Wtf+9rGz5sW1+zg8xzTGlwr5G0WLPqaLJttFHCvfOUrqyc84Qlp0YnMaMyf97znVU960pPSve/c3PzmN08Nmk6ozo+Oig4QcZe58sor07Ye//jHV694xSs673Zwj+Wbzv3TuqeSfei8lcjf6Xzeu/e81WmEa9vp/p0oBEHfuvUGvve90qPjb9/r22RJa5tZVJRCop8GwTDkuHYfw2CkcVx44YWp0+/cD1o4C/7bf/tv6Vj+43/8j6kjqnPZ9N28uG5ve9vbOr/Uonae1/J6JRquB4bs++79XG3CA7dltEN0bYTU8t+ryDrt6zxYxePfxGuyjXbr7//+71OOp+X73/9+5912B+e73/1uev873/lOSvHQyD/4wQ+uPvvZz3bfs5QdVtvI27PtPlI6Qadh7o4KbHUK0muNdatT4/N9rX9LT0/nu7mxTkv2ihBU3e/1lnbjW2w7vdd+nRrrVgO91/fS64ZWPIuLtqDpeeR6+1cXdgRE6/0Bx7XrGIYoBx1D5975zee/afEdToKHPexh1XOf+9zG79QX2+SJ67Jh16u7D4nZXZNVIATcliE3S+5ASobvMzarxzrt6zxYxePf9msSrAitxrvXtLYa5db9uHZswjGMyroc65pdkxBwQRBsNWG31o8+L8/AUYirzSYcw6isy7Fu6jWJHLilI6cqL523mjjY6kGMkpy05/d83vkzs8c6gwr4dve787r1TnodBKtACLggCNaR8MCtC2LznXh8u0RFGdcvaH2vm5A5jIHfaxBumWHbbu1T8jbnfzvY13b5CmE36x5sv24tI+zlmpKFtqXzVhNLFNvtfez82cf2ieuwW/OlV7trFM/GgREr9GdG+b5cqZzL1WPwYIQe2SOTk+e71HKluqlSnZytXu7YejHetcI412vU7056vTr5bYPO/ZpfmyZCwC0II0+NJLI0Ddfek0LAgWFJIx13WoKpdVMTSunmziIrNeDtEaFtsnAiqHzuey0RVVvfdhmrdrHZ2rp+s7VOe7v9Aqz3cLUevqbEz2L/xivoW9vvKZjovE9Cca1WUmy36I407WMbxHWAUZ6FaZ6X/nVrDbfnY4AwSIJpZEGw1/cH2CIM2YcuvtNZvy4eysE8Xdvmz4EP5Low+rXCONdr4muFUa5XgohrFmjrf212EwJuChipH/zgB2kElpFXw5b3vOc9aYi3Om+q+zd9p7701VM6+LxdAi6P0klv539bN7qGu21gejdzKuPh5q99b9f69c/Tn50HovWeHllq5Fu/X3raenXGmh9E5UNK7H/f13b9bns7u/Z7SoycazrXTYtr++d//udppFbT501LKgvTcK2WI7a9135dF9yN57P1O8sS18skOp6DMfoxF4UtyxqNR00UoHX/5YKwvdGGGuiWzSrKRvR7gVrb6XqGWkvbYLS+33oOdm2n/Ru+l36n+/vZS9O03fy6TZ+NSvtbfFigJmL7k852GkRK2lbLRvrd7r/d56/puJbFONfKh+3rxd40n9PymPK1bX/Wt62WTfG99jku96F+vfJ2+69VD99vEnCd9db62kxO5MA1wLC9+93vrm644YbqLW95y8DlrW99a/XGN74xDce/5JJL0uum75XLm9/85upTn/pU55daaFyLm6fbI2w9AOnt/G9HFOTGvlfQtd2Ij1wUNn+e3qoJuPRuP12hVazXo/Xb9ZVa3+t7b9fvth4cb9T3e0qIsVHOv+9cffXV1VlnnVVddtllqU5S0/fKxX1gxgbHsApi23tjzcDQoa/hwq7faV+bWYvrZbGNAk5Ho6mOYX3R2dTpPP/886uPfexjfXUqBy223U/rfqk3nK17KT0jrXsnC6O2TcuNfEG+v3Z911+d7zd8lt5L92nP89N9FsvvFfdx/gzd99svus9YP+xT5/3Wvqe/WtvpFwodEdA53vRvub2Gfa/DWTDKubc4/x/5yEdSnb6mz5uWXkmYca5V+rD/erW+s+e1ar/Z9/l8Z19oMcdrs0zCAzclbvxRFg/gX/3VX6UGvunzpqWvx+shcuO1bkRiJk/RlG6w1k2ngU43Wut1arjTQ+Fh7Nx06Xutz1oPUFq1872m9VNR2AO1m9h6HjI3e+sB2VUQNgmttnBsb78QaDw0nT+TUUyCot8j5P30/HYfnta+dx6qWRaOdR2aznXTQvhcdNFF1TXXXJO8oU3fqS8pdJQNXofug++cezv/2znWeYlt7/U8ozXyuk201u1eO+z6nc61mbG4XhbbaLduuummdH83dUTKRUfmOc95Tup8vulNb2r8Trn4jhlp+r11DaKgdU/17E2+dz0npSDoNK6tJd+ru2t7DRZw7tf2c9jbZtkIZ4HW3aaleCj6OjLF9vtg5xre7hN/yM9Q3k7xzKK5ZlkP9ued73xn6tg3nfe8uF6vf/3rU8FfzoK3v/3tjd8rF/fBpz/96c4vjXOt/JXP7RjXqv1h/7Za57FnMwdfr4lnXyiY9bVZJiHgtoR1LcC6zP3OjVASZeOg4fCwL1tst7470gwMHbGdDFvrHC9LXAeLI099VZ9Wqb7I3f3c5z5XffSjH03rNH2nvuTUj95zUxMFno8cAisay3ZD2bq3u413pyF2r/oj/9tHp7HftZ3Wun6nfeN2BUHp0cmenoEdkO76ttkTEiXW3f12g4gojmGXSGg8rn6cS9ei6XyXi++8613vSuk6L37xi1PEoel75ZKn0mozzrVyjO1za37ndAijXKv0Z31braW7wpDr1fre8FPVcO77mP21WSYh4LaE1MhrbDXOnXtzHVjX/Z6GdRHb69opqBN2a74MH9nY89xYyhyk3GCnJXWIiIned7thr9bffVX50+vetuV11t9r+l56r/1GlywuShHR+0oRPm3R29+62CMaWu+3jmER1f9LcT5u53Osa2U3O+c/n+O07HmtmrbVuVZ+bITvpdcN56krBpMw712rVbk2yyJy4IJgQayLaN0UcR0Cbk1oNd695rPV8Lbuu41gE49rU45pxY8jPHBBEGw1Ybf2hidn7FSCGdPnkdvlSVlfNvG4NuWYVv04QsAFQRAEQRCsGSHggiDYasJuBUGwyUQOXBAEG0kIuCAI1pHwwAVBsNWE3QqCYB0JARcEQRAEQbBmhIALgmCrCbsVBMEmM3IOHGOYl3gdr+N1vI7X8Tpex+t4PZ/XoxCDGIIgCIIgCFaIyy67bM8lBFwQBEEQBMEKQaDtRQi4IAiCIAiCFWJvAVdV/z9R05ezf5t16wAAAABJRU5ErkJggg==" /></p><p><strong>Figure 2 Mean change in HbA<sub>1c</sub> (%) and body weight (kg) from baseline to week 40</strong></p><p><strong>&nbsp;</strong></p><p><em><u>SUSTAIN 3 &ndash; Ozempic vs. exenatide ER both in combination with metformin or metformin with</u> <u>sulfonylurea</u></em></p><p>In a 56-week open-label trial, 813 patients on metformin alone (49%), metformin with sulfonylurea (45%) or other (6%) were randomised to Ozempic 1 mg or exenatide ER 2 mg once weekly.</p><p>&nbsp;</p><p>Table 5 SUSTAIN 3: Results at week 56</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Semaglutide 1 mg</strong></p></td><td><p><strong>Exenatide ER 2 mg</strong></p></td></tr><tr><td><p>Intent-to-Treat (ITT) Population (N)</p></td><td><p>404</p></td><td><p>405</p></td></tr><tr><td><p><strong>HbA</strong><strong>1c (%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>8.4</p></td><td><p>8.3</p></td></tr><tr><td><p>Change from baseline at week 56</p></td><td><p>-1.5</p></td><td><p>-0.9</p></td></tr><tr><td><p>Difference from exenatide [95% CI]</p></td><td><p>-0.6 [-0.8, -0.4]<sup>a</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA</strong><strong>1c &lt;7%</strong></p></td><td><p>67</p></td><td><p>40</p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>10.6</p></td><td><p>10.4</p></td></tr><tr><td><p>Change from baseline at week 56</p></td><td><p>-2.8</p></td><td><p>-2.0</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>96.2</p></td><td><p>95.4</p></td></tr><tr><td><p>Change from baseline at week 56</p></td><td><p>-5.6</p></td><td><p>-1.9</p></td></tr><tr><td><p>Difference from exenatide [95% CI]</p></td><td><p>-3.8 [-4.6, -3.0]<sup>a</sup></p></td><td><p>-</p></td></tr></tbody></table><p><sup>a</sup>p &lt;0.0001 (2-sided) for superiority</p><p>&nbsp;</p><p><em><u>SUSTAIN 4 &ndash; Ozempic vs. insulin glargine both in combination with 1&ndash;2 oral antidiabetic drugs</u> <u>(metformin or metformin and sulfonylurea)</u></em></p><p><em><u>SUSTAIN 3 &ndash; Semaglutide vs. exenatide ER both in combination with metformin or metformin with sulfonylurea</u></em></p><p>In a 56-week open-label trial, 813&nbsp;patients on metformin alone (49%), metformin with sulfonylurea (45%) or other (6%) were randomised to <u>semaglutide</u><em> </em>1&nbsp;mg or exenatide ER 2&nbsp;mg once weekly.</p><p>&nbsp;</p><p><strong>Table 5 SUSTAIN 3: Results at week 56 </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Semaglutide</strong></p><p><strong>1&nbsp;mg</strong></p></td><td><p><strong>Exenatide ER</strong></p><p><strong>2&nbsp;mg</strong></p></td></tr><tr><td><p>Intent-to-Treat (ITT) Population (N)</p></td><td><p>404</p></td><td><p>405</p></td></tr><tr><td><p><strong>HbA<sub>1c</sub> (%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>8.4</p></td><td><p>8.3</p></td></tr><tr><td><p>Change from baseline at week 56</p></td><td><p>-1.5</p></td><td><p>-0.9</p></td></tr><tr><td><p>Difference from exenatide [95% CI]</p></td><td><p>-0.6 [-0.8, -0.4]<sup>a</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA<sub>1c</sub> &lt;7%</strong></p></td><td><p>67</p></td><td><p>40</p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>10.6</p></td><td><p>10.4</p></td></tr><tr><td><p>Change from baseline at week 56</p></td><td><p>-2.8</p></td><td><p>-2.0</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>96.2</p></td><td><p>95.4</p></td></tr><tr><td><p>Change from baseline at week 56</p></td><td><p>-5.6</p></td><td><p>-1.9</p></td></tr><tr><td><p>Difference from exenatide [95% CI]</p></td><td><p>-3.8 [-4.6, -3.0]<sup>a</sup></p></td><td><p>-</p></td></tr></tbody></table><p><sup>a</sup>p &lt;0.0001 (2-sided) for superiority</p><p>&nbsp;</p><p><em><u>SUSTAIN 4 &ndash; </u></em><u>Semaglutide</u><em><u> vs. insulin glargine both in combination with 1&ndash;2 oral antidiabetic </u></em><u>medicinal products</u><em><u> (metformin or metformin and sulfonylurea) </u></em></p><p>In a 30-week open-label comparator trial 1&nbsp;089&nbsp;patients were randomised to semaglutide 0.5&nbsp;mg once weekly, <u>semaglutide</u> 1&nbsp;mg once weekly, or insulin glargine once-daily on a background of metformin (48%) or metformin and sulfonylurea (51%).</p><p>&nbsp;</p><p><strong>Table 6 SUSTAIN 4: Results at week 30 </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Semaglutide</strong></p><p><strong>0.5&nbsp;mg</strong></p></td><td><p><strong>Semaglutide</strong></p><p><strong>1&nbsp;mg</strong></p></td><td><p><strong>Insulin Glargine</strong></p></td></tr><tr><td><p>Intent-to-Treat (ITT) Population (N)</p></td><td><p>362</p></td><td><p>360</p></td><td><p>360</p></td></tr><tr><td><p><strong>HbA<sub>1c</sub> (%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>8.1</p></td><td><p>8.2</p></td><td><p>8.1</p></td></tr><tr><td><p>Change from baseline at week 30</p></td><td><p>-1.2</p></td><td><p>-1.6</p></td><td><p>-0.8</p></td></tr><tr><td><p>Difference from insulin glargine [95% CI]</p></td><td><p>-0.4 [-0.5, -0.2]<sup>a</sup></p></td><td><p>-0.8 [-1.0, -0.7]<sup>a</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA<sub>1c</sub> &lt;7%</strong></p></td><td><p>57</p></td><td><p>73</p></td><td><p>38</p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>9.6</p></td><td><p>9.9</p></td><td><p>9.7</p></td></tr><tr><td><p>Change from baseline at week 30</p></td><td><p>-2.0</p></td><td><p>-2.7</p></td><td><p>-2.1</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>93.7</p></td><td><p>94.0</p></td><td><p>92.6</p></td></tr><tr><td><p>Change from baseline at week 30</p></td><td><p>-3.5</p></td><td><p>-5.2</p></td><td><p>+1.2</p></td></tr><tr><td><p>Difference from insulin glargine [95% CI]</p></td><td><p>-4.6 [-5.3, -4.0]<sup>a</sup></p></td><td><p>-6.34 [-7.0, -5.7]<sup>a</sup></p></td><td><p>-</p></td></tr></tbody></table><p><sup>a</sup>p &lt;0.0001 (2-sided) for superiority</p><p><u>&nbsp;</u></p><p><em><u>SUSTAIN 5 &ndash; </u></em><u>Semaglutide</u><em><u> vs. placebo both in combination with basal insulin</u></em></p><p>In a 30-week double-blind placebo-controlled trial, 397&nbsp;patients inadequately controlled with basal insulin with or without metformin were randomised to <u>semaglutide</u> 0.5&nbsp;mg once weekly, <u>semaglutide</u> 1&nbsp;mg once weekly or placebo.</p><p>&nbsp;</p><p><strong>Table 7 SUSTAIN 5: Results at week 30</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Semaglutide</strong></p><p><strong>0.5&nbsp;mg</strong></p></td><td><p><strong>Semaglutide</strong></p><p><strong>1&nbsp;mg</strong></p></td><td><p><strong>Placebo</strong></p></td></tr><tr><td><p>Intent-to-Treat (ITT) Population (N)</p></td><td><p>132</p></td><td><p>131</p></td><td><p>133</p></td></tr><tr><td><p><strong>HbA<sub>1c</sub> (%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>8.4</p></td><td><p>8.3</p></td><td><p>8.4</p></td></tr><tr><td><p>Change from baseline at week 30</p></td><td><p>-1.4</p></td><td><p>-1.8</p></td><td><p>-0.1</p></td></tr><tr><td><p>Difference from placebo [95% CI]</p></td><td><p>-1.4 [-1.6, -1.1]<sup>a</sup></p></td><td><p>-1.8 [-2.0, -1.5]<sup>a</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA<sub>1c</sub> &lt;7%</strong></p></td><td><p>61</p></td><td><p>79</p></td><td><p>11</p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>8.9</p></td><td><p>8.5</p></td><td><p>8.6</p></td></tr><tr><td><p>Change from baseline at week 30</p></td><td><p>-1.6</p></td><td><p>-2.4</p></td><td><p>-0.5</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>92.7</p></td><td><p>92.5</p></td><td><p>89.9</p></td></tr><tr><td><p>Change from baseline at week 30</p></td><td><p>-3.7</p></td><td><p>-6.4</p></td><td><p>-1.4</p></td></tr><tr><td><p>Difference from placebo<sup> </sup>[95% CI]</p></td><td><p>-2.3 [-3.3, -1.3]<sup>a</sup></p></td><td><p>-5.1 [-6.1, -4.0]<sup>a</sup></p></td><td><p>-</p></td></tr></tbody></table><p><sup>a</sup>p &lt;0.0001 (2-sided) for superiority</p><p>&nbsp;</p><p><em><u>SUSTAIN FORTE &ndash; Semaglutide 2&nbsp;mg vs. semaglutid</u></em><em>e</em><em><u> </u></em><em><u>1&nbsp;m</u></em><em><u>g</u></em></p><p><u>In a 40-week double-blind trial, 961&nbsp;patients inadequately controlled with metformin with or without sulfonylurea were randomised to</u> <u>semaglutide</u> <u>2&nbsp;mg once weekly or semaglutide 1&nbsp;mg once weekly. </u></p><p>&nbsp;</p><p><u>Treatment with semaglutide</u> <u>2&nbsp;mg resulted in a statistically superior reduction in HbA1c after 40&nbsp;weeks of treatment compared to semaglutide</u> <u>1&nbsp;mg.</u></p><p><em><u>&nbsp;</u></em></p><p><u>Table 8 SUSTAIN FORTE: Results at week 40 </u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><u>&nbsp;</u></p></td><td><p><u>Semaglutide</u></p><p><u>1&nbsp;mg</u></p></td><td><p><u>Semaglutide</u></p><p><u>2&nbsp;mg</u></p></td></tr><tr><td><p><u>Intent-to-Treat (ITT) Population (N)</u></p></td><td><p><u>481</u></p></td><td><p><u>480</u></p></td></tr><tr><td><p><u>HbA1c (%)</u></p></td><td><p><u>&nbsp;</u></p></td><td><p><u>&nbsp;</u></p></td></tr><tr><td><p><u>Baseline (mean)</u></p></td><td><p><u>8.8</u></p></td><td><p><u>8.9</u></p></td></tr><tr><td><p><u>Change from baseline at week 40</u></p></td><td><p><u>-1.9</u></p></td><td><p><u>-2.2</u></p></td></tr><tr><td><p><u>Difference from semaglutide 1&nbsp;mg [95% CI]</u></p></td><td><p><u>-</u></p></td><td><p><u>-0.2 [-0.4, -0.1]a</u></p></td></tr><tr><td><p><u>Patients (%) achieving HbA1c &lt;7%</u></p></td><td><p><u>58</u></p></td><td><p><u>68</u></p></td></tr><tr><td><p><u>FPG (mmol/L)</u></p></td><td><p><u>&nbsp;</u></p></td><td><p><u>&nbsp;</u></p></td></tr><tr><td><p><u>Baseline (mean)</u></p></td><td><p><u>10.9</u></p></td><td><p><u>10.7</u></p></td></tr><tr><td><p><u>Change from baseline at week 40</u></p></td><td><p><u>-3.1</u></p></td><td><p><u>-3.4</u></p></td></tr><tr><td><p><u>Body weight (kg)</u></p></td><td><p><u>&nbsp;</u></p></td><td><p><u>&nbsp;</u></p></td></tr><tr><td><p><u>Baseline (mean)</u></p></td><td><p><u>98.6</u></p></td><td><p><u>100.1</u></p></td></tr><tr><td><p><u>Change from baseline at week 40</u></p></td><td><p><u>-6.0</u></p></td><td><p><u>-6.9</u></p></td></tr><tr><td><p><u>Difference from semaglutide 1&nbsp;mg [95% CI]</u></p></td><td><p><u>&nbsp;</u></p></td><td><p><u>-0.9 [-1.7, -0.2]b</u></p></td></tr></tbody></table><p><u><sup>a</sup></u><u>p&lt;0.001 (2-sided) for superiority</u></p><p><u><sup>b</sup></u><u>p&lt;0.05 (2-sided) for superiority</u></p><p><u>&nbsp;</u></p><p><em><u>SUSTAIN 9 &ndash; </u></em><em><u>Semaglutide</u></em><em><u> vs. placebo as add-on to SGLT2 inhibitor &plusmn; metformin or </u></em><em><u>sulfonylurea</u></em></p><p>In a 30-week double-blind placebo-controlled trial, 302&nbsp;patients inadequately controlled with SGLT2 inhibitor with or without metformin or s<u>ulfonylure</u>a were randomised to semaglutide 1&nbsp;mg once weekly or placebo.</p><p>&nbsp;</p><p><strong>Table </strong><strong><u>9</u></strong><strong> SUSTAIN 9: Results at week 30 </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Semaglutide</strong></p><p><strong>1&nbsp;mg</strong></p></td><td><p><strong>Placebo</strong></p></td></tr><tr><td><p>Intent-to-Treat (ITT) Population (N)</p></td><td><p>151</p></td><td><p>151</p></td></tr><tr><td><p><strong>HbA<sub>1c</sub> (%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>8.0</p></td><td><p>8.1</p></td></tr><tr><td><p>Change from baseline at week 30</p></td><td><p>-1.5</p></td><td><p>-0.1</p></td></tr><tr><td><p>Difference from placebo [95% CI]</p></td><td><p>-1.4 [-1.6, -1.2]<sup>a</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA<sub>1c</sub> &lt;7%</strong></p></td><td><p>78.7</p></td><td><p>18.7</p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>9.1</p></td><td><p>8.9</p></td></tr><tr><td><p>Change from baseline at week 30</p></td><td><p>-2.2</p></td><td><p>0.0</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline (mean)</p></td><td><p>89.6</p></td><td><p>93.8</p></td></tr><tr><td><p>Change from baseline at week 30</p></td><td><p>-4.7</p></td><td><p>-0.9</p></td></tr><tr><td><p>Difference from placebo [95% CI]</p></td><td><p>-3.8 [-4.7, -2.9]<sup>a</sup></p></td><td><p>-</p></td></tr></tbody></table><p><sup>a</sup>p &lt; 0.0001 (2-sided) for superiority, adjusted regarding multiplicity based on hierarchical testing of the HbA<sub>1c</sub> value and body weight</p><p>&nbsp;</p><p><em><u>Combination with sulfonylurea monotherapy</u></em></p><p>In SUSTAIN 6 (see subsection &ldquo;Cardiovascular disease&rdquo;) 123&nbsp;patients were on sulfonylurea monotherapy at baseline. HbA<sub>1c</sub> at baseline was 8.2%, 8.4% and 8.4% for <u>semaglutide</u> 0.5&nbsp;mg, <u>semaglutide</u> 1&nbsp;mg, and placebo, respectively. At week&nbsp;30, the change in HbA<sub>1c </sub>was ‑1.6%, -1.5% and 0.1% for s<u>emaglutide</u> 0.5&nbsp;mg, <u>semaglutide</u> 1&nbsp;mg, and placebo, respectively.</p><p><u>&nbsp;</u></p><p><em><u>Combination with premix insulin &plusmn; 1&ndash;2 OADs</u></em></p><p>In SUSTAIN 6 (see subsection &ldquo;Cardiovascular disease&rdquo;) 867&nbsp;patients were on premix insulin (with or without OAD(s)) at baseline. HbA<sub>1c</sub> at baseline was 8.8%, 8.9% and 8.9% for s<u>emaglutide</u> 0.5&nbsp;mg, <u>semaglutide</u> 1&nbsp;mg, and placebo, respectively. At week 30, the change in HbA<sub>1c</sub> was ‑1.3%, -1.8% and -0.4% for <u>semaglutide</u> 0.5&nbsp;mg, <u>semaglutide</u> 1&nbsp;mg, and placebo, respectively.</p><p>&nbsp;</p><p><em><u>Cardiovascular disease</u></em></p><p>In a 104-week double-blind trial (SUSTAIN 6), 3&nbsp;297&nbsp;patients with type 2&nbsp;diabetes mellitus at high cardiovascular risk were randomised to either <u>semaglutide</u><em> </em>0.5&nbsp;mg once weekly, <u>semaglutide</u> 1&nbsp;mg once weekly or corresponding placebo in addition to standard-of-care hereafter followed for 2&nbsp;years. In total 98% of the patients completed the trial and the vital status was known at the end of the trial for 99.6% of the patients.</p><p>&nbsp;</p><p>The trial population was distributed by age as: 1&nbsp;598&nbsp;patients (48.5%) &ge;65&nbsp;years, 321&nbsp;(9.7%) &ge;75&nbsp;years, and 20&nbsp;(0.6%) &ge;85&nbsp;years. There were 2&nbsp;358&nbsp;patients with normal or mild renal impairment, 832 with moderate and 107&nbsp;with severe or end stage renal impairment. There were 61% males, the mean age was 65&nbsp;years and mean BMI was 33&nbsp;kg/m<sup>2</sup>. The mean duration of diabetes was 13.9&nbsp;years.</p><p>&nbsp;</p><p>The primary endpoint was time from randomisation to first occurrence of a major adverse cardiovascular event (MACE): cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.</p><p>&nbsp;</p><p>The total number of primary component MACE endpoints was 254, including 108 (6.6%) with semaglutide and 146 (8.9%) with placebo. See figure&nbsp;4 for results on primary and secondary cardiovascular endpoints. Treatment with semaglutide resulted in a 26% risk reduction in the primary composite outcome of death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke. The total numbers of cardiovascular deaths, non-fatal myocardial infarctions and non-fatal strokes were 90, 111, and 71, respectively, including 44 (2.7%), 47 (2.9%), and 27 (1.6%), respectively, with semaglutide (figure&nbsp;4). The risk reduction in the primary composite outcome was mainly driven by decreases in the rate of non-fatal stroke (39%) and non‑fatal myocardial infarction (26%) (figure&nbsp;3).</p><p><strong>&nbsp;</strong></p><p><img alt="" width="512" height="363" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p><strong>Figure 3 Kaplan-Meier plot of time to first occurrence of the composite outcome: cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (SUSTAIN 6)</strong></p><p><strong><img alt="" width="617" height="302" src="data:image/png;base64,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" /><br /><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="Word.Document.12" ShapeID="_x0000_i1030"
  DrawAspect="Content" ObjectID="_1669471199">
  <o:WordFieldCodes>\s</o:WordFieldCodes>
 </o:OLEObject>
</xml><![endif]--></strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span lang=EN-US style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span></span></b><![endif]--><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Figure 4 Forest plot: analyses of time to first occurrence of the composite outcome, its components and all cause death (SUSTAIN 6)</strong></p><p><strong>&nbsp;</strong></p><p>There were 158&nbsp;events of new or worsening nephropathy. The hazard ratio [95% CI] for time to nephropathy (new onset of persistent macroalbuminuria, persistent doubling of serum creatinine, need for continuous renal replacement therapy and death due to renal disease) was 0.64&nbsp;[0.46; 0.88] driven by new onset of persistent macroalbuminuria.</p><p>Kidney Outcomes Trial of OZEMPIC in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease</p><p><strong>&nbsp;</strong></p><p>FLOW (NCT03819153) was a multi-center, multi-national, randomized, placebo-controlled, double- blind parallel-group, event driven trial to determine the effect of OZEMPIC relative to placebo in adults with type 2 diabetes and chronic kidney disease (eGFR 25 to 75 mL/min/1.73 m<sup>2</sup> with urine albumin to creatinine ratio [UACR] &gt; 100 mg/g and &lt;5000 mg/g). All patients needed to have HbA1c &le; 10% at screening and be receiving standard of care background therapy, including a maximum tolerated labeled dose of a renin-angiotensin-aldosterone system (RAAS) blocking agent including an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment was contraindicated or not tolerated. The trial excluded patients with congenital or hereditary kidney diseases including polycystic kidney disease, autoimmune kidney diseases including glomerulonephritis or congenital urinary tract malformations or classified as being in New York Heart Association (NYHA) Class IV heart failure. Concomitant CV therapies could be adjusted, at the discretion of the investigator, to ensure participants were treated according to the standard of care.</p><p>The primary objective of FLOW was to demonstrate that OZEMPIC delays the progression of renal impairment and lowers the risk of renal and cardiovascular mortality compared to placebo, both added to standard-of-care, in subjects with type 2 diabetes and chronic kidney disease. The secondary outcomes of FLOW were annual rate of change in eGFR (CKD-EPI) (total eGFR slope), time to first occurrence of a composite major adverse cardiovascular event (MACE) endpoint (consisting of non- fatal myocardial infarction, non-fatal stroke, CV death) as well as all-cause death.</p><p>&nbsp;</p><p>In FLOW, a total of 3533 patients were randomized to receive OZEMPIC or placebo and were followed for a median of 40.9 months. The mean age of the study population was 66.6 years, and 69.7% of patients were male and 30.3% of patients were female. This global trial population was 65.8% White, 23.9% Asian, and 4.5% Black or African American. At baseline, the mean eGFR was 47 mL/min/1.73m<sup>2</sup>, with 11.3% of patients having an eGFR &lt;30 mL/min/1.73m<sup>2</sup>. Median urine albumin to creatinine ratio (UACR) was 568 mg/g with 68.5% of patients with UACR &gt;300 mg/g.</p><p>&nbsp;</p><p>At baseline, 95.3% of patients were treated with an ACE inhibitor or ARB, 15.6% were on sodium- glucose cotransporter 2 [SGLT2] inhibitors, 76.1% were on a statin, and 50.2% were on an antiplatelet agent.</p><p>&nbsp;</p><p>OZEMPIC was superior to placebo in reducing the incidence of the primary composite endpoint of a sustained decline in eGFR of &ge;50%, sustained eGFR &lt; 15 mL/min/1.73 m<sup>2</sup>, chronic renal replacement therapy, renal death, CV death (HR 0.76 [95% CI 0.66, 0.88], p=0.0001) as shown in Table 10 and Figure 7. The treatment effect reflected a reduction in a sustained decline in eGFR of &ge;50%, progression to kidney failure and CV death. There were few renal deaths during the trial.</p><p>&nbsp;</p><p>OZEMPIC also reduced the annual rate of change in eGFR(CKD-EPI)(total eGFR slope) and reduced the risk to time to first occurrence of a composite cardiovascular major adverse cardiovascular event (MACE) (Table 10 and Figure 8).</p><p>&nbsp;</p><p>The treatment effect on the primary composite endpoint was generally consistent across the pre- specified subgroups examined, including age, biological sex, eGFR and UACR.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Table 10: Analyses of the Primary and Secondary Endpoints and their Individual Components in</strong></p><p><strong>FLOW Trial</strong></p></td><td><p>&nbsp;</p><p><strong>Placebo N=1766 (%)</strong></p></td><td><p><strong>OZEMPIC</strong></p><p><strong>1 mg N=1767 (%)</strong></p></td><td><p><strong>Hazard ratio vs placebo (95% CI)<sup>1</sup></strong></p></td><td><p><strong>p- value<sup>2</sup></strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:1061px"><tbody><tr><td style="width:544px"><p>&nbsp;</p></td><td style="width:130px"><p><strong>Number of</strong></p><p><strong>Patients (%)</strong></p></td><td style="width:113px"><p>&nbsp;</p></td><td style="width:205px"><p>&nbsp;</p></td><td style="width:67px"><p>&nbsp;</p></td></tr><tr><td style="width:544px"><p>Composite Endpoint (&ge; 50% sustained eGFR decline, sustained eGFR &lt; 15 mL/min/1.73 m<sup>2</sup>, chronic renal replacement therapy, or renal or cardiovascular death</p><p>(time to first occurrence)<sup>3</sup></p></td><td style="width:130px"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>410 (23.2)</p></td><td style="width:113px"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>331 (18.7)</p></td><td style="width:205px"><p>&nbsp;</p><p>&nbsp;</p><p>0.76 (0.66,</p><p>0.88)</p></td><td style="width:67px"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>0.0001</p></td></tr><tr><td style="width:544px"><p>&ge; 50% sustained eGFR</p><p>decline<sup>3</sup></p></td><td style="width:130px"><p>213 (12.1)</p></td><td style="width:113px"><p>165 (9.3)</p></td><td style="width:205px"><p>0.73 (0.59,</p><p>0.89)</p></td><td style="width:67px"><p>&nbsp;</p></td></tr><tr><td style="width:544px"><p>Sustained eGFR</p><p>&lt;15mL/min/1.73 m<sup>2</sup> <sup>3</sup></p></td><td style="width:130px"><p>110 (6.2)</p></td><td style="width:113px"><p>92 (5.2)</p></td><td style="width:205px"><p>0.80 (0.61,</p><p>1.06)</p></td><td style="width:67px"><p>&nbsp;</p></td></tr><tr><td style="width:544px"><p>Chronic renal replacement</p><p>therapy</p></td><td style="width:130px"><p>100 (5.7)</p></td><td style="width:113px"><p>87 (4.9)</p></td><td style="width:205px"><p>0.84 (0.63,</p><p>1.12)</p></td><td style="width:67px"><p>&nbsp;</p></td></tr><tr><td style="width:544px"><p>Renal death</p></td><td style="width:130px"><p>5 (0.3)</p></td><td style="width:113px"><p>5 (0.3)</p></td><td style="width:205px"><p>0.97 (0.27,</p><p>3.49)</p></td><td style="width:67px"><p>&nbsp;</p></td></tr><tr><td style="width:544px"><p>Cardiovascular death</p></td><td style="width:130px"><p>169 (9.6)</p></td><td style="width:113px"><p>123 (7.0)</p></td><td style="width:205px"><p>0.71 (0.56,</p><p>0.89)</p></td><td style="width:67px"><p>&nbsp;</p></td></tr><tr><td style="width:544px"><p>Composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke</p><p>(time to first occurrence)</p></td><td style="width:130px"><p>&nbsp;</p><p>254 (14.4)</p></td><td style="width:113px"><p>&nbsp;</p><p>212 (12.0)</p></td><td style="width:205px"><p>0.82 (0.68,</p><p>0.98)</p></td><td style="width:67px"><p>&nbsp;</p><p>0.0145</p></td></tr><tr><td style="width:544px"><p>All-cause death</p><p>(time to first occurrence)</p></td><td style="width:130px"><p>279 (15.8)</p></td><td style="width:113px"><p>227 (12.8)</p></td><td style="width:205px"><p>0.80 (0.67,</p><p>0.95)</p></td><td style="width:67px"><p>0.0052</p></td></tr><tr><td style="width:544px"><p>&nbsp;</p></td><td colspan="2" style="width:243px"><p><strong>Estimated yearly change in eGFR </strong><sup>4</sup></p></td><td style="width:205px"><p><strong>Treatment difference vs placebo</strong></p><p><strong>(95% CI)<sup>4</sup></strong></p></td><td style="width:67px"><p>&nbsp;</p></td></tr><tr><td style="width:544px"><p>Annual rate of change in eGFR</p><p>(CKD-EPI) (total eGFR slope) (mL/min/1.73 m<sup>2</sup>/year)</p></td><td style="width:130px"><p>-3.36</p></td><td style="width:113px"><p>-2.19</p></td><td style="width:205px"><p>1.16 (0.86,</p><p>1.47)</p></td><td style="width:67px"><p>&nbsp;</p><p>&lt;0.0001</p></td></tr></tbody></table><p><sup>1</sup>Cox proportional hazards model with treatment as factor and stratified by baseline use of SGLT2- inhibitor at baseline (yes or no).</p><p><sup>2</sup>One-sided p-value for the test of no difference. The significance level was 0.01612</p><p><sup>3</sup>Sustained was defined as having 2 consecutive measurements &ge;28 days apart fulfilling the criteria. <sup>4</sup>Linear random effects model with treatment, use of SGLT-2 inhibitors (yes/no) at baseline, time (as a continuous variable) and treatment time interaction as fixed effects, and including subject effect as a random intercept and time as a random slope</p><p>&nbsp;</p><p>Figure 7. Cumulative Incidence: Time to First Occurrence of the Primary Composite - Sustained Decline in eGFR &ge; 50%, Sustained eGFR&lt;15 mL/min/1.73m<sup>2</sup>, Chronic Renal Replacement Therapy, Renal Death or CV death in FLOW Trial</p><p><img alt="" width="721" height="478" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>Cumulative incidence estimates are based on time from randomisation to first composite renal event with non- CV and non-renal death modelled as competing risk using the Aalen-Johansen estimator. The x-axis is truncated at 52 months where approximately 5% of the population was in the trial. Sustained was defined as having 2 consecutive measurements &ge;28 days apart fulfilling the criteria.</p><p>&nbsp;</p><p>Figure 8. Cumulative incidence: Time to First Occurrence of MACE in FLOW Trial</p><p><img alt="" width="696" height="478" src="data:image/png;base64,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" /></p><p>Cumulative incidence estimates are based on time from randomisation to first EAC-confirmed MACE with non-CV death modelled as competing risk using the Aalen-Johansen estimator. The x-axis is truncated at 52 months where approximately 5% of the population was in the trial.</p><p><em><u>Body weight</u></em></p><p>After one year of treatment, a weight loss of &ge;5% and &ge;10% was achieved for more subjects with <u>semaglutide</u> 0.5&nbsp;mg (46% and 13%) and 1&nbsp;mg (52 &ndash; 62% and 21 &ndash; 24%) compared with the active comparators sitagliptin (18% and 3%) and exenatide ER (17% and 4%).</p><p>&nbsp;</p><p>In the 40-week trial versus dulaglutide a weight loss of &ge;5% and &ge;10% was achieved for more subjects with <u>semaglutide</u> 0.5&nbsp;mg (44% and 14%) compared with dulaglutide 0.75&nbsp;mg (23% and 3%) and <u>semaglutide</u> 1&nbsp;mg (up to 63% and 27%) compared with dulaglutide 1.5&nbsp;mg (30% and 8%).</p><p>&nbsp;</p><p>A significant and sustained reduction in body weight from baseline to week&nbsp;104 was observed with <u>semaglutide</u> 0.5&nbsp;mg and 1&nbsp;mg vs placebo 0.5&nbsp;mg and 1&nbsp;mg, in addition to standard-of-care (‑3.6&nbsp;kg and ‑4.9&nbsp;kg vs -0.7&nbsp;kg and -0.5&nbsp;kg , respectively) in SUSTAIN 6.</p><p>&nbsp;</p><p><em><u>Blood pressure</u></em></p><p>Significant reductions in mean systolic blood pressure were observed when semaglutide 0.5&nbsp;mg (3.5‑5.1&nbsp;mmHg) and 1&nbsp;mg (5.4&ndash;7.3&nbsp;mmHg) were used in combination with oral antidiabetic medicinal products or basal insulin. For diastolic blood pressure, there were no significant differences between semaglutide and comparators. The observed reductions in systolic blood pressure for semaglutide 2&nbsp;mg and 1&nbsp;mg at week&nbsp;40 were 5.3&nbsp;mmHg and 4.5&nbsp;mmHg, respectively.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with <u>Ozempic</u> in one or more subsets of the paediatric population in type 2&nbsp;diabetes (see section 4.2 <u>for information on paediatric use</u>).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Compared to native GLP‑1, semaglutide has a prolonged half-life of around 1 week making it suitable for once weekly subcutaneous administration. The principal mechanism of protraction is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilised against degradation by the DPP-4 enzyme.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_1ccab291-c898-457e-8bd6-0fb03711f4c1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><u>Absorption</u></p><p>&nbsp;</p><p>Maximum concentration was reached 1 to 3&nbsp;days post dose. Steady state exposure was achieved following 4&ndash;5&nbsp;weeks of once weekly administration. In patients with type 2&nbsp;diabetes, the mean steady state concentrations following subcutaneous administration of 0.5&nbsp;mg and 1&nbsp;mg semaglutide were approximately 16&nbsp;nmol/L and 30&nbsp;nmol/L, respectively. In the trial comparing semaglutide 1&nbsp;mg and 2&nbsp;mg, the mean steady state concentrations were 27&nbsp;nmol/L and 54&nbsp;nmol/L, respectively. Semaglutide exposure increased in a dose proportional manner for doses of 0.5&nbsp;mg, 1&nbsp;mg and 2&nbsp;mg. Similar exposure was achieved with subcutaneous administration of semaglutide in the abdomen, thigh, or upper arm. Absolute bioavailability of subcutaneous semaglutide was 89%.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The mean volume of distribution of semaglutide following subcutaneous administration in patients with type 2&nbsp;diabetes was approximately 12.5&nbsp;L. Semaglutide was extensively bound to plasma albumin (&gt;99%).</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Prior to excretion, semaglutide is extensively metabolised through proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid sidechain. The enzyme neutral endopeptidase (NEP) is expected to be involved in the metabolism of semaglutide.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>&nbsp;</p><p>In a <u>trial</u> with a single subcutaneous dose of radiolabelled semaglutide, it was found that the primary excretion routes of semaglutide-related material were via urine and faeces; approximately 2/3 of semaglutide-related material were excreted in urine and approximately 1/3 in faeces. Approximately 3% of the dose was excreted as intact semaglutide via urine. In patients with type 2&nbsp;diabetes clearance of semaglutide was approximately 0.05&nbsp;L/h. With an elimination half-life of approximately 1&nbsp;week, semaglutide will be present in the circulation for about 5&nbsp;weeks after the last dose.</p><p><u>&nbsp;</u></p><p><u>Special population</u></p><p><u>&nbsp;</u></p><p><em><u>Elderly</u></em></p><p>Age had no effect on the pharmacokinetics of semaglutide based on data from phase 3a studies including patients of 20&ndash;86&nbsp;years of age.</p><p>&nbsp;</p><p><em><u>Gender, race and ethnicity</u></em></p><p>Gender, race (White, Black or African-American, Asian) and ethnicity (Hispanic or Latino, non-Hispanic or -Latino) had no effect on the pharmacokinetics of semaglutide.</p><p>&nbsp;</p><p><em><u>Body weight </u></em></p><p>Body weight has an effect on the exposure of semaglutide. Higher body weight results in lower exposure; a 20% difference in body weight between individuals will result in an approximate 16% difference in exposure. Semaglutide doses of 0.5&nbsp;mg and 1&nbsp;mg provide adequate systemic exposure over a body weight range of 40&ndash;198&nbsp;kg.</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>Renal impairment did not impact the pharmacokinetics of semaglutide in a clinically relevant manner. This was shown with a single dose of 0.5&nbsp;mg semaglutide for patients with different degrees of renal impairment (mild, moderate, severe or patients in dialysis) compared with subjects with normal renal function. This was also shown for subjects with type 2&nbsp;diabetes and with renal impairment based on data from phase 3a studies, although the experience in patients with end-stage renal disease was limited.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>Hepatic impairment did not have any impact on the exposure of semaglutide. The pharmacokinetics of semaglutide were evaluated in patients with different degrees of hepatic impairment (mild, moderate, severe) compared with subjects with normal hepatic function in a trial with a single-dose of 0.5&nbsp;mg semaglutide.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Paediatric population</u></em></p><p>Semaglutide has not been studied in paediatric patients.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p><u>Development of anti-semaglutide antibodies when treated with semaglutide 1&nbsp;mg and 2.4&nbsp;mg occurred infrequently (see section 4.8) and the response did not appear to influence semaglutide pharmacokinetics.</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeat-dose toxicity or genotoxicity.</p><p>&nbsp;</p><p>Non-lethal thyroid C-cell tumours observed in rodents are a class effect for GLP‑1 receptor agonists. In 2-year carcinogenicity studies in rats and mice, semaglutide caused thyroid C-cell tumours at clinically relevant exposures. No other treatment-related tumours were observed. The rodent C-cell tumours are caused by a non-genotoxic, specific GLP‑1 receptor mediated mechanism to which rodents are particularly sensitive. The relevance for humans is considered to be low, but cannot be completely excluded.</p><p>&nbsp;</p><p>In fertility studies in rats, semaglutide did not affect mating performance or male fertility. In female rats, an increase in oestrous cycle length and a small reduction in <em>corpora lutea</em> (ovulations) were observed at doses associated with maternal body weight loss.</p><p>&nbsp;</p><p>In embryo-foetal development studies in rats, semaglutide caused embryotoxicity below clinically relevant exposures. Semaglutide caused marked reductions in maternal body weight and reductions in embryonic survival and growth. In foetuses, major skeletal and visceral malformations were observed, including effects on long bones, ribs, vertebrae, tail, blood vessels and brain ventricles. Mechanistic evaluations indicated that the embryotoxicity involved a GLP‑1 receptor mediated impairment of the nutrient supply to the embryo across the rat yolk sac. Due to species differences in yolk sac anatomy and function, and due to lack of GLP‑1 receptor expression in the yolk sac of non-human primates, this mechanism is considered unlikely to be of relevance to humans. However, a direct effect of semaglutide on the foetus cannot be excluded.</p><p>&nbsp;</p><p>In developmental toxicity studies in rabbits and <em>cynomolgus</em> monkeys, increased pregnancy loss and slightly increased incidence of foetal abnormalities were observed at clinically relevant exposures. The findings coincided with marked maternal body weight loss of up to 16%. Whether these effects are related to the decreased maternal food consumption as a direct GLP‑1 effect is unknown.</p><p>&nbsp;</p><p>Postnatal growth and development were evaluated in <em>cynomolgus</em> monkeys. Infants were slightly smaller at delivery, but recovered during the lactation period.</p><p>&nbsp;</p><p>In juvenile rats, semaglutide caused delayed sexual maturation in both males and females. These delays had no impact upon fertility and reproductive capacity of either sex, or on the ability of the females to maintain pregnancy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Disodium phosphate dihydrate</p><p>Propylene glycol</p><p>Phenol</p><p>Hydrochloric acid (for pH adjustment)</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Before first use
	
	Ozempic 0.25 mg, 0.5 mg and 1 mg
3 years.


	
	After first opening

In-use shelf life: 6 weeks.

Store below 30 °C or in a refrigerator (2 °C–8 °C). Do not freeze Ozempic and do not use Ozempic if it has been frozen. Keep the pen cap on when the pen is not in use in order to protect it from light. 

Always remove the injection needle after each injection and store the pen without a needle attached. This may prevent blocked needles, contamination, infection, leakage of solution and inaccurate dosing.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before first use: Store in a refrigerator (2&nbsp;&deg;C&ndash;8&nbsp;&deg;C). Keep away from the cooling element.</p><p>Do not freeze Ozempic and do not use Ozempic if it has been frozen.</p><p>&nbsp;</p><p>Keep the pen cap on in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after first opening of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.5&nbsp;ml or 3&nbsp;ml glass cartridge (type I glass) closed at the one end with a rubber plunger (chlorobutyl) and at the other end with an aluminium cap with a laminated rubber sheet (bromobutyl/polyisoprene) inserted. The cartridge is assembled into a disposable pre-filled pen made of polypropylene, polyoxymethylene, polycarbonate and acrylonitrile butadiene styrene.</p><p>&nbsp;</p><p><u>Pack sizes</u></p><p>&nbsp;</p><p><em><u>Ozempic 0.25&nbsp;mg solution for injection</u></em></p><p>Each pre-filled pen contains 1.5 ml of solution, delivering 4 doses of 0.25 mg.</p><p>1 pre-filled pen and 4 disposable NovoFine Plus needles</p><p>&nbsp;</p><p><em><u>Ozempic 0.5&nbsp;mg solution for injection</u></em></p><p>Each pre-filled pen contains 1.5 ml of solution, delivering 4 doses of 0.5 mg.</p><p>1 pre-filled pen and 4 disposable NovoFine Plus needles</p><p>3 pre-filled pens and 12 disposable NovoFine Plus needles</p><p>&nbsp;</p><p><em><u>Ozempic 1&nbsp;mg solution for injection</u></em></p><p>Each pre-filled pen contains 3 ml of solution, delivering 4 doses of 1 mg.</p><p>1 pre-filled pen and 4 disposable NovoFine Plus needles</p><p>3 pre-filled pens and 12 disposable NovoFine Plus needles</p><p>&nbsp;</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The patient should be advised to discard the injection needle after each injection and store the pen without an injection needle attached. This may prevent blocked needles, contamination, infection, leakage of solution and inaccurate dosing. Needles and other waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>The pen is for use by one person only.</p><p>Ozempic should not be used if it does not appear clear and colourless or almost colourless.</p><p>Ozempic should not be used if it has been frozen.</p><p>&nbsp;</p><p>Ozempic can be administered with needles up to a length of 8&nbsp;mm. The pen is designed to be used with NovoFine or NovoTwist<sup> </sup>disposable needles. NovoFine Plus needles are included in the package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>